The role of replacement fluids in plasma exchange and therapeutic applications of apheresis by Watkins, Rhona
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
The Role of Replacement Fluids in Plasma Exchange and 
Therapeutic Applications of Apheresis
by
©Rhona Watkins
Submitted for the degree of M.D. in the Faculty of Medicine, 
University of Glasgow.
This work was performed in the Department of Haematology, 
Royal Infirmary, Glasgow.
MARCH 1987
ProQuest Number: 10948153
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10948153
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
CONTENTS
Page
LIST OF TABLES 8
LIST OF FIGURES 11
ACKNOWLEDGEMENTS 13
DECLARATION 14
SUMMARY 15
INTRODUCTION 23
1. Review of the Literature 29
1.1 Basis for Apheresis 29
1.2 Types of Procedures 30
1. Plateletpheresis 30
2. Erythrocytapheresis 32
3. Stem Cell Collection 32
4. Lymphocytapheresis 33
5. Leukapheresis 33
6. Plasmapheresis 35
1.3 Methods of Component Removal . 36
1.3.1 Physical Separation of Components 36
Centrifugation Methods 38
1. Discontinuous Flow Machines 39
Haemonetics V50 Cell Separator 39
2. Continuous Flow Machines 43
IBM Type 2997 Cell Separator 45
Celltrifuge II Cell Separator 52
3. Other Developments 52
1. Haemonetics V50 Cell Separator with 53 
Surge Pump
2. IBM Type 2997 Cell Separator with 55 
Dual Channel
Membrane Filtration Methods 58
Principle of Operation 58
Dideco Filtra BT 810 59
Factors in the Filtration Procedure 62
2
Page
1.3.2 Chemical Separation of Components 65
Haemoperfusion 66
Plasma Perfusion 66
Column Technology 67
1.3.3 Other Procedures 73
1.3.4 Comparison of Centrifugation and Filtration 
Procedures
75
1.4 Plasma Exchange - Practical Considerations 77
1.4.1 Vascular Access 81
1. Ante-cubital Venepuncture 81
2. Femoral Vein Catheterisation 81
3. Subclavian Vein Catheterisation 82
4. Arteriovenous Shunts 83
5. Arteriovenous Fistulae 83
6. Complications of Access 84
1.4.2 Anticoagulation 85
1. Heparin 85
2. Citrate 87
1.4.3 Replacement Fluids 90
1. Consequences of Plasma Removal 90
2. Available Replacement Products 99
1. Patient's Own Plasma 99
2. Fresh Frozen Plasma 99
3. Cryopreci pi tate 101
4. Albumin Solutions 102
Albumin 5% 104
Plasma Protein Fraction 104
Albumin 20-25% 105
Adverse Effects 105
5. Plasma Volume Expanders 107
Dextrans 107
Gelatins 108
Hydroxyethyl Starch 108
Electrolytes 109
1.5 Plasma Exchange - Applications 111
1.5.1 Rationale for Treatment 111
1.5.2 Protocols for Treatment 111
1.5.3 Evidence of Efficiacy 113
1.5.4 Implications for Treatment 116
3
Page
1.5.5 Typical Applications 121
Hyperviscosity States 121
1. Paraproteinaemias 121
2. Waldenstrom's Macroglobulinaemia 125
3. Multiple Myeloma 125
4. Cryoglobulinaemia 126
Immune-Based Haematological Disorders 127
1. Auto-immune Haemolytic Anaemia 127
2. Idiopathic Thrombocytopenic Purpura 127
3. Thrombotic Thrombocytopenic Purpura 128
4. Factor VIII Inhibitors 129
Alloimmunisation 129
1. Rhesus Haemolytic Disease 129
Antibody Mediated Non-Haematological Disorders 130
1. Myasthenia Gravis 130
2. Goodpasture's Syndrome 131
3. Refsum's Disease 131
4. Guillain- Barre Syndrome 131
5. Aplastic Anaemia 132
6. Neoplasia 132
Plasma Exchange in Children 134
1. Preparation for Plasma Exchange 135
2. Management During Exchange 136
3. Post Exchange 136
4. Complications 136
1.6 Plasma Exchange - Side Effects 137
1.6.1 Vascular Problems 137
1.6.2 Procedural Problems 138
1. Circulation Effects 138
2. Anticoagulant Effects 139
3. Replacement Media Effects 140
Plasma Products 
Albumin Solutions 
Gelatins
4. Hypothermia 140
5. Haemolysis 141
6. Loss of Medication 142
1.6.3 Mortality 142
2. Scope of Thesis 144
4
Page
2.1 Details of Patients and Exchange Procedure 145
2.1.1 Study of Selected Replacement Fluids 145
2.1.2 Study of Selected Disorders 147
2.1.3 Study of Leukapheresis 153
2.2 Parameters Studied 154
2.2.1 Study of Selected Replacement Fluids 154
1. Sampling 154
2. Haematological Parameters 155
1. Standard Full Blood Count
2. White Blood Count
3. Platelet Count
4. Coagulation Screening
5. Quantitative Assays of Coagulation 
Factors
3. Biochemical Parameters 158
1. Urea and Electrolyte Evaluation
2. Liver Function Tests
3. Plasma Protein Evaluation
4. Serum Immunoglobulin Assays
4. Statistical Analysis of Data 159
1. Standard Parameters
2. Significance Tests
2.2.2 Study Of Selected Disorders 160
1. Cold Haemagglutinin Syndrome
2. Waldenstrom’s Macroglobulinaemia and 
Hyperviscosity due to IgA and IgM Myeloma
3. Immune Haemolytic Anaemia
4. Factor'VIII Inhibitors
5. Chronic Polyneuropathy
6. Myasthenia Gravis and Eaton-Lambert Syndrome
7. Guillain-Barre Syndrome
8. Glomerulonephritis and Goodpasture's 
Syndrome
9. Aplastic Anaemia/Pure Red Cell Aplasia
10. Polymyositis
2.2.3 Study of Leukapheresis 164
3. Results 165
3.1 Study of Selected Replacement Fluids 165
3.1.1 Haematological Parameter Response to 165
Plasma Exchange
1. Standard Full Blood Counts 165
5
Page
2. Platelet Counts 167
3. Coagulation Screening 167
4. Quantitative Assays of Coagulation 173
Factors
3.1.2 Biochemical Parameter Response to Plasma Exchange 186
1. Urea and Electrolytes 186
2. Liver Function Tests 190
3. Plasma Protein 192
4. Serum Immunoglobulins 196
3.1.3 Clinical Response 201
3.2 Study of Selected Disorders 206
1. Cold Haemagglutinin Syndrome 206
2. Waldenstrom's Macroglobulinaemia and 206
Hyperviscosity due to IgA and IgM Myeloma
3. Immune Haemolytic Anaemia 211
4. Factor VIII Inhibitors 215
5. Chronic Polyneuropathy 215
6. Myasthenia Gravis and Eaton-Lambert Syndrome 219
7. Guillain-Barre Syndrome 219
8. Glomerulonephritis and Goodpasture's 223
Syndrome
9. Aplastic Anaemia and Pure Red Cell Aplasia 225
10. Polymyositis ' 228
11. Clinical Status of Patients 228
3.3 Study of Leukapheresis 235
4. Discussion of Results 239
4.1 Study of Replacement Fluids 239
4.2 Study of Selected Disorders 246
1. Cold Haemagglutinin Syndrome 246
2. Waldenstrom's Macroglobulinaemia and 249
Hyperviscosity due to IgA and IgM Myeloma
3. Immune Haemolytic Anaemia 254
4. Factor VIII Inhibitors \ 257
5. Chronic Polyneuropathy 261
6. Myasthenia Gravis and Eaton-Lambert Syndrome 264
7. Guillain-Barre Syndrome v 270
8. Glomerulonephritis and Goodpasture's 273
Syndrome
9. Aplastic Anaemia and Pure Red Cell Aplasia 280
10. Polymyositis 285
11. Clinical Status of Patients 289
4.3 Study of Leukapheresis 290
5. Future Developments 296
6
Page
5.1 Technical 296
5.2 Therapeutic 300
5.3 Replacement Fluids 300
6. Conclusions. 302
References. 305
Appendix A Results of Statistical Analysis 328
7
LIST OF TABLES
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
' Page
1 Consumption of Plasma Products 25
2 Consumption of Albumin 5% 26
3 Some Protocols Possible on the IBM 2997 50
Blood Cell Separator
4 Performance Data for IBM 2997 Blood Cell 51 
Separator
5 Performance of Centrifugation Equipments in 78
Plateletpheresis
6 Performance Characteristics of Four Equipments 79
in Plasmapheresis
7 Plasma Products - Fresh Frozen Plasma 100
8 Plasma Products - Albuminoid Solutions 103
9 Comparison of Plasma Substitutes 110
10 Possible Mechanisms of Action in Therapeutic 112
Plasma Exchange
11 Disorders in which the Efficacy of Therapeutic 115
Plasma Exchange can be Monitored by Measurements
of a Pathogenic Substance in Plasma
12 Controlled and Uncontrolled Trials in Therapeutic 118
Plasmapheresis
13 List of Diseases in which Plasmapheresis has been 122
used
14 Deaths Associated with Therapeutic Plasmapheresis 143
15 Clinical Conditions of Patients Treated By Plasma 146
Exchange Using Selected Replacement Fluids
16 Age and Sex Distribution of 186 Patients Treated 148
for various Disorders by Plasma Exchange at the
Glasgow Royal Infirmary over the period 1981-1985
17 Variations in Full Blood Counts during Plasma Exchange 166
18 Values of Platelet Counts Pre-Plasma Exchange 168
19 Values of Platelet Counts Post-Plasma Exchange 168
20 Values of Coagulation Screening Pre and Post-Plasma 170
Exchange
8
Table 21 Quantitative Assays of Coagulation Factors
Pre-Plasma Exchange
Table 22 Quantitative Assays of Coagulation Factors
Post-Plasma Exchange - Factor I
Table 23 Quantitative Assays of Coagulation Factors
Post-Plasma Exchange - Factor II
Table 24 Quantitative Assays of Coagulation Factors
Post-Plasma Exchange - Factor VIIIC
Table 25 Quantitative Assays of Coagulation Factors
Post-Plasma Exchange - Factor IX
Table 26 Quantitative Assays of Coagulation Factors
Post-Plasma Exchange - Factor X
Table 27 Values of Electrolyte Change During Plasma
Exchange
Table 28 Changes in Liver Function Test Values During
Plasma Exchange
Table 29 Mean Values of Serum Plasma Protein Concentration
Pre and Post-Plasma Exchange
Table 30 Values of Serum Iron and Total Iron Binding
Capacity Pre and Post-Plasma Exchange
Table 31 Mean Values of Serum Immunoglobulins Pre and
Post-Plasma Exchange
Table 32 Summary of Short-Term Side Effects arising from
Selected Replacement Fluids used in Plasma 
Exchange 1981-1985
Table 33 Clinical Status of Patients after Treatment by
Plasma Exchange using Selected Replacement Fluids
Table 34 Cold Haemagglutinin Disease: Measurements of
Haematological and Serological Parameters Pre- 
and Post-Plasma Exchange
Table 35 Immune Haemolytic Anaemia
Table 36 Factor VIII Inhibitors: Values of Coagulation
Screening performed Pre and Post-Plasma Exchange
Table 37 Chronic Polyneuropathy: Performance Grading of
Patients Pre and Post-Plasma Exchange
Table 38 Myasthenia Gravis: Performance Grading of
Patients Pre and Post-Plasma Exchange
Page
175
176 
178 
180 
182 
184 
188 
191 
194
197
198 
202
205
207
214
216
218
220
9
Table 39 Effect of Plasma Exchange on Clinical Status 
of Patients with Eaton-Lambert Syndrome
Table 40 Guillain-Barre Syndrome: Results and
Performance Grading Pre and Post-Plasma 
Exchange
Table 41 Glomerulonephritis: Biochemical Results Pre and
Post-Plasma Exchange
Table 42 Results of Regular Plasma Exchange in
Goodpasture's Syndrome
Table 43 Effect of Plasma Exchange on Pure Red Cell
Aplasia and Aplastic Anaemia
Table 44 Effects of Plasma Exchange on Biochemical
Parameters and Clinical Status in Patients 
with Polymyositis
Table 45 Short-Term Side Effects observed during
Treatment of Selected Disorders
Table 46 Clinical Status of Patients with Selected
Disorders after Treatment with Plasma Exchange
Table 47 Summarised Results of Leukapheresis Study
Table 48 Serological Characteristics of Patients with
Cold Haemagglutinin Disease
Table 49 Serological Characteristics of Patients with
Auto-Immune Haemolytic Anaemia
Page
221
222
224
226
227
229
230
236
237 
248
255
10
LIST OF FIGURES
Page
Figure 1 Haemonetics V50 Cell Separator 40
Figure 2 Plasma Separation in Rotating Haemonetics 42
Bowl
Figure 3 IBM Type 2997 Cell Separator 46
Figure 4 Circuit Arrangement of IBM Cell Separator 47
Figure 5 (a) Separation Channel of IBM Cell Separator 48
(b) Port Arrangement of IBM Cell Separator 48
Figure 6 . Haemonetics V50 Cell Separator with 54
Surge Pump
Figure 7 IBM Type 2997 Cell Separator with Dual 56
Stage Channel
Figure 8 Dideco Filtra BT 810 6(3
Figure 9 Circuit Arrangement of Dideco Filtra BT 810 51
Figure 10 Effect of Replacement Fluids on Values of 159
Platelet Counts Post-Plasma Exchange
Figure 11 Effect of Replacement Fluids on Values of 171
Coagulation Screening Post-Plasma Exchange
Figure 12 Effect of Replacement Fluids on Coagulation 177
Factor I Post-Plasma Exchange
Figure 13 Effect of Replacement Fluids on Coagulation 179
Factor II Post-Plasma Exchange
Figure 14 Effect of Replacement Fluids on Coagulation 181
Factor VIIIC Post-Plasma Exchange
Figure 15 Effect of Replacement Fluids on Coagulation 183
Factor IX Post-Plasma Exchange
Figure 16 Effect of Replacement Fluids on Coagulation 185
Factor X Post-Plasma Exchange
Figure 17 Effect of Replacement Fluids on Mean Serum 1^5
Plasma Protein Concentrations Post-Plasma 
Exchange
Figure 18 Effect of Replacement Fluids on Mean Serum 199
Immunoglobulins Post-Plasma Exchange
11
Page
Figure 19 Whole Blood Viscosity at three Shear
Rates Pre and Post-Plasma Exchange 
. (Waldenstrom's Macroglobulinaemia)
Figure 20 Plasma Viscosity Pre and Post-Plasma
Exchange (Waldenstrom's Macroglobulinaemia)
Figure 21 Effect of number of Plasma Procedures on
values of Serum IgM Immunoglobulin 
(Waldenstrom's Macroglobulinaemia)
Figure 22 Whole Blood Viscosity at three Shear Rates
Pre and Post-Plasma Exchange in 
Hyperviscosity due to IgG and IgA Myeloma
Figure 23 Plasma Viscosity Pre and Post-Plasma
Exchange in Hyperviscosity due to IgA 
and IgG Myeloma
208
209
210
212
213
12
ACKNOWLEDGEMENT
I am deeply indebted to Dr G A McDonald, Consultant Haematologist, 
Department of Haematology, Glasgow Royal Infirmary for his constant 
help and encouragement during the preparation of this thesis.
I acknowledge, with appreciation, the co-operation offered to me by 
Dr A K Burnett, Consultant Haematologist at the Royal Infirmary, during 
the course of these studies and for stimulating my original interest 
in Plasmapheresis.
It is a pleasure to acknowledge the help and unreserved co-operation 
from:-
»
1) Miss Carol Fraser, Senior Chief Medical Laboratory Scientific 
Officer and Mrs Sheila Gibson, Chief Medical Laboratory Scientific 
Officer, Department of Haematology, Glasgow Royal Infirmary.
2) The Department of Biochemistry, Glasgow Royal Infirmary, for their 
prompt analysis of considerable numbers of samples and for their most 
helpful collaboration over the period of the studies.
I am particularly grateful to Miss Karen McNay, Department of 
Haematology, Glasgow Royal Infirmary, for the considerable effort 
expended by her in the typing of the preliminary draft manuscript.
13
DECLARATION
The planning and initiation of all the investigations in this thesis 
are entirely my own work, as was the co-ordination of laboratory data 
and the analysis of results. All specimen collection and supervision 
of all patients undergoing plasma exchange was Carried out by myself.
The majority of the laboratory techniques utilised were of a routine 
nature and I have received the willing co-operation and assistance of 
my colleagues. The extent of my personal contribution in relation to 
this technical assistance can be outlined as follows:-
1. Coagulation Screening
All coagulation screening was carried out by me. Individual Factor 
Assays of all patients were carried out by me. The remainder of the 
haematological investigation, namely a routine full blood count was 
carried out by the technical staff using a Coulter 'S' Counter.
2. Clinical Response
The clinical response to plasma exchange was determined by me. I 
personally examined all patients before and after plasma exchange and 
carried out any further investigations as required.
3. Statistical Methods
I personally carried out the statistical tests.
14
SUMMARY
By 1981 it had become apparent that a new technique, plasmapheresis, 
offered considerable potential in the treatment of an ever increasing 
number of diseases by its ability to remove an affecting component 
from the patient's blood. Plasmapheresis involved the selective 
removal of a small volume of plasma which was not replaced, whereas 
plasma exchange involved the removal of a large volume of plasma which 
was replaced by an almost equal volume of appropriate fluid.
A blood cell separator (IBM Type 2997) was acquired by the Department 
of Haematology, Glasgow Royal Infirmary, and during the period 1981-1985, 
2685 plasma exchange procedures were carried out on.201 female and 125 
male patients being treated for a range of clinical disorders. During 
this period I carried out a number of individual studies which form the 
basis of this thesis.
The thesis first reviews the literature relating to the application of 
therapeutics plasma exchange in the treatment of selected disorders. It 
outlines the types of exchange procedures and the methods of component 
removal based on physical and chemical means. Some continuous flow and 
discontinuous flow centrifugation equipments and membrane filtration 
equipments are described and a comparison made of centrifugation and 
filtration procedures. The potential offered by chemical separation 
procedures is indicated. The practical considerations, particularly 
those of vascular access, anticoagulation and the choice of replacement 
fluids, are discussed. The rationale for treatment by plasma exchange, 
evidence of its efficacy and the implications of such treatment are 
considered. Some applications of plasma exchange in the treatment of
15
selected disorders are described. Whilst exchange procedures are 
relatively safe they are not without risk and some of the adverse 
reactions and hazards are indicated.
The thesis has three basic objectives.
1. To assess the effectiveness of three selected replacement fluids 
used in the plasma exchange procedures carried out on three 
groups, each with patients being treated for myasthenia gravis, 
Guillain-Barre Syndrome,* chronic polyneuropathy and polymyositis.
2. To assess the effectiveness of plasma exchange procedures in the
treatment of patients with cold haemagglutinin disease,
Waldenstrom's macroglobulinaemia and hyperviscosity due to
multiple myeloma, immune haemolytic anaemia, Factor VIII
inhibitors, polyneuropathy., myasthenia gravis and Eaton-Lambert
/
syndrome, Guillain-Barre syndrome, glomerulonephritis and 
Goodpasture's disease, aplastic anaemia together with pure red 
cell aplasia and polymyositis.
3. To undertake a preliminary assessment of the potential offered 
by leukapheresis as an adjunct to conventional chemotherapy in 
the treatment of patients with acute myeloid and lymphatic 
leukaemias and with chronic myeloid and lymphatic leukaemias.
In the first study, three groups of patients with selected disorders 
were treated by plasma exchange procedures in which their plasma was 
replaced by Plasma Protein solution (2 litres 5% albumin plus 0.5 litre 
normal physiological saline), Polygeline 1 (1 litre 5% albumin plus 1 
litre Haemaccel plus 0.5 litre normal physiological saline), and 
Polygeline II (2 litres Haemaccel plus 0.5 litre normal physiological 
saline) respectively. The haematological response, as assessed by
16
changes in standard full blood count, white blood count, platelet count, 
coagulation screening and quantitative assays of coagulation factors; 
the biochemical response, as assessed by changes in urea and electrolyte 
values, liver function evaluation, plasma protein evaluation and serum 
immunoglobulin assays; and the clinical response of each patient was 
continuously monitored throughout the sequences of exchange procedures. 
The mean value of each measured haematological and biochemical parameter 
was calculated for all the patients in each of the three groups. The 
number of patients was sufficiently large to permit a statistical 
comparison to be made of the changes in mean values of each parameter, 
throughout the exchange procedure. Significant differences in values 
were thus a direct consequence of the choice of replacement fluid used 
by each group in the plasma exchange procedure.
In the remaining studies specific haematological and biochemical 
parameters only were measured as required. Changes in parameter values 
and in the clinical response to treatment were monitored continuously 
throughout the procedure. Patients treated for the different disorders 
and those involved in the leukapheresis procedures varied greatly in 
numbers, but were not sufficiently numerous at any one time to permit 
the setting up of controlled trials.
From this study I have obtained the following results and conclusions.
1. For each of the three groups of patients, the mean values of the 
full blood counts, platelet counts, prothrombin time, Kaolin cephalin 
clotting time, thrombin time, assays of coagulation factors I,II,VIII,
IX and X; of urea, sodium,potassium, chloride, creatinine, calcium, 
magnesium, phosphate, serum bilirubin, asparate transaminase, alanine 
transaminase, alkaline phosphatase, total protein, albumin, globulin,
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serum iron, total iron binding capacity and serum immunoglobulins IgG, 
IgM and IgA pre and post-plasma exchange differed only slightly. The 
change in mean values at intervals post-plasma exchange exhibited 
similar trends although the absolute values of change were slightly 
different in the three groups. It was noted that in the case of some 
individual parameter measurements the differences in the mean values 
were statistically significant, and these occurred randomly within the 
three groups.
In the treatment of myasthenia gravis, Guillain-Barre syndrome, 
polyneuropathy and polymyositis the three groups of patients exhibited 
similar clinical response to the exchange of plasma with the three 
replacement fluids, namely plasma protein solution, polygeline I and 
polygeline II. The incidence of side effects arising from the use of 
polygeline II was marginally greater than,the incidence of side effects 
observed in patients exchanged with plasma protein solution and 
polygeline I. On the basis of the haematological, biochemical and 
clinical assessments it is concluded that the three selected fluids are 
equally effective in the replacement of plasma in the plasma exchange 
procedures•
The data obtained in this study and the conclusions drawn are in 
general agreement with those noted in other studies of different 
clinical disorders treated by plasma exchange using similar replacement 
fluids but involving considerably fewer patients.
2. Plasma exchange in the treatment of patients with cold 
haemagglutinin disease produced a significant increase in haemaglobin 
and a decrease in the cold antibody titre. Four patients required to
18
be transfused during the period of exchange, one patient relapsed and 
died from a myocardial infarction. In general, only transient 
responses to plasma exchange have been obtained, the antibody titres 
returning to their pre-exchange levels in only seven days.
Plasma exchange in the treatment of patients with Waldenstrom's 
macroglobulinaemia and hyperviscosity due to IgA and IgG myeloma 
produced significant reductions in the whole blood viscosity at all 
three shear rates and in plasma viscosity immediately after plasma 
exchange. The value of serum immunoglobulin IgM also decreased in 
patients with Waldenstrom's macroglobulinaemia and all but one patient 
noticed a marked improvement in clinical status. All but two patients 
with hyperviscosity due to IgA and IgG myeloma showed improvement in 
clinical status.
In the treatment of patients with immune haemolytic anaemia, plasma 
exchange resulted in a significant increase in haemoglobin associated 
with a decrease in warm antibody titre. This permitted temporary 
control of . haemolysis and a measure of patient stability, giving 
other modalities time to act.
In the treatment of patients with Factor VIII inhibitors values of 
prothrombin time, thrombin clotting time and Factor VIII Rg were not 
significantly altered by plasma exchange. The values of Kaolin 
cephalin clotting time and inhibitor screen were reduced and the Factor 
VIII C concentration was markedly increased. The patients being 
treated for a range of disorders reacted favourably to the procedure.
Half of the patients with chronic inflammatory polyneuropathy improved
19
after treatment by plasma exchange. No change was discernable in the 
others and one patient unfortunately died.
In patients with myasthenia gravis, plasma exchange resulted in a 
significant reduction in Anti-AchR values and a corresponding increase 
in vital capacity. The clinical status of three patients was unchanged 
by the procedure but in three patients with high initial vaues of Anti- 
AchR a marked improvement was seen.
Patients with Eaton-Lambert syndrome reacted similarly to treatment by 
plasma exchange.
In the treatment of patients with the Guillain-Barre syndrome an 
improvement in clinical status of one grade was observed in seven 
patients, of two grades in seventeen patients, and of three grades in 
three patients in whom the duration of the symptoms ranged from nine 
to twelve days and for whom the procedure was initiated one day after 
diagnosis of the disorder.
The serum creatinine concentrations in patients being treated for 
glomerulonephritis were markedly lowered as a result of plasma exchange. 
Regular plasma exchange appeared to prevent progression to renal 
failure in nine out of twelve patients with mesangiocapillary Type 1
t
GN, for a mean period of eighteen months. In one patient the procedure 
was stopped following a rise in serum creatinine. Four patients with 
mesangiocapillary Type II GN progressed to renal failure despite 
continuing plasma exchange, whilst two patients did not progress to end 
stage renal failure. Three patients with mesangial IgA disease had 
virtually stable serum creatinine during nine months of procedures.
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Two patients with idiopathic membranous nephropathy progressed to end 
stage renal failure despite plasma exchange. Pulmonary haemorrhage 
occurred in ten patients and was rapidly controlled in four. Long term 
follow up revealed that eight patients were still alive, five with 
functioning allografts and three maintained on dialysis.
Both serum creatinine and anti IgM Ab {% binding) were significantly 
lowered by plasma exchange in the treatment of patients with Goodpasture's 
syndrome. Improvement in clinical status was noted in six patients, 
four patients proceeded to dialysis and two ultimately died. In both 
disorders recovery of renal function was clearly related to the severity 
of glomerular damage. The prognosis for patients presenting with 
creatinine of 550 y  mol/1 or less was significantly better than for 
those with creatinine levels of 600 y  mol/1 or greater.
Plasma exchange in the treatment of patients with red cell aplasia and 
aplastic anaemia produced a marked increase in the numbers of CFU-C units. 
Values of creatinine kinase,- asparate transaminase, alanine transaminase 
and lactate dehydrogenase were all reduced by plasma exchange in the 
treatment of patients with polymyositis. The clinical status of three 
patients showed an improvement of one grade whilst that of seven 
patients was improved by two grades.
Short term side effects were observed during the treatment of the above 
disorders, some of which could be attributed to the choice of 
replacement fluid and others to the exchange procedure itself. The 
longer term effects embraced the hypercoagulable state, bacterial 
infection and Viral infection. No patient developed side effects which 
have had deleterious consequences on health.
21
In some disorders the clinical effect of plasma exchange could be 
subjectively correlated with the level of specific disease marker. In 
other disorders correlation between the serological findings and the 
disease activity was poor and the assessment of the therapeutic value 
of the procedure was based on clinical evaluation. Where improvements 
in clinical status were observed these were generally due to relief of 
clinical manifestations rather than to any effect on the underlying disease 
itself. The favourable response of many disorders to plasma exchange 
was short term and this limits its value to therapy for acute conditions.
3. Leukapheresis provided a relatively rapid means of safely
reducing the circulating white cell count and resulted in clinical 
improvement. It did not provide a superior form of treatment for 
chronic myeloid leukaemia and did not appear to delay blastic 
transformation. In the treatment of chronic lymphathic leukaemia, 
leukapheresis did reduce the lymphocyte count, spleen size, lymph node 
size, bone marrow infiltration and liver size , but it should be used 
primarily for those patients failing other forms of treatment.
The application of Blood Cell separators and plasma exchange procedures 
will be justified by their contribution to the improvement of the 
clinical management of disorders by cellular or plasma depletion or by 
plasma replacement. Hopefully, they may add to the understanding of 
the separation characteristics and the kinetics of cell population which 
should lead to an improvement in the rationale of treatments based on 
apheresis procedures. There is however, a need for a procedure that 
wilT provide the expeditous return of the patient's own plasma from 
which the offending component(s) have been selectively removed in the 
course of the exchange.
22
INTRODUCTION
Blood cell separators were initially introduced and subsequently 
developed to provide granulocyte transfusions for patients, with acute 
leukaemia, who become profoundly neutropoenic secondary to induction 
therapy and then subsequently infected. Such separators also proved 
to be highly efficient in reducing the numbers of circulating blast 
cells and thereby decreasing the complications of leukostasis, namely
i
the incidence of pulmonary and cerebral insufficiency.
Cell separators were later developed for the exchange of large volumes 
of plasma and this procedure was performed on small numbers of patients 
with diverse pathological conditions where there were known, or presumed, 
abnormal plasma factors contributing to the aetiology, or pathogenesis, 
of the particular conditions. Whilst beneficial results were reported, 
the absence of well-controlled randomised studies made if difficult 
to assess the efficacy of the procedures.
It was established that some 75% of a patient's plasma could be removed 
safely in one to two hours provided that an appropriate replacement 
fluid was substituted to maintain colloid osmotic pressure and thus 
prevent formation of peripheral oedema. At the time no information was 
available as to which replacement fluid would be of optimum benefit to 
the patient. The choice was determined primarily by the replacement 
fluid's ability to:
1 restore volume and oncotic pressure
2 replace the constituents removed during plasma exchange, 
namely, coagulation factors, immunoglobulins and fibronectin.
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At Glasgow Royal Infirmary, plasma exchange has provided a basis for 
the treatment of selected patients with:
1. Antibody Mediated Diseases
a. Myasthenia Gravis, b. Guillain-Barre Syndrome, 
c. Polymyositis and d. Factor VIII Inhibitors.
2. Immune Complex Diseases
a. Rapidly progressive Glomerulonephritis, b. Goodpasture's 
Syndrome, c. Systemic Lupus Erythematosus, d. Rheumatoid 
Arthritis, e. Dermatomyositis.
3. Non-Immune Mediated Diseases
a. Hyperviscosity Syndrome (Waldenstrom's Macroglobulinaemia)
b. Raynaud's Phenomenon.
Over the period 1980-1985, I carried out 2685 therapeutic plasma 
exchanges on an IBM 2997 cell separator. Circulatory access was 
achieved by venepuncture of the antecubital veins with 19 Gauge cannulae. 
Those patients with renal disorders had either Scribner shunts, or 
latterly, arteriovenous fistulae. Each patient underwent a minimum of 
five daily plasma exchanges with 2.5 litres of plasma being removed 
during each procedure. Heparin was used as anticoagulant, 5000 IU 
being given to the patient at the start of the procedure and 3000-5000 
IU during the procedure.
The main replacement fluids used were plasma protein fraction and 
albumin 5% and, very occasionally, fresh frozen plasma. With albumin- 
5% and plasma protein fraction there was no risk of transmitting 
hepatitis and no matching for ABO incompatibility required, factors 
which had to be taken into consideration if fresh frozen plasma was used.
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During the period 1980-1982 the consumption of plasma products was as 
shown in Table 1.
Table 1
Consumption of Plasma Products
Year 1980 1981 1982
Number of Plasma 
Exchange procedures 
Undertaken 332 222 237
Albumin 5% (litres) 200 285 300
Plasma Protein 
Fraction (litres) 100 98 75
The consumption of albumin 5% was a large percentage of the hospital's 
total allocation and alternative replacement media were sought. It was 
known that dextrans, gelatins and hydroxyethyl starch (HES) were widely 
accepted where rapid expansion of plasma volume was required and that 
synthetics were generally more efficient than albumin in the immediate 
restitution of blood volume e.g., dextran has a colloid osmotic pressure 
approximately twice that of albumin and therefore pulls more water out 
of tissue into the vasculature. Whilst gelatins have been in use for 
a considerable period they are known to have three major drawbacks 
namely:
1 Alteration of the haemostatic mechanism due to defects in
platelet function
2 Transient effects on renal function
3 Incidence of anaphylactoid reactions
25
Polygeline (Haemaccel) was known to have a low incidence of adverse 
reactions and was introduced as the main replacement fluid in 1983. 
Since then the consumption of albumin 5% used in plasma exchange 
procedures has decreased dramatically as shown in Table 2.
Table 2 
Consumption of Albumin 5%
Year 1983 1984 1985
Number of Plasma 
Exchange procedures 
Undertaken 276 286 295
Albumin 5%
(litres) used 310 201 175
Since the introduction of polygeline it has not been necessary for the 
Infirmary to use commercial albumin as a replacement fluid.
At that time, data on the efficacy of polygeline as a replacement 
fluid in plasma exchange were limited. Results had been published^" of 
a study in which polygeline had been compared with plasma protein 
fraction as the sole replacement fluid in a sequence of four to six 
plasma exchange procedures undertaken in the treatment of six patients 
with various types of glomerulonephritis and deteriorating renal function. 
Measurements had been made of full blood count, blood concentrations of 
urea, electrolytes, proteins, immunoglobulins, complement and 
coagulation factors before and at one hour and fifteen hour post—exchange. 
Creatinine clearances were measured between exchanges which were 
undertaken at four to seven day intervals. There was no evidence of
26
hypoalbuminaemic hypovolaemia and no postural hypotension occurred; 
but it was thought that low albumin concentrations could be a problem 
if multiple procedures were carried out at very short intervals.
i
Also available were the findings of studies undertaken to establish the
2
effect of plasma exchange on fibrinogen and platelet levels and on
3serum immunoglobulins and complement components . Plasma protein 
solution was used as the replacement fluid but the studies included 
data for a limited number of exchanges (37 in all) carried out on five 
patients using plasma protein solution supplemented by Haemaccel. No 
significant effect attributable to the addition of Haemaccel was detected.
There was clearly a need for more detailed information of the effect, 
on the routine haematological, biochemical and coagulation screening of 
patients, of replacing plasma wholly, or partially, by polygeline 
during plasma exchange in the treatment of various disorders and of any 
consequential adverse effects of the procedure. It was also desirable 
that a datum for comparison should be provided by a similar evaluation 
of the effect of replacing plasma by plasma protein solution.
In the course of further studies, in which albumin 5% was also used as 
a replacement fluid, it was possible to assess the efficacy of plasma 
exchange in the treatment of patients with:
1. Cold haemagglutinin disease
2. Waldenstrom's macroglobulinaemia and hyperviscosity due to 
multiple myeloma.
3. Immune haemolytic anaemia
4. Factor VIII inhibitors
5. Chronic polyneuropathy ^
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6. Myasthenia gravis and Eaton-Lambert syndrome
7. Guillain-Barre syndrome
8. Glomerulonephritis and Goodpasture's disease
9. Aplastic anaemia together with pure red cell aplasia
10. Polymyositis
Experience was gained in the use of leukapheresis in the treatment of 
patients with acute and chronic leukaemias ,both myeloid and lymphatic, 
as an adjunct to conventional chemotherapy. A preliminary study was 
made of the factors involved in the conduct of such procedures.
This thesis is based on the above studies of plasma exchange and 
leukapheresis procedures carried out over a four year period 1981-1985 
during the tenure of my post as Registrar in Haematology at the Glasgow 
Royal Infirmary.
The clinical indications for therapeutic plasma exchange, the efficiacy 
of fluid replacement and the nature of concomitant side effects have 
been critically analysed and the results of these studies are presented 
and discussed.
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1. REVIEW OF THE LITERATURE
The Basis of Apheresis
The history of contemporary apheresis predates Hippocrates.
4  5
Apheresis * means 'taking off' and is applied to the individual
components of whole blood, plasma, platelets and white blood cells.
It will be of benefit if the circulating product is pathological
and is no longer being introduced, synthesised, or accumulating.
In the case of an immune disorder, the offending antibody (or
cellular agent) is being synthesised continuously. The end-organ,
whether it be nerve, muscle junction, synovial membrane, or renal
glomerulus can repair itself at some finite rate, provided the
disease is of long duration and the end-organ1s ability to repair
has suffered no, or only limited, damage. If, following the
effective removal of a circulating antibody, repair can occur
quickly, then improvement will be visible rapidly. If there is
no repair, or it occurs only slowly, improvement will be limited,
or the condition will remain stable. If the circulating antibody
is re-synthesised rapidly then only limited benefits will be
derived from its removal, even in the presence of a rapidly
5repairing end-organ .
The extent to which the re-synthesis, or re-introduction, of the 
offending factor occurs and to which the end-organ can repair 
itself, will markedly influence the benefit gained from apheresis 
and the length of time over which the procedure may have to be 
applied. If the medication given to reduce re-synthesis acts 
slowly the apheresis procedure may have to be repeated over a
29
period of time. This intermittent mechanical removal of the
factor could however be preferred to long-term medication with
cumulative risks. If the rate of repair of the end-organ is
slow the apheresis procedure may be of no more value than the
5
agents which only reduce re-synthesis .
Clearly, effective treatment of a disorder by an apheresis
procedure requires the causative role of the postulated
circulating factor to be specifically established. This could
be achieved by measuring the removal of the factor which is
thought to be pathogenic, studying the effects of its removal,
the duration of any observed effect on both clinical and
laboratory measurements and the influence of removal of a
factor of known laboratory markers of disease activity. If the
removal of a factor correlates strongly with clinical improvement
or stability, coupled with changes towards normality in other
laboratory parameters of disease activity, then that circulating
5
factor may be presumed pathogenic .
1.2 Types of Procedures
Therapeutic apheresis now includes a range of procedures to 
remove one or more circulating products pathogenic to a given end- 
organ and which are re-synthesised at a variable rate.
1. Plateletpheresis
Marked elevations of the platelet count to levels greater
9
than 1000 x 10 /I can be seen in all the myeloproliferative 
disorders, as a reactive thrombocytosis, in post-surgical
30
patients (particularly post-splenectomy), and in patients
fi
with a variety of malignancies, or infections .
Plateletpheresis provides means for the safe and rapid
7 8removal of large numbers of platelets from patients * .
Depending on the initial platelet count it is possible to
12
remove as many as 5-10 x 10 platelets (equivalent to more 
than 100 units of platelet concentrate) in a single 
donation. Whilst this results in a rapid lowering of the 
platelet count, the effect is temporary and the count rises 
again within the next 24-48 hours. The procedure may be 
repeated until conventional therapy has time to become 
effective, e.g.,before chemotherapy becomes operative.
In-vitro abnormalities of platelet function can sometimes
7
be corrected following plateletpheresis . Depending on the 
cell separator used and the centrifugation setting, it is 
sometimes possible to remove sub-populations of platelets, 
particularly larger platelets, more selectively. It is 
possible that circulating platelet aggregates of differing 
size are more effectively removed.
Immediate plateletpheresis appears to be indicated in 
patients with a significant elevation in platelet count and 
signs or symptoms attributable to thrombocytosis. It is not 
clear whether plateletpheresis is also indicated as a 
prophylactic measure in the asymptomatic patient and if so, 
at what level of platelet count it is indicated.
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Erythrocytapheresis
The removal of red blood cells from patients with
polycythaemia is easily accomplished using phlebotomy
techniques and there is no advantage in the use of blood
9
cell separator for this purpose . However, exchange
transfusions have been used, but infrequently, in the
10 11
treatment of sickle cell disease * . Indications have
included priapism, unrelenting painful crises, pregnancy 
and preparation for surgery. The rationale is to remove 
erythrocytes containing haemoglobin S and replace them with 
normal red cells containing haemoglobin A. The introduction 
of cell separators has enabled large volume exchanges to be 
undertaken with the possibility of achieving higher 
concentrations of haemoglobin A, generally in excess of 90% 
in a 3-4 hours procedure.
Stem Cell Collection
Mononuclear cell fractions which can be efficiently
collected by all the continuous-and intermittent-flow
centrifugation devices have been shown to contain a
variable number of CFU-GM (myeloid), BFU-E (erythroid) and
12 13megakaryocytic precursors *
It is likely that harvesting peripheral blood stem cells by 
leukapheresis will be evaluated more fully for the 
management of patients with other forms of malignant 
neoplasms even in cases where peripheral blood leukocyte 
counts are normal. Precursor cells as measured by CFU-C 
assay can be collected in quantities that approach the 
' theoretical number required for bone marrow re-population if
five to ten procedures are performed. Furthermore, it has 
been found that after a single plateletpheresis, wherein 
30% of peripheral blood progenitor cells are collected 
concomitantly, there occurs a doubling of both erythroid 
and myeloid precursors in the donor's peripheral blood 
48-72 hours later. Thus cell separator technology may be 
used as an instrument for facilitating autologous marrow 
reconstitution after chemotherapy.
Lymphocytapheresis v
Intensive lymphocytapheresis can result in lymphocyt&penia 
comparable to that achieved by thoracic duct drainage14. 
Lymphocytopenia is due predominantly to a loss of circulating 
T-lymphocytes which in turn can be reflected functionally in 
a decrease of in-vitro response to T-cell mutogens. Repeated 
aphereses are necessary.
Lymphopheresis has been used mainly in the treatment of 
patients with systemic lupus erythematosus and rheumatoid 
arthritis15 1^.
Leukapheresis
Leukocytes are less deformable than red blood cells with
primitive blasts considerably less distensible than mature
myeloid cells. With increasing numbers of blast cells
(100 x 10 /l) in acute and chronic myeloid leukaemia the blood
flow in the micro-circulation can be impeded by plugs of
5
poorly deformable blasts . Local hypoxaemia may be 
exaccerbated by the high metabolic activity of the 
continuously dividing blasts with endothelial damage and
haemorrhage. The situation can be further exaccerbated by
red blood cell transfusions that rapidly increase whole blood
viscosity in the presence of high circulating white cell count,
18thereby further compromising local blood flow .
Although pathological evidence of leukostasis can be found
in most organs in patients with extremely high white cell
counts, clinical symptomatology is usually related to central
19nervous system and pulmonary involvement . Occasionally 
pulmonary symptomatology with worsening hypoxaemia can occur 
with therapy and lysis of entrapped leukaemic cells.
9Should the white cell count reach 100 x 10 /I it may
constitute a medical emergency and the count must be reduced.
Often it takes a period of time for chemotherapy to work and
because of metabolic problems it may well be contraindicated
for 48-72 hours. There are numerous reports of intensive
leukapheresis leading to improvement of pulmonary and
19-21haematological symptoms . However, there may be life- 
threatening side effects. These patients tend to be 
extremely ill with marked pulmonary vascular insufficiency 
characterised by tachycardia, dyspnoea and hypoxia.
Vascular insufficiency can lead to priapism and necrosis of 
the finger tips. Due to central nervous system effects, 
patients may become delirious, stuporose or dizzy. 
Leukapheresis itself may worsen these problems.
Leukapheresis is thought to be of short-term value in the
22
treatment of chronic myeloid leukaemia . It will provide
34
symptomatic relief only and there is no evidence that it will 
increase overall survival. Hyperleukocytosis is rarely a 
problem in chronic lymphatic leukaemia. Leukapheresis may 
produce improvements in spleen size, lymph node size and bone 
marrow infiltration but will not increase haematocrit or
19
platelet count . There is no evidence that intensive
leukapheresis will provide clinical improvement or control of
5
the peripheral blood eosinophil count . There may have been 
a few reports of favourable thereapeutic effects of leukapheresis
in patients with hairy cell leukaemia despite low yields of
, . 6,23,24
hairy cells .
6 Plasmapheresis
In plasmapheresis a limited volume of blood is collected by
venesection and the plasma separated from the red cells by
25-29centrifugation and removed . The red cells are returned 
subsequently to the donor after re-suspension in isotonic 
saline. In plasma exchange however, large volumes of plasma 
may be removed rapidly from the circulation and simultaneously 
replaced with red cells by an equivalent volume of suitable 
substitute fluid. The development of cell separators has 
made large volume exchange possible and allowed the expansion 
of therapeutic applications. As a result, automated plasma 
exchange has been attempted in treating every condition in 
which there is a known or presumed abnormal plasma factor, 
contributing to the aetiology or pathogenesis of that disease .
Originally plasma exchange was thought to be a benign procedure, 
thus encouraging the tremendous growth of interest in its use. 
The increasing need for blood components (plasma, albumin, etc)
35
as replacement fluids provided further impetus directed
towards removal of specific pathogenic substance.
This considerable activity has masked the fact that, in the
vast majority of cases, the efficacy of plasma exchange has
28
not been critically evaluated . This and other considerations, 
such as cost and the recognition that plasma exchange can be 
a potentially dangerous therapy, have finally prompted a 
more careful evaluation of the role, if any, of plasma
exchange in those diseases where proof of efficacy is ’
.... 30 lacking
The terms, plasmapheresis, and plasma exchange tend to be 
used indiscriminately but this present study is concerned 
with plasma exchange.
1.3 Methods of Component Removal
Plasma exchange requires that the removed plasma be replaced.
The use of the patient's own plasma is a more physiologic, less
costly and often more efficient replacement, provided the plasma
31constituents deemed to be harmful can be selectively removed . 
This can be accomplished by physical, chemical, or immunological 
means, in either on-line, or off-line circuits.
1.3.1 Physical Separation of Components
In theory, any physical property of the blood cells can be used 
to permit selective separation and collection of components and 
particularly properties such as density, volume, surface charge, 
adhesiveness and membrane receptors.
36
Cell separation has been achieved by gravitational forces in
32 33
gravity leukapheresis ’ and by filtration in the collection 
of g r a n u l o c y t e s ^ * I n  practice, however, differences in
density provide the most convenient means of separating the
ii i 36-38cellular components
Granulocytes are lighter- than red cells, but are much heavier 
than plasma, lymphocytes and platelets. When granulocytes are 
subjected to centrifugal forces they become concentrated in a 
layer 'inside1 the red cells and 'outside' the plasma, 
lymphocytes and platelets. At low G forces, with sedimenting 
agents the layer can be preferentially removed and the 
granulocytes collected whilst the majority of platelets are 
left free in the plasma. This provides optimal collection of 
granulocytes and adequate, but less than optimal, yields of 
platelets. To obtain sufficient granulocytes a continuous flow 
circuit, broadly analogous to that used in dialysis, is 
necessary. As the G forces are increased, granulocytes are 
replaced by mononuclear cells in the leukocyte-rich interface 
and are extracted with the buffy coat. That increases platelet
39
yield but sacrifices yield of neutrophils .
The donor or patient forms part of a closed loop circuit 
coupled with the centrifugation equipment, wherein the patient's 
total blood volume becomes available for processing, extracting 
or replacing specific cellular constituents of the cellular 
fraction.
The early types of cell separator were cumbersome to use and a
37
number of parts required sterilisation before each operation.
The development of more sophisticated machines with disposable 
items such as bowls, collection bags, ancillary containers, 
tubing etc has greatly facilitated the procedure.
The discovery that granulocytes in the presence of calcium
(heparinised blood) will adhere to scrubbed nylon wool fibres
40led to the development of filtration procedures . The 
granulocytes collected on the fibres can be eluted with citrated 
plasma. WftiXstrmore granulocytes can be harvested (per litre of 
blood processed) by filtration than by centrifugation method, 
the granulocyte concentrates obtained are associated with a
higher incidence of febrile reactions as a result of membrane
41changes caused by the adherence-elution process . Severe
priapism has also been experienced, which required surgical
decompression and whilst a direct cause and effect has not been
established, the same unusual complication has been found in
42patients undergoing renal haemodialysis .
1. Centrifugation Methods
A wide variety of commercial equipments based on either
discontinuous or continuous centrifugation cell separation 
43
is now available . These include:
a) Discontinuous Flow Machines
i) Haemonetics Model 30S, Model V 50
ii) Dideco Progress BT 970
b) Continuous Flow Machines
i) IBM Cell Separator Series 2990, Series 2997.
ii) Fenwal Celltrifuge II, Series CS 3000
38
iii) Dideco Viva BT 790
A) Discontinuous Flow Machines
37In cell separators of the discontinuous flow type , the 
blood components are separated within the bowl and removed 
through a centrally placed channel starting with the 
lightest components, namely the plasma and ending with the 
heaviest, the red cells. At the end of each cycle the bowl 
is temporarily filled with air so that the process is 
essentially discontinuous or intermittent. The apparatus 
is relatively cheap and easy to operate and is particularly 
useful for the collection of platelets and granulocytes as 
required. The donor's fluid balance is disturbed more than 
during continuous flow centrifugation and the volume of 
blood that can be processed in unit time is somewhat less.
Haemonetics Cell Separator V 50
The Haemonetics V50 cell separator consists of a desk type 
console, the lower part of which contains the rotating bowl, 
its motor drive unit and speed control. (Figure 1). The 
upper part of the console carries two peristaltic pumps 
together with the control panel and alpha-numeric display 
unit. Different extracorporeal volumes are accommodated by 
centrifuge bowls of various sizes which are coupled to 
pre-connected sterile disposable sets which provide the 
external fluid pathway. The array of collapsible sterile 
containers complete the assembly with the minimum of set up 
time.
39
M R !
W$&Mmmmm^
iUMvxsrricx
- r,‘-f^:t^ * 1
Figure 1. Haemonetics V50 Cell Separator
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The machine automatically draws anticoagulated whole blood 
which is pumped to the rotating bowl and plasma separation 
begins. As the bowl fills, component bands appear, plasma 
(the lightest component), platelets and white cells are 
sequentially expelled through a centrally located channel 
in the rotating seal. (Figure 2). When the bowl is full 
of red cells (the heaviest component), the centrifuge stops 
and the uncollected components pumped to a container bag for 
for gravity reinfusion. At the end of each cycle, the bowl 
is temporarily filled with air, so that the procedure is 
discontinuous or intermittent. When a preset volume of 
plasma has been collected (as determined by weight) the 
procedure is automatically terminated.
During the procedure the display panels continuously 
indicate the volume of plasma removed, the pump speed, the 
processing cycle and other data. A special programmed 
display up-dates the operator on the states of the 
instruments and prompts the operator through the procedure. 
Flow indicator lights confirm adequate flow. In the event 
of a decrease in flow a monitoring system slows or stops 
the pumps until adequate flow is achieved. The presence of 
air in the circuit is detected ultrasonically. Many 
variables are pre-programmed but the automatic protocols 
can be manually over-ridden at the time.
This instrument collects therapeutic quantities of platelets 
and granulocytes, either simultaneously or separately.
Other products collected include cell-poor plasma and
4i
Anticoagulated blood is pumped 
to the rotating bowl and plasma 
separation begins. As the bowl 
fills, component bands appear. 
Plasma, platelets and white cells 
are sequentially expelled. When 
the bowl is full of red cells, the 
centrifuge stops, and uncollected 
elements are pumped to a bag 
for gravity reinfusion.
Figure 2. Plasma Separation in Rotating Haemonetics Bowl
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lymphocytes. Procedures have been developed for plasma 
exchange, lymphocytapheresis, leukapheresis, 
plateletpheresis and erythrocytapheresis. A single or 
double-venepuncture technique may be used.
B) Continuous Flow Machines
44-46
In continuous flow cell separators , whole blood is 
drawn from a vein in one arm and returned to a vein in the 
other arm of the donor. From the donor the anticoagulated 
blood passes to the centrifuge bowl, or rotor, in the 
machine. As it enters the channel and flows in a clockwise 
direction, parallel to the axis of rotation, towards the 
collection chamber, the blood separates into three principal 
fractions, namely plasma, granulocytes (buffy coat) and 
packed red cells. The interface position between fractions 
and collection are under the direct control of the operator, 
who must vary the extraction rates of packed red cells and 
. plasma to obtain the desired component which is removed 
through the lid of the separator bowl. The packed red 
cells and plasma are then recombined and returned to the 
donor while the buffy coat is fed into a collection bag.
A special seal permits the continuous transfer of whole 
blood from the stationary to rotating portions of the bowl 
and the simultaneous removal of the separated components in 
the reverse direction throughout the procedure.
The centrifugal separation which allows the leukocytes to be
47
collected, can be expressed in terms of a packing factor
P_ defined as 
F
43
pF = Gts
d
Where G = separation acceleration, t = time of separation, 
s = sedimentation rate of blood, and d = distance through 
which sedimentation takes place for the channel used. The 
separation time t is expressed as
Where A = channel area, L = channel length, and Q = mean
flow through the channel.
Thus P_ = G . SF — '
The channel area A, length L and distance d through which
which sediment takes place, are geometrical properties of
the system and are fixed. Sediment (S) is variable and
not directly controllable. Thus the degree of separation
in the single-stage channel can be characterised by the
ratio of separation acceleration G to flow rate 0 through
the channel. If this ratio is held constant, similar
separation should be obtained at different values of G
and 0. Using channels of different geometric design,
9
acceptable yields of 3.0 x 10 cells/litre of blood 
processed were found at a packing factor equivalent to 
580 rpm/40 ml/min flow rate. For the same constant ratio, 
comparable yields would also have been obtained at flow 
rates of 650 rpm/50 ml/min, 720 rpm/60 ml/min and 
820 rpm / 80 ml/min.
The continuous flow cell separator can also be used with a 
single site of vascular access if fitted with a device that 
intermittently reverses the direction of flow through the
t = AL
Q
0
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cannula every few seconds^.
The IBM 2997 Cell Separator
4 4
The IBM 2997 cell separator consists of a desk-type unit 
which carries the centrifuge bowl with its motor drive unit, 
the cOlour-coded peristaltic pumps and control box (Figure 3). 
The latter contains the digital flow rate counters for all 
input and output pumps and a comprehensive system of fault 
detectors which immediately stop the pumps if air is detected 
in the donating, or return tubes or, if they become blocked. 
Simultaneously the operator is warned by both audible and 
visible signals. The rotational speed of the centrifuge bowl 
can be varied by controls located in the desk itself. The 
equipment is completed by sets of appropriate tubing, delivery 
containers, collection bags and circular separation channel 
which fits into the centrifuge bowl. All the tubing and the 
separation channel itself is sterile pyrogen-free and 
disposable. It is supplied in two packs with one sample 
sterile connector, needing only to be placed in position and 
run through the colour-coded, peristaltic, collection pumps.
The essential components and tubing circuits are shown in 
Figure 4.
Blood is drawn through a central rotating seal (Figure 5a) into 
the separation channel at one side of a sealed bulkhead and 
flows around it as the centrifuge rotates. By the time the 
blood arrives at the collection chamber on the other side Of 
the bulkhead, it has been separated by centrifugal action into 
red blood cells on the outside, plasma on the inside, and the
45 .
Figure 3. IBM Type 2997 Cell Separator
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buffy coat of platelets and white cells in between. Three 
tubes run radially from the collection chamber through their 
individual channels in the rotating ceramic seal and out 
through the peristaltic pumps to the point at which the blood 
components are recombined. One tube, which penetrates almost 
to the outside of the collection chamber, is the exit port 
for the packed cells (Figure 5 b). Another tube, penetrating 
roughly half way up is the white cell port. This and the 
interface positioning (third) port are radially located to be 
on the centre-line of the channel. They are separated from 
each other by a barrier that extends from the top to the 
bottom of the chamber. Plasma can pass around the barrier 
along the inner wall and the red cells flow around the barrier 
along the centre wall of the chamber. Downstream from the 
barrier the red blood cells and plasma are recombined and 
extracted by the third port. Alterations in the pumping rate 
of the pump that controls the extraction from the third exit 
port will adjust the radial position of the red cell/plasma 
interface. The adjustment of the interface position relative 
to the fixed tube port by varying the pumping rates allows the 
white cell port to draw off from the buffy coat, either a 
mixture rich in platelets or rich in white cells.The continuous 
centrifuge technique allows a steady extra-corporeal blood 
averaging only 280 ml total volume to be maintained and permits 
donors and patients to be balanced under safe equilibrium 
conditions. A relatively low amount of anticoagulant is used, 
the ratio of which relative to the replacement fluid, can be 
raised. Clear LED display of the actual ratio allows positive 
and uniquely sensitive control of this potentially hazardous 
element.
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The machine is accurate enough to deliver white cell 
concentrates, preferentially rich in lymphocytes or 
granulocytes. Not only can undesirable plasma or unwanted 
blood cells be removed, but concentrates of platelets or 
granulocytes can be collected for therapeutic infusion. 
Similarly lymphocytes can be collected for immunological 
studies or the production of the transfer factor.
Typical procedures possible on the IBM 2997 blood cell 
separator and data on performance are given in Tables 3 and 
4. New procedures may be easily developed to meet specific 
situations. The equipment is already being used routinely 
in combination with a number of different affinity 
chromatography columns for plasma modification as an 
alternative to plasma exchange.
TABLE 3
Some of the Protocols Possible on the IBM 2997 Blood Cell Separator
Exchanges
Plasma Exchange (Platelet Poor) 
Plasma/Red Cell Exchange 
>Red Cell/Red Cell Exphange
Red Cell/Plasma Exchange 
Plasma Modification 
(using affinity 
chromatography columns)
Depletions •
Platelets
Lymphocytes (Including
simultaneous Plasma Exchange)
Granulocytes
Red Cells (Including old 
cells)
Harvest
Plasma (from high titre donors) 
Platelets (Including Leukocyte and 
Red Cell poor)
Lymphocytes/Monocytes
Granulocytes 
Red Cells (Including 
Neocytes, young cells)
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TABLE 4
Performance Data for IBM 2997 Blood Cell Separator
Plasma Exchange
Volume Exchanged 
Procedure Time
RBC Exchange
Volume of Packed Red Cells 
Procedure Time
Cytapheresis - Leukocytes
Patients - children (5 years, 44 lb)
Post WBC counts decreased average of 54.7%
Granulocyte Collection
13.9 x 109 
138 minutes
19.3 - 31.8 x 109 
138 - 168 minutes
Granulocyte Platelet Collection
Granulocyte Yield 
Platelet Yield 
Procedure Time
Lymphocyte Collection
Lymphocyte Yield 
Procedure Time
Platelet Collection
Dual Stage (Leuko-RBC Poor)
Platelet Yield 
WBC
Haematocrit 
Procedure Time 
Bleeding Time
Single Stage
4.3 - 6.6 x 10*
3.2 - 7.0 x 10 
1.0 - 2.0 %
90 - 130 minutes
9.3 days
Platelet Yield 
WBC
Haematocrit (%) 
Procedure Time 
51
Cr Life Span
4.8 x 10 *
0.31 x 109 
Not measurable 
90 minutes 
Corrected
11.0 x 109
150 - 180 minutes
24.1 x 109 
3.8 x 10 
126 minutes
Non-stimulated donors
PMN Yield 
Procedure Time
Stimulated donors
PMN Yield 
Procedure Time
6 - 8  units 
90 minutes
2.6 - 4.0 litres 
62 - 120 minutes
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Celltrifuge II Cell Separator
The rotating seal is a potential source of trouble and a con­
tinuous flow cell separator has been produced in which the 
rotating seal has been replaced by a loop of tubes twirling like
a skipping rope in the opposite direction to the rotation of the
49centrifuge and which is based on work on a flow through 
centrifuge.
Other Developments
The increasing clinical demand for fresh plasma and platelet 
concentrates cannot always be met from conventionally collected 
whole blood donations. The first generation cell separator 
equipments yield products heavily contaminated with leukocytes 
and whilst concentrates may be collected with 0 ’haematocrit* 
there is still some red cell contamination. Further equipment 
development has permitted the harvesting of platelet concen­
trates from single donors with maximal yield and minimum white
50 51
blood cell contamination ’ .
In the Haemonetics V50 cell separator this is achieved by
incorporating a surge pump. Once the buffy coat shows optimal
separation during the first cycle, autologous plasma is
reinjected at high speed into the spinnning centrifuge bowl and
the platelets are separated from the white blood cells and the
red blood cells. The optimal buffy coat position depends on
the haematocrit, plasma viscosity, draw speed and platelet
shape, consequently the procedure was neither automatic nor
reproducible. New platelet programmes have been developed to
51
overcome these difficulties .
Similarly, in the IBM type 2997 cell separator, a dual stage 
channel has been incorporated which combines a two-step
52
centrifugation procedure into a continuous method to collect
platelet concentrates which are virtually free of leukocyte
52and red blood cell contamination
Haemonetics V50 Cell Separation with Surge Pump 
The Haemonetics V50 Cell Separator is connected up as shown in 
Figure 6. Blood is drawn from the donor, mixed with anti­
coagulant and is pumped at 55 to 65 ml/min. into the centrifuge 
bowl spinning at 4800 rpm, where it is separated into plasma 
components. When the buffy coat reaches the shoulder of the 
bowl (i.e. about 1.5 cm from the top) it is optically detected.
The filling of the bowl with whole blood from the donor is
automatically stopped and the surge pump is activated. The 
plasma accumulated in the plasma air bag during the 
centrifugation is reinjected back into the centrifuge bowl at
high speed 200 ml/min. This results in resolution of the
platelets from white blood and red blood cells (the surging 
effect). The valve to the collection bag then opens to collect 
the surged platelets. As soon as the platelet band disappears 
the surge stops before red blood cells are removed. Three main 
interdependent operating variables control the surge procedure 
and determine the quality of the final platelet product; namely, 
the volume off-set which determines the point where the surge of 
plasma from the air/plasma bag begins, the collect delay volume, 
which is that occupied during the time interval from the 
initiation of the surge to the opening of the collection bag for 
platelets and the platelet/white cell factor, . which determines 
the end point of the surge. Whilst there are recommended 
settings, optimal values are usually established by trial.
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54
The automated cell separator has also been used for the combined 
procurement of platelet-poor plasma and platelet concentrate, 
the two products being obtained from the one collection harness
without compromising the yield of factor VIII in platelet-poor
, 53,54plasma
IBM Type 2997 Cell Separator with Dual Stage Channel 
The dual-stage channel consists of an extruded semi-rigid 
plastic tube of rectangular cross-section, 25 mm x 6 mm, which 
has a transitional area about one-third of the way down its 
length where it measures 30 mm x 1.5 mm (Figure 7). This tube 
is attached at both ends to the input/collection chamber and 
forms a closed loop. The larger cross-section area portion of 
the tube is formed in a circular arc. The transition region 
curves inward so that the thin portion of the channel can form 
a spiral. Four tubes from the face seal assembly attached to 
the chamber,provide passages for whole blood, packed red cells, 
platelet-poor plasma, and platelet concentrate. The chamber is 
shaped so that two separated regions of radial extent are formed. 
The shorter region contains the input port and the packed red 
cell port which are at the inner and outer radial extremes of 
the chamber respectively. The longer region, which also has 
ports at both radial extremes allows collection of platelet-poor 
plasma from the inside port and platelet concentrate from the 
outside port.
The channel assembly is mounted in the centrifuge with the axis 
of rotation in the centre of the loop. It is supported by the 
centrifuge assembly containing a removable plastic insert. The
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channel is spun at 2400 rpm, and experiences internal pressures 
of up to 7 bar. The centrifugal acceleration experienced by 
the blood components is in the range of 530 to 1000 G. The 
channel volume is 70 ml.
Anticoagulated blood is drawn into the channel by initiating 
flow with the plasma pump. As the channel fills with blood, the 
plasma port extracts saline first, then mixture of saline plus 
plasma, and finally plasma alone. Red cells accumulate in the 
first stage of the channel and are extracted through the red 
cell port when the interface nears the inside channel wall in 
the transition zone. The relative flow rates of the plasma and 
red cells are a function of donor haematocrit. The total blood 
flow rate through the channel is predetermined by donor blood 
volume estimates and relate to expected ionized calcium 
depletion from the ACD-A anticoagulant used in processing.
Platelet rich plasma enters the spiral stage of the channel, 
platelets are concentrated along the outer wall of the channel, 
and are extracted into a sterile transfer bag through the 
collect line. As in all continuous flow systems, the remaining 
donor red cells, leukocytes, plasma and platelets are 
continuously recombined and returned to the donor.
Two factors, ACD-A flow rate (calcium binding) and AC:WB 
dilution (appropriate pH) determine the processing rate per 
minute, the procedure time and therefore the total blood 
processed.
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Membrane Filtration Methods
In recent years membrane filtration has been increasingly used
55-57
in apheresis procedures . Plasmapheresis or plasma 
separation involves the use of filters which produce a plasma 
filtrate from whole blood. Plasma fractionation involves the 
use of a second and tighter filter (i.e. cascade filtration) 
which yields a globulin-depleted solution of albumin for return 
to the patient and a globulin-rich retinate.
Equipments and filtration systems now available include:
Fenwal PS 400
58
Cobe Centry TPE System
59
Dideco Filtra BT 810 , Separa BT 796 .
Organon Teknika Curesis
AGB Semca Media Micro labo 85
Kuraray System KM 8500
Plasauto 1000
NIPR0 DP-1
60
Also Hemascience Autopheresis C in which 
filtration is combined with centrifugation.
Principle of Operation
The various equipments are similar in function but differ in the 
general layout of the pumps, disposable circuit tubing and 
containers, pressure sensors, flow sensors, electronic control/ 
programming for various operating procedures, safety devices and 
the use of either single or double-vascular sites.
In all equipments, blood is removed from the donor, citrated,
58
pumped through a membrane filtration unit and returned to the 
donor. The plasma and red cells are separated in the filtration 
chamber as dictated by the operating characteristics of the 
filter.
Dideco Filtra BT 810
The equipment consists of a single, compact, L-shaped console 
which can be placed on a table (Figure 8). The flat-topped 
horizontal module contains the three pumps, whilst the vertical 
module contains the electrical control equipment, measuring 
instruments, stands for the disposable circuitry/container bags 
and for the vertical mounting of the filter. The filter 
contains hollow propylene fibres of 0.5 jam mean bore size 
having an active surface of 0.1 m2 , 160 mm total length, steam 
sterilized and without surfactant addition. Using a single 
needle system, blood is drawn from the donor's vein and after 
the addition of an antocoagulant, is delivered by the draw 
pump to the filter while the reinfusion pump is stopped (Figure 
9). This produces a pressure increase in the filter. When 
the pressure reaches a maximum value pre-set by the operator, 
the draw pump is automatically stopped and the reinfusion pump 
is started. The blood is returned to the donor through the 
same needle and this produces a pressure decrease in the filter. 
When a value, pre-set by the operator is reached, reinfusion 
automatically stops and a new draw phase begins. Thus, the 
donor blood flow is discontinuous whilst the flow through the 
filter is continuous. The flow rate of the filtered plasma is 
about 12-17 ml/min. and is dependent on the blood flow rate, 
hematocrit and blood lipid content. The extra-corporeal blood
59
Figure 8. Dideco Filtra BT 810 Cell Separator
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volume is about 70 ml, whilst the amount of blood processed 
during a draw/reinfusion cycle is 12-15 ml. A vein sensor on 
the draw line automatically stops the pumps when donor blood 
flow is inadequate.
A deep, chamber-level, sensor and a bubble detector in the 
reinfusion line prevents infusion of air to the donor. 500 ml 
plasma is collected per procedure, in about 40 min with an 
average blood flow of 55 to 60 ml/min. Approximately 160 ml 
of anticoagulant is used per procedure, about half of which is 
collected with the filtrate.
Factors in the Filtration Procedure
The effectiveness of the equipment and procedure depends on the
capacity of the filter to remove defined substances from the
blood. Unfortunately, there is no standardized method of
valuating capacity, nor are there precise definitions of
SI
various test parameters used . Performance has been assessed
on a number of criteria which make comparative valuations very
difficult. Thus, coagulation and fibrinolysis parameters have
been used to assess plasma protein removal and coagulation
and fibrinolysis activation. Platelet number and granule
content have been used to study platelet loss and platelet
activation. The sieving coefficient of membranes has been
62evaluated by studying von Willebrand factor multipliers
The operating characteristics of a filter depend on the membrane
material, its geometric form and physical arrangement, on the
63
rate of blood flow and on the transmembrane pressure . The
62
filter systems are of two kinds, one employing a flat bed 
58
filter , the geometry of which may be varied and one employing
64 65fixed geometrical arrangements of hollow fibres *
Scouring efficacy and platelet loss of both types of filters
appear to be similar but platelet activation is less for the
62
flat bed filter than the capillary filter . The physical
arrangement of membrane material and the conditions under
which it operates does influence the degree of blood trauma
63and the level of plasma extraction
The filtration rate in plasmapheresis is not a linear function
of filter area and applied transmembrane pressure and cannot
be uniquely evaluated (i.e. a fixed value of permeability).s
Filtration rate initially increases with applied transmembrane
pressure up to a plateau value beyond which no further increase
in rate occurs. Filtration rate also increases with blood
flow rate in a complex manner. At the plateau level of
transmembrane pressure a maximum value of filtration rate
could be ascribed for a given blood flow rate but unfortunately
this value decreases during the course of a plasma filtration 
61
procedure .
The contact surface between blood and membrane can result in
63haematological and biochemical changes . Material from the
blood may be deposited on the membrane surface as a
consequence of net passage of filtrate and this reduces the
overall membrane permeability (i.e. a progressive plugging of
66
the membrane occurs) . Material deposition is particularly 
influenced by the composition of the membrane material and to
63
a.lesser extent by the membrane geometry, flow rate and
63
transmembrane pressure . Further membrane material greatly
influences complement activation; significant activation of
the anaphylatoxins C3a and C5a is found with cellulose
diacetate membranes but not with polycarbonate membrane which
correlates with a drop followed by an overshoot of both
leukocytes and lymphocytes. Both membranes generate significant
amounts of anaphylatoxins in the filtrates, reflecting high
67
intermembrane activation .
The progressive loss of filter efficiency during the procedure
can be countered by increasing the transmembrane pressure, but
in a whole plasma volume exchange the pressure, would rise
beyond practical limits and the procedure would have to be 
66
terminated . Further, membrane plasma separation may be
limited by the onset of hemolysis which is generally associated
68
with a high mean transmembrane pressure . However, very high 
transmembrane pressures can be used without hemolysis if 
applied for only a short time, as with pulsatile blood flows at 
frequency of 2 Hz, and this can increase the filtration rate by 
30 to 50%. Increasing transmembrane pressure leads to a greater 
deposition of material on the membrane. Membrane plugging can 
be prevented by wetting the membrane surface with a surfactant 
but this raises ethical issues*^.
The selective removal of pathologic macromolecules with cascade 
membrane (double-filtration) systems is primarily dependent on 
the transport characteristics of the second filter which will
69be exposed to increasing protein concentrations during treatments
64
The plasma filtrate in the re-circulation circuit will contain
various substances, depending on the patient's disorder, that
can interact directly with the membrane and this makes
prediction of membrane performance more difficult. Assessments
based on sieving coefficients of the cascade filter or on
direct analysis of the retentate are open to doubt . The
former are misleading because the separations are highly
irreversible and the latter is unreliable because non-permeable
proteins are often aggregated, de-natured or bound to membranes.
Indirect methods have been used to measure the removal of known
marker molecules, (e.g. albumin, IgG, IgM and B-lipoprotein).
The need for substitution fluids is greatly reduced with
cascade filtration compared with plasmapheresis but the removal
71of IgG and IgM is less efficient . The amount of C3a and
C5a returned to the patient is significantly higher with
67cascade as opposed to single filtration procedures .
The high cost of plasma filters is a limiting factor in their
use for plasma exchange and the possibility of reusing filters
is economically attractive. Filters have been used at
monoclonal gammapathies of the IgA and IgM types up to four
times provided adequate rinsing is undertaken after each 
72
application .
1.3.2 Chemical Separation of Components
The plasma constituents can be removed by perfusion of whole
73-75blood (haemoperfusion) or plasmaperfusion . Alternately 
some constituents of plasma or whole blood can be precipitated
65
or absorbed from blood or plasma which is subsequently transfused 
back to the patient.
Haemoperfusion
Haemoperfusion involves the direct passage of anticoagulated 
blood over activated charcoal. Its role has been limited 
because of potentially life-threatening thrombocytopenia and 
charcoal embolisation.
Plasma Perfusion
Plasma is separated from the formed elements of blood by
centrifugation or filtration, and then pumped over an affinity
column or a filter with an immobilised sorbent. The effluent
of column or filter is re-constituted with the formed elements
of blood and returned to the patient after passage through a
blood filter. Thrombocytopenia is avoided and sorbents can be
used that need not be bio-compatible with the formed elements
of blood. The bio-compatibility of the column is improved
when plasma only is passed through the column and the by-passed
cellular elements are returned directly to the patient. This
removes the problem of platelet depletion and it allows a wider
70choice of type and concentration of anticoagulant . It permits 
the use of smaller bead packing and adisorption is therefore
i
faster and more efficient. The patient's own plasma is 
returned without the need for artificial plasma expanders or 
plasma products. This eliminates one of the major hazards of 
apheresis and should reduce the cost of the procedure.
66
Column Technology
73The technique is based on the disposable (orreusable) column . 
It includes the container, its sterile packing, connectors and 
associated reusable apparatus. The latter is based on 
haemodialysis and haemoperfusion machines with added 
anticoagulant pumps, temperature controls, flow reversal and 
regeneration mechanisms, pH and optical detectors.
A volume of 300 ml is used to avoid excessive haemodilution, 
plasma proteinsjthe red cells are returned directly to the 
patient. The plasma flow rate of 60 ml/min is based on an 
assumed maximum venous blood flow of 100 ml/min and a maximum 
procedure time of 3-6 hours for treatment of patients or 1-2 
hours for donors. Because of the limited performance of 
peristaltic pumps a maximum back pressure of 0.7 bar is 
specified, but ideally the pressure is less than this. The 
absence of most cellular elements allows a wider choice of 
pressure and shear than is the case with blood perfusion with 
rigid packing materials. Typically, spherical beads of 50 jim 
diameter are used with a plasma flow of 50 ml/min, a back 
pressure of 0.7 bar, a temperature of 37° C (which almost 
halves the viscosity of plasma compared with that at 15° C), 
and a packing geometry 6 cm diameter and 6 cm high. Semi-rigid 
beads are generally larger, around 70 jum diamter whilst the 
lower limit of particle size for gels is 150 pm diameter. The 
smallest size of bead is chosen in the interest of efficiency, 
speed, capacity and cost.
Because of the clogging effect of even small amounts of
67
platelets which are inevitably left in the plasma (typically 
9
2 x 10 /l), the back pressure will increase with time of 
perfusion and the longer treatment sessions could become 
painful. Thus, it is desirable that 99% of the beads should 
be within the range 40-60 jim. Because of the dilution of the 
returned plasma the reduction in any particular component 
follows an exponential law so that treatment times of 2,4, and 
6 hours could, at best, produce final concentrations of 30, 10 
and 3% of starting levels. Column adsorption efficiencies of 
80% and extra-vascular pools will significantly reduce such 
performance.
More recent treatments differ from charcoal haemoperfusion on 
renal dialysis in that the molecular size of the material to 
be removed is many orders of magnitude greater. Since 
adsorptive capacity is dependent on total surface area whose 
capacity for protein is typically 1-5 mg/m2 , several hundred 
square metres are needed to remove mg/g of substance. Both 
static (steric hindrance) and dynamic (non-equilibrium with 
flow) factors reduce the efficiency of any given absorbent 
and the reduction in potential adsorptive capacity can be 
alleviated by using tandem columns operated alternately with 
regeneration of the resting column. This approach is limited 
and it is more effective to ensure that the surface area and 
the porosity are sufficient for species to be removed.
The properties of the column are such that a space twice the 
size of a molecule allows access to, on average, only 5% of 
absorptive area. It is not until the cavity is 10-20 times
68
larger than the molecule that efficiency of access reaches 
80-90%. Thus immunoglobulins and Ag/Ab complexes which may 
readily exceed 10 nm in stokes radius (functional radius in 
solution) would need cavities of around 400 nm diameter for 
90% efficiency of access. Larger species such as very low 
density lipoprotein (30 nm radius) and viruses (50-100 nm 
radius) would need cavities of around 1200-4000 nm diameter.
These molecular dimensions are also approached by asymmetric 
molecules in solution such as DNA and Factor VIII so that 
large cavities are likely to be a common requirement for both 
therapeutic and procurement procedures.
The surfaces exposed to plasma and the ligands (or affinity 
reagents) immobilised thereon should not initiate coagulation, 
or excessive aggregation of platelets, or of other cells, such 
that flow ceases, or capacity within beads is severely reduced. 
The correct choice of solid phase chemistry and anticoagulant 
should minimise this problem. Where solid phases are not 
inherently non-thrombogenic (and considering the relatively 
short treatment time compared to, for example indwelling 
prostheses) this is unlikely to be a major problem. When a 
surface coating needs to be applied to improve bio-compatibility, 
coating procedures that are satisfactory for charcoal 
haemoperfusion are unlikely to work with these larger molecules. 
The pores in cellulose nitrate, cellulose acetate and 
polyhydroxyethylmethacrylate coatings are approximately 3 nm 
and are inadequate to permit free access of larger molecules.
Thus coatings should be grafted onto skeletal molecular 
structure of the bead prior to subsequent grafting of the
69
affinity ligand
The particulate material may be shed during manufacture,
transport and use. This can be serious with rigid bead
materials like charcoal, silica or other metalic oxides because
it impairs column performance by reducing flow and embolism
can occur in the patient's vasculature causing long-term
toxicity. This may be alleviated by careful handling and
washing during manufacture and by the choice of spherical
particles and smooth surfaces (reducing fragmentation sites).
A number of groups have successfully used agarose as a bio-
78compatible macroporous coating . The leakage of soluble 
material from beads, coatings and ligands is a possibility 
that has to be considered.
Only a limited number of substances mak& useful beads which
have adequate pore size, internal surface area and strength.
These include the natural polymers agarose and cellulose and
synthetic and semi-synthetic polymers such as
polyhydroxyethylmethacrylate, allyl-dextran and poly-vinyl
alcohol. Silica has found widespread application in beaded
form as a porous solid phase because of its ease of fabrication,
manipulation of pore size and strength. It is biocompatible
with plasma only if coated. Alumina can be used for phosphate
79removal, zirconia for oxalate/glyoxalate removal and ion 
exchange resin for bilirubin removal.
It is difficult to produce affinity ligands with multiple 
purpose applications. Monoclonal antibodies are limited to a
70
single epitope and unless this is widely distributed, they will 
always suffer from limited areas of application.
Group specific ligands such as heparin, being both non- 
immunogenic and having several specificities of binding have 
had some success. Both synthetic and semi-synthetic polymers 
and dyestuffs can be expected to have 'accidental' group 
specific binding effects. They are also attractive being 
non-immunogenic and low in cost compared to proteins. Polymers 
such as gelatin and collagen can be useful for binding 
fibronectin and coagulation FVIII.
Specific antibodies can be removed by immobilising the
appropriate antigen (where this is known). Methods of Ab
removal include lectins such as concavlin A, which has been
80
used to remove IgM, IgA, IgD and IgE myeloma proteins and 
the bacterial cell-wall protein A from Staphylococculus Aureus 
which displays specificity for the Fc region of many mammalian 
IgG molecules and may be useful as a universal affinity system 
for procurement of IgG antibodies from immunised volunteer 
donors.
Enzymes may also be immobilised and used, though few 
biochemical applications have been reported.
The largest number of applications involve protein.A which not
only has the useful property of removing IgG subclasses 1,2
and 4 but can also reactivate a suppressed immune system either
81
by removing blocking Ab or by stimulating the cellular system
71
The treatment of colonic cancer and the effects on the immune
system of adsorption on Staphylococculus Aureus ex—vivo have
been described. Canine mammary adenocarcinoma has been treated
and a system is being developed for treating human patients in
82
an off-line system . A direct immobilised Fab antibody 
technique for the treatment of a patient with hypernephroma 
has been described. The application of protein A is not 
limited to soluble immunoglobulins for cells bearing IgG on 
their surface may be adsorbed provided the size of beads in the 
column is increased to 300 jjlm to allow free passage of cells 
through the interstices.
The use of totally synthetic blood group antigens A and B for
removal of AB prior to marrow transplantation has been 
83
described . These commercially available adsorbents were 
rendered biocompatible by cellulose citrate/albumin coating.
There has been much interest in the removal of cholesterol 
and/or low density lipoprotein for the treatment of 
hyperlipoproteinaemia. Heparin agarose has been used, also 
a sheep polyclonal to apolipoprotein B, and a combination of
W x-U84 .both
Plasma perfusion over charcoal has been tried for the removal 
of bile acids in the treatment of systemic lupus erythematosus. 
Inhibitors to Factor IX have been removed prior to surgery by 
using protein A - sepharose.
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1.3,3 Other Procedures
Several schemes to recycle the plasma in a closed loop circuit
have been proposed and are in various stages of development and
85^87application. Cascade filtration systems have been examined ,
but the selective removal of macromolecules from blood can only
partially be achieved. Currently available second filters do
not give optimal selectively between albumin recovery and
macromolecule removal. Whilst existing systems are clinically
acceptable and cheaper than plasma filtration, further
71refinement of cascade filtration is necessary .
88
Electroplasmapheresis combines a flow membrane separation 
and fluid phase electrophoreses. Plasma is separated into 
two fractions; the bottom fraction contains 80% albumin input 
and is returned to the patient with a sterile electrolyte 
solution. The top fraction contains 70% gamma globulin and is 
discarded.
Cryoglobulins precipitate readily at freezing and subfreezing
temperatures to form a dense floccular material that can be
89
removed by filtration, sedimentation or centrifugation
Cryoglobulin-poor plasma can be frozen and stored for subsequent
autologous use after an initial plasma exchange in which
conventional replacement is used. This procedure results in
90
substantial savings for the patients thus treated . When 
heparin, dextran and magnesium chloride are added to heparinized, 
hyperlipoproteinemic plasma, a visible lipoprotein precipitate 
develops rapidly. The precipitate, containing 97% of the
73
original content of Low Density Lipoprotein and Very Low
Density Lipoprotein can be removed totally by centrifugation
or filtration to produce a lipoprotein-depleted plasma. Zinc
diglycinate specifically precipitates immunoglobulins (92.4% of
IgG, 44.4% of IgA and 25% of IgM) from plasma, which are then
7 4
readily removed by centrifugation . It also precipitates 
immune complexes and anti-acetylcholine receptor antibodies.
The precipitate however does not contain albumin, haptoglobin, 
complement or coagulation factors VIII and X or prothrombin.
The residual zinc must be reduced to non-toxic levels from 
treated plasma by dialysis or exchange resins.
Macromolecules have been separated by cryogelation and
filtration from plasma previously separated by filtration from
91
the formed elements of blood . A membrane filter, with a 
molecular cut-off of about 100,000 daltonst'permits the passage 
of albumin but excludes gammaglobulins. The effluent of the 
cryoprecipitation circuit and macromolecule filter is 
reconstituted with the mainstream blood flow before it is 
returned to the patient. This system is capable of 
substantially reducing circulating immune complexes. It also 
appears to be simple and safe, but expensive and there are 
high non-specific losses of all plasma c6mponents. Red cell 
antibodies have been removed from maternal plasma of patients 
undergoing plasma exchange for treatment of haemolytic disease 
of the newborn and the absorbed plasma used for autologous 
replacement of subsequent exchanges. An anti-M antibody was 
greatly reduced in titre by incubation of the plasma with M- 
positive red cells; plasma thus treated was then reinfused
74
back to the patient . Anti-D and Anti-C antibody levels have 
been reduced substantially by absorbing plasma containing the 
antibodies with red cells that possess the corresponding 
antigens. The absorbed autologous plasma was reinfused back 
to the patient. The recipient, unlike the patient with Anti-M, 
had a dramatic and unexpected rise of antibody levels, 
suggesting that she may have received Rh-positive material with 
the absorbed plasma".
No procedure proposed for closed loop plasmapheresis
(cryofiltration, cascade filtration, fractional precipitation,
electrophoresis, selective adsorption) is capable of complete 
70
separation • Some useful proteins will always be lost and 
some toxins will always be returned to the patient.
1.3.4 Comparison of Centrifugation and Filtration Procedures
There are a number of possible criteria on which an assessment 
of the advantages and disadvantages of various equipments and 
procedures may be based. These include safety of separation, 
initial equipment and procedural costs, the complexity of and 
the time for setting up a procedure, the efficiency of equipment 
and procedure,, the type of vascular access required (i.e. one 
or two sites), the reliability of equipment and associated 
disposable ancillaries, the maintenance of plasma volume, 
especially in sick people, etc. In practice, comparisons of 
procedures are made on the basis of one or a limited number of 
criteria.
75
Alternatively, the equipments and procedures may be used in 
studies which permit a comparison of their performance in 
essentially similar applications, as in the production of 
leukocyte concentrates, in the collection of platelets and in 
therapeutic treatment of a range of disorders.
Considerable data now exist on the comparative performances, 
in similar procedures, of various centrifugation equipments, 
e.g.! Haemonetics Model 30, Bellco Progress (intermittent 
flow) versus IBM Type 2997 and Fenwal CS 3000 (continuous flow)
94
in the production of leukocytes ; Dideco Vivacell, versus
46
IBM Type 2997, versus Fenwal CS 3000 in plateletpheresis ;
Haemonetics V50 with surge pump, versus Fenwal CS 3000, versus
manual Fenwal quadruple triple-blood packs for the collection
95
of platelet and granulocyte concentrates ; Haemonetics 30,
versus Haemonetics V50 with surge pump, versus Fenwal CS 3000,
versus IBM 2997 Single Channel, versus IBM 2997 Dual Channel
96
in plateletpheresis ; of filtration systems, e.g.) C0BE
(PVC membrane), versus Organon Teknika (polypropylene membrane),
97versus Kuraray (PVA membrane) in plasmapheresis ; Plasauto
1000 using a single filter cascade filter, versus Plasauto
1000 using a single filter, versus Dialysetichnik with single
71
filter m  plasmapheresis ; and of centrifugation and
filtration equipments, e.g. Haemonetics V50, versus Dideco
98
Filtra BT 810 in plasmapheresis ; Haemonetics PCS, versus
Dideco Filtra (Hemaplex), versus Organon Teknika (Plasmapur),
99
versus Hemascience (Autopheresis-C) in plasmapheresis ;
Organon Teknika Curesis, versus Fenwal CPS 10, versus IBM Type 
2997, versus Haemonetics V50 in plasmapheresis^^.
76
Typical data obtained in such studies are shown in Tables 5 and 
6. No overall comparison of all equipments and procedures 
mentioned is possible because data were collected under 
different operating conditions. All systems were safe and 
relatively efficient. All procedures were well tolerated by 
donors, some were more prone to adverse technical incidents 
than others.
Theoretical modelling has also been suggested as a basis for 
comparison of equipments but clearly conclusions drawn will be 
dependent on the validity of the selected model^^^""^^.
1.4 Plasma Exchange - Practical Considerations
Codes of practice for the clinical use of cell separators
and the automated plasmaphereses of volunteer donors have been
issued by the Department of Health and Social Security. These
documents, however, say little about therapeutic plasma
exchange'*^ 106^ general, patients are accepted for a trial
of plasma exchange only when more conventional therapy has been
instituted and has failed and when the procedure is judged to
be beneficial for the patient. A typical plasma exchange
procedure necessitates the patient to be supported on a bed
107inclined at 30° to facilitate the circulation . Procedures 
are carried out by an experienced medical staff with the help 
of a technician.
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1.4.1. Vascular Access
Problems with vascular access have been common in the 
management of patients with chronic renal failure by 
haemodialysis. This experience can be applied to plasma 
exchange which requires lower blood flow rates than those used 
in dialysis. Whilst venepuncture of antecubital veins are 
adequate in many patients, alternative techniques are 
available'*^.
1. Antecubital Venepuncture
This is the method selected for most patients managed by
intermittent therapy, i.e., patients with mixed
109cryoglobulinaemia or cutaneous vasculitis . When more 
intensive exchange is needed as in cases of Goodpasture's
Syndrome, arm veins are not always adequate^^.
The antecubital fossae are cannulated with approximately 16 
gauge needles. Flow rates of 60-80 ml/min. can often be 
achieved, but when necessary the procedure can be performed 
with lower flows of 20-40 ml/min. Approximately 66% of patients 
are cannulated via antecubital veins. Of these some 10% will 
require other forms of access. In cases of severe systemic
disease other forms of access will be used.
2. Femoral Vein Catheterisation
This method of vascular access was widely used for 
haemodialysis^'1'1,112, especially in cases of acute renal 
failure. It Is particularly suitable for patients requiring
81
prolonged intensive plasma, e.g., those with Goodpasture's 
Syndrome, who require daily exchanges for more than two weeks.
It has now been largely superseded by arteriovenous fistulas.
Flow rates in excess of 100 ml/min. can be achieved and with
continuous flow centrifugal system an automatic alternating
47
flow device can be used , which allows rapid exchange with 
minimal recirculation. Membrane plasma filtration can also 
be operated using a single femoral vein catheter and automated
113
alternating flow, as has been described for subclavian cannulae 
With membrane filtration a dual lumen catheter has been used.
Flow rates of up to 70 mm/min can be achieved.
Extremely low incidence of complications have been experienced 
with femoral catheters. There have been well documented 
episodes of clinical infection, venous thrombosis, external 
haemorrhage and retroperitoneal haemorrhage. This contrasts
114
with a high incidence of infection at arteriovenous shunt sites , 
which proved a major problem in immunosuppressed patients.
3. Subclavian Vein Catheterisation
The catheterisation of the subclavian vein may be used in
115
patients with unsuitable femoral vessels . Subclavian 
catheters are used rarely because of the greater risk of
XX6
complications including pneumothorax and cardiac arrhythmias 
Cardiac complications may be related to the use of citrate as 
an anticoagulant with the subsequent risk of hypocalcaemia.
The catheter is situated however in a more hygenic site and 
obviously allows the patient greater mobility.
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4. Arteriovenous Shunts
The use of surgically implanted shunts for vascular access was
117a major advance in haemodialysis, although a recent review
shows that infection and thrombosis remain considerable
problems. The method was accompanied by an unacceptable
incidence of infection at the shunt site. Many patients were
on immunosuppressive drugs rendering them more susceptible to
infection, and such infections led to an increase in disease
118
activity in both Goodpasture's Syndrome and Wegener's 
Granulomatosi s ^ ^ .
5. Arteriovenous Fistulae
Surgically created subcutaneous fistulae are the method of
choice of vascular access in chronic haemodialysis. The radio-
cephalic fistula is most commonly used but many variations have 
120
been described . The long-term survival of these fistulae
makes them suitable for some patients whose underlying disease
predisposes them to complications including thrombosis and
gangrene of the hand, e.g., those diseases in which vasculitis
or severe Raynaud's phenomena are major features, namely SLE 
121
and scleroderma
A wide range of arteriovenous grafts, both biological and
synthetic are available for patients in whom all other vascular 
122
access has failed . A patient who has had multiple operations 
for access over six years currently receives intermittent 
plasma exchange via a femoro-popli.teal Dacron graft.
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6. Complications of Access
The commonest cause of fistula or graft failure among these 
patients is thrombosis. Other complications such as infection, 
haemorrhage and aneurysm formation are much less common.
123
A recent survey of 86 arteriovenous graft insertions for 
haemodialysis performed over a five year period showed that 
8 out of 29 biological grafts and 20 of 57 synthetic grafts 
became thrombosed, while there were no major surgical septic 
complications which resulted in graft loss. Arteriovenous 
grafts were performed only in patients whose arteriovenous 
fistulae had thrombosed and these constituted 11.5% of the 
haemodialysis pool. Patients with renal failure have a 
haemorrhagic diathesis and in patients with normal haemostasis 
the risk of thrombosis is likely to be even higher. In patients 
with immune complex disease, vasculitis will further increase 
the risk of thrombosis and some of these patients will suffer 
from recurrent thrombophlebitis. Cryoglobulins and circulating 
anticoagulants, if present, are likely to add to the problem. 
Thrombotic phenomena have occasionally been observed inpatients 
undergoing plasma exchange, and it has been suggested that
reduced levels of Antithrombin III might lead to a
124 125
hypercoagulable state . Subsequent work , has not
substantiated that patients undergoing plasma exchange and
receiving corticosteroids and cytotoxic drugs are particularly
liable to infection. The consequence of. infection were
particularly severe and led to amputation. This complication -
X26
has also been reported in a patient with scleroderma .
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Whilst the morbidity associated with the construction of AV
fistulae and grafts appears to be high, other procedures used
to gain access to the circulation are not without complications.
Superior vena-caval cannulation appears to be associated with
a high incidence of cardiac arrhythmias, probably because
XX6citrated plasma is returned direct to the right atrium . In
addition the risk of traumatic complications is significant
and in one series of 160 SVC cannulations major traumatic
complications occurred in 6 cases - one perforation of the
subclavian vein, one perforation of the subclavian artery, one
122innominate vein thrombosis and three cases of pneumothorax
Femoral vein cannulation may be complicated by thrombosis,
sepsis, accidental arterial puncture, etc, but the incidence of
such complications appears to be low even in emergency
situations. Whilst thrombosis occurred shortly after femoral
vein cannulation in one patient, no complications were reported
in one series of 350 femoral vein cannulations, and this method 
127
is now preferred
.2 Anticoagulation
In cell separator procedures heparin and citrate are normally
128
used for anticoagulation . Side effects may be encountered 
with both drugs.
1. Heparin
Heparin is widely used in filtration leukapheresis, initially 
in the pre-anticoagulation of the donor and subsequently when 
added slowly to the extracorporeal circulation to prevent
85
coagulation during the procedure. Recommended doses have ranged
129from 15,000-20,000 units over periods of 2-4 hours and are
well above those used to prevent thromboses in abdominal or
thoracic procedures. These doses also exceed those used to
prevent progression of venous thrombosis and are at the upper
limit of normal for the initial treatment of patients with
130
pulmonary thromboembolism . Thus, for a short period, there 
is a risk to the patient of potential bleeding although this is 
rarely seen in practice, except as haematoma around the 
venepuncture site.
Adequate anticoagulation in a leukapheresis procedure over a 
2-3 hour period is provided by a loading dose of 2500 units 
followed by a further 9000-10,000 units at a rate of 1 unit/ml 
of exchange. Coagulation in-vitro is prevented by a single 
intravenous injection of 10,000 units followed by 1 unit/ml.
This is equivalent to a concentration of 3'units/ml in a 
patient of 70 kg weight.
Filtration leukapheresis is now being used to lesser extent 
because of the side effects produced in donors and recipients
131arising from suspected complement activation during filtration
In plasma exchange, the most widely used dosage schedule 
involves a bolus of 5000 units immediately prior to the 
procedure, followed by an infusion of 2 units of heparin for 
each ml of blood processed.
A combination of heparin and citrate has been used for both
86
centrifugal leukapheresis and plasma exchange. The donor is
provided with an initial anticoagulant dose of 5000-6000 units
of heparin followed by additional extracorporeal anticoagulation 
132
using ACD—A^L:20 . This produces less severe citrate toxicity
than ACD-A alone and reduces the risk of serious reactions to 
heparin.
2. Citrate
The anticoagulant effect of citrate is achieved by the 
complexing of ionised calcium in plasma to a level which will 
not support the proteolytic activities of factors IXa, Xa,
Villa even in the presence of extrinsic stimuli. In practice 
a ratio of 10 mol citrate to 1 mol calcium is an effective 
extracorporeal anticoagulant. In plasma containing 14 nmol/1 
citrate, ionised calcium is not detectable by calcium electrodes. 
Below 14 nmol/1 citrate, variable low levels of ionised calcium 
are found and occasional small clots are seen.
The symptoms of citrate toxicity due to hypocalcaemia and
possibly hypomagnesaemia begin with circumoral of peripheral
paraesthesia, increasing intensity and duration and spreading
133
to the face and trunk . More severe reactions are 
characterised by chills, painful pressure in the chest, 
generalised neuromuscular tension, nausea and abdominal cramps.
A reduced ionised calcium is associated with prolongation of the
QT interval and there is good correlation with the plasma citrate 
134
level . Symptoms rapidly cease when the infusion rate is 
reduced but often reappear as the rate is increased. Symptoms
- . 87 ■
are less frequent on the discontinuous flow separator because 
there is a break in the infusion during the bleed cycle and the 
citrate build-up is less marked.
The occurrence of citrate toxicity is more common in 
leukapheresis, plateletpheresis and plasma exchange, all of 
which involve the processing of large volumes of blood and 
citrated plasma is returned together with cells at rates often 
in excess of 60 ml/min. Obviously slowing the flow rate over 
the whole procedure would be counter-productive and cause the 
patient discomfort.
A reduction of the citrate load would reduce the degree of
hypocalcaemia and its associated effects and can be achieved
either by reducing the anticoagulant ratio or by using an
135anticoagulant with a lower citrate concentration . Decreases 
in ionised calcium of 32% have been reported for ACD-A 
compared to 16% with half-strength ACD-A and of 22% compared to 
13% with ACD-B respectively. Plasma protein fraction (PPF) or 
albumin (which have low citrate concentrations) in place of 
fresh frozen plasma (FFP) for plasma exchange reduces the 
citrate load but unfortunately presents other problems when 
used extensively^^.
The fall in ionised calcium has also been reduced by prophylactic
addition of calcium gluconate to irrigation solutions in
discontinuous flow leukapheresis and replacement PPF in plasma
exchange, instead of using bolus injections of calcium when 
137
symptoms occur . The addition to an extracorporeal circulation
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must be made with care to ensure that it is not added in
X16excess or at a point where coagulation could be induced
Further, hypercalcaemia is as dangerous as hypocalcaemia and
death from over-correction of citrate-induced hypocalcaemia
following cardiac surgery has been reported. The occurrence
of hypocalcaemia cannot be reliably predicted from the weight
of donor, or patient and the infusion rate of the citrate, nor
XX6is the reporting of symptoms by the patient reliable 
Several patients receiving 60-80 mg/kg/hour citrate without 
prophylactic calcium showed severe hypocalcaemia without 
reporting symptoms. The ionised calcium levels were 0.6-0.7 
mmol/1 and plasma citrate 20-24 mmol/1 which is on the
X38
borderline of the range reputed to cause cardiac depression
The citrate anticoagulant also alters and buffers plasma pH to 
optimise conditions for the collection and storage of blood 
components. Thus, despite adequate anticoagulation, platelets 
have a tendency to aggregate during centrifugation at a pH 
value above 7.2 and become non-viable in storage if the pH 
value falls below 6.0. Because the collection of blood 
components by cell separator is being increasingly used to 
augment routine blood bank products, anticoagulant systems 
must be developed which will permit long-term storage of 
components, whilst avoiding undesirable donor side effects.
Continued use of ACD-A at a ratio of 1:7 for leukapheresis or 
plateletpheresis or the use of FFP for plasma exchange without 
calcium supplementation will produce paraesthesia in the 
majority of cases and constant interruption of the exchange
89
flow would be necessary to prevent more serious symptoms.
This can be avoided by using ACD—A at a larger ratio where 
possible, or by changing to ACD-B where the ratio is fixed.
ACD-A at half strength could result in wider coagulation in 
some instances, especially in conjunction with a low haemato- 
crit. For plasma exchange the use of PPF, or albumin, possibly 
in conjunction with FFP, will by reducing the citrate load, 
lower the incidence of hypocalcaemia. Since plasmapheresis 
involves minimal return of anticoagulant, the ratio may be 
chosen to best suit the conditions for optimal preservation of
the plasma components. In routine transfusion practice ACD
solutions have now been superseded by CPD. It would then seem
logical to use CPD in cell separator procedures where appropriate, 
with adjustments in pH and citrate content to provide optimal 
condition.
1.4.3 Replacement Fluids
1. Consequences of Plasma Removal
Therapeutic plasmapheresis is of three forms, namely:
1. Partial plasma exchange involving the removal of 
small quantities of plasma.
2. Total plasma exchange involving the removal of almost 
total effective plasma volume. Depending on the 
patient's size and weight this usually involves the 
removal of some 3 litres of plasma.
3. Selective plasma exchange in which a specific antigen, 
antibody complex, or toxin is removed from the plasma 
with the return of the denuded plasma to the patient.
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The removal of 0.5 litres of plasma, twice a week, from healthy
donors will result, over a number of years, in a reduction of
139
immunoglobulins within the normal range . Without replacement
with crystalloid solutions this approaches the limit for the
resynthesis of albumin 30-40 g/day. In the large volume plasma
exchanges, required for the removal of pathogenic factors, there
is a coincidental removal of normal constituents, e.g. albumin,
2 3 140-144
immunoglobulins, complement and the coagulation factors * *■
The removal of more than one litre of plasma will result in haemo-
dilution, with the formation of peripheral oedema because of the
reduction in colloid osmotic pressure, if albumin is not replaced
with colloid. The duration of the effect on protein depletion
depends on the portion that is intravascular, the extent and rate
of redistribution and the fractional catabolic rate, because
soluble factors of the cell micro-environment appear to be
necessary for the development and regulation of the immune
system. The removal of the plasma fluid for therapeutic purposes
may therefore decrease humoral components of immunoglobulins,
circulatory immune complexes, complement components, cleavage
145products, prostaglandins and neurotransmitter
It seems unlikely that the removal of plasma interferes in the 
sophisticated micro-environment system of immunoregulatory 
cytokines where minute amounts are involved in the triggering 
of cell membrane.
The removal of larger humoral components, such as immunoglobulins 
or circulatory immune complexes, may alter cellular functions.
The rebound phenomenon observed after plasma exchange in some
91
autoimmune diseases, (e.g. Goodpasture's Syndrome, Bullous
pemphigoid) obviously implicates the immunoregulatory circuits
of the idiotypic network and subsequently the mediators of the
T-B interaction. Similarly, extraction of circulating immune
complexes may not only restore the physiological clearance
capacity of the mononuclear phagocyte system, but also reverse
functions such as antibody-dependent cytotoxicity, antibody
formation and lymphokine production. These limited plasma
exchange-dependent changes in T-subsets and con-A induced
145suppressor activity remain to be confirmed and explained .
The simultaneous taking of immunosuppressive drugs by most
146patients markedly increased the difficulties of such studies
The physiological and haemostatic modifications induced in the 
donor or patient during and for selected periods of time after 
a single or multiple plasma exchanges have been widely studied 
over the past fifteen years and considerable data are now 
available.
Changes in blood pressure are commonly present during the course 
of plasma exchange, possibly the consequence of variations in 
blood volume or in hormonal parameters. Measurements of blood 
pressure, plpsma renin activity, aldosterone, plasma catechol­
amines, natriuesis and blood before and after plasma exchange 
showed that in normotensive patients significant changes
occurred during and immediately after PE but they are not related
147
to changes in blood volume or to hormonal changes . Blood 
volume and natiuresis values remained unchanged.
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Changes in plasma renin activity, antidiuretic hormone and
insulin have been determined in patients with a spectrum of
immunologically related diseases in order to assess the
response of the releasing cells to removal from plasma of their
148
product of secretion . The response kinetics differed for 
the three peptides. Compensation was fast and nearly total 
(91.4%) for antidiuretic hormone, whereas for plasma renin 
activity and insulin compensation had not occurred even at the 
end of the exchange procedure. Plasma volume and plasma 
osmolality were not changed significantly.
Plasmapheresis influences the composition of plasma electrolytes
149
and hormones which in turn may influence cardiac contractility, 
The function of the left ventricular pump has been assessed by 
time-motion echocardiography before and after plasmapheresis in 
patients with systemic lupus erythematosus, progressive glomeru­
lonephritis and Graves Disease. No changes in blood pressure and 
heartrate were found. The left ventricular dimensions were 
comparable before and after plasmapheresis and no change was 
detected in the fractional fibre shortening ratio. Ionised 
calcium levels decreased significantly during treatment.
There is now a wealth of information on the effect of plasma 
exchange on serum immunoglobulin concentrations, complement con­
centrations and coagulation parameters during individual and
successive procedures using coagulation factor-free replacement
^  J 2, 3, 150-153 
fluids ’ *
Analyses have shown that platelet counts are lowered to 50% of
93
their pre-exchange levels after the first exchange to 21% after
142
the fifth exchange and 23% after the tenth exchange . The 
time needed for recovery was dependent mainly on the intensity 
of the previous exchange programme, but only 2 - 3  days were 
needed for platelets to return to normal, regardless of the 
actual level^* 142^
The concentrations of the serum immunoglobulins IgG, IgA and IgM
were reduced to 45%, 47% and 38% of the pre-exchange values after
a single procedure. The times for recovery of immunoglobulin
concentrations to pre-exchange values have been variously
3 141 143reported as 24-48 hours and in excess of two weeks * * .
With consecutive daily plasma exchanges the cumulative percentage 
reductions in immunoglobulins concentrations continued to decrease, 
e.g. to approximately 20%, 23% and 21% for IgG, IgA and IgM 
respectively after the fifth procedure. The decreases are main­
tained when the period between procedures does not exceed two 
days. With longer intervals between procedures the concentrations 
of serum immunoglobulins begin to increase again.
If immunosuppression is used, the plateau level may be below 2g/l
and remain low for several months. This may result in complicating
infections in immunocompromised patients (particularly in renal 
143patients) and the replacement of some immunoglobulin may be 
153desirable . When the IgG level is low its functional catabolic
rate decreases and this may prolong the half-life of a pathological
antibody. Kapid synthesis during an immune response may reduce
the efficiency of the pathological antibody removal particularly
93
in immune diseases and in haemolytic diseases of the newborn .
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Most coagulation proteins have a short half-life with synthesis
rates of hours and rapid re-equilibrium occurs between the intra-
142 143 150and extra-vascular compartments. Measurements * * have
been made on groups of patients, of the circulating levels of 
coagulation factors I (fibrinogen), II, V, VII, VIII, IX and X, 
and antithrombin III during, and in a 24 hour period after a 
single plasma exchange, after consecutive daily exchanges and 
after exchanges at intervals of two days or more. The circulating 
levels of all factors were reduced by differing amounts after a 
single exchange using coagulation factor-free replacement.
The reduction for each individual factor expressed as a percentage 
of the pre-exchange level did not differ for the various patients, 
nor were they significantly influenced by the interval between 
exchanges. Further, the extent of the percentage reduction during 
exchange was not influenced by the pre-existing level of the 
coagulation factors. After a single exchange, Factor I (fibrinogen) 
and Factor II were reduced to approximately 30%, Factors V and X 
to approximately 38%, Factors VII and VIII to approximately 45%
143
and Factor IX to around 60% of the pre-exchange levels .
The cumulative effects of a course of five plasma exchanges on a 
daily or two-daily basis showed that Factors I, II and X were 
removed more efficiently than Factors V, VII and IX. All factors 
exhibited a rapid recovery in the four-hour period after exchange, 
but thereafter the levels increased more, slowly. Factors V, VII, 
VIII and IX had returned to their normal values within 24 hours 
but Factors I, II and X had not achieved normality even after 48 
hours. Thus, exchange on a daily or two-daily basis without
95
plasma replacement will gradually deplete levels below those 
thought to be necessary to maintain haemostasis. Provided the 
platelet levels are maintained there is little danger of spon-
143
taneous haemorrhage . However replacement of plasma may be
153desirable if surgical procedures are to be undertaken, . 
Alternatively, normality can be restored by endogenous replace­
ment if the exchange is stopped 48 hours beforehand. Coagulation 
inhibitors such as ATIII also exhibited a fall in the level of 
activity after a single procedure. The drop to approximately 40% 
of its pre-exchange value is thought to be partly due to con­
sumption as well as physical removal. Levels are restored to 
normality in 2 to 3 days. Reports of the occurrence of spon­
taneous thrombosis are conflicting and most patients tolerate 
this transient coagulopathy without haemorrhage or thrombosis 
unless there is a pre-disposing factor, or the exchange is 
repeated in less than 48 hours. Immediately after one plasma 
exchange with plasma protein fraction there is a significant 
decrease in plasma fibronectin levels which are restored to 
pre-exchange levels within 48 hours presumably by redistribution
144
between compartments and increased synthesis . Daily plasma 
exchange produces progressive depletion of plasma fibronectin, 
whereas levels were maintained close to the initial value with 
longer intervals between exchanges, except in the more severly 
ill patients. Reduction of plasma fibronectin by exchange may 
increase susceptibility to infection and reduce the efficacy of 
the procedure if used to reverse reticuloendothelial blockade.
Factor VIIIC and VIIIRAg and ristocetin Co Factor are significantly 
depressed immediately after plasma exchange (to 50%, '35% and 40%
96
activity levels respectively) but recover to pre-exchange
142
values within 24 hours . The prothrombin time (PT), kaolin 
cephalin clotting time (KCCT) and thrombin time (TT) are signif­
icantly prolonged (by 60%, 100% and 300% respectively) immediately 
after plasma exchange. KCCT and TT return to within the normal
range after four hours and all return to pre-exchange values after 
143
24 hours .
Further studies have involved measurements of the total haemoly-
tic complement (CH50) and the fractions C3, C4, B, C3d before
and immediately after plasma exchange and thereafter at specified
intervals^*-^1,152^ After a single exchange, concentrations of
CH50, C3, C4 were lowered to 50%, 45% and 38% of their pre-exchange
values respectively. Resynthesis is rapid and levels return to
normality within 24 to 48 hours. During periods of consecutive
daily exchanges the concentration levels of C4 and particularly
of CH50 fall much less rapidly than that of C3. The substitution
of Ig during plasma exchange with 5% human albumin will reduce the
153
extent of the fall in serum levels of C3 and C4
Complement activation and C3a, C5a generation is found in the
154
extracorporeal circuit during membrane plasmapheresis . This 
has been accounted for in neutropenia and pulmonary leukostasis 
which may occur under such conditions. The observed increase in 
C3a production is attributed to the filtration circuit and the 
possibility of massive infusion of active C3a should be a matter 
of concern when fresh frozen plasma is used as the replacement 
fluid.
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64% of plasma cholinesterase is removed in a single whole
volume plasma exchange using plasma protein fraction as the 
155replacement fluid . A series of daily plasma exchanges 
almost completely removes circulating cholinesterase, 
particularly in those patients with initially low levels and 
suxamethonium apnoea may occur during induction anaesthesia due 
to raised sensitivity to the drug.
The kinetics of removal and subsequent recovery have been
investigated for other plasma constituents namely calcium,
uric acid, sodium, potassium, chloride, bicarbonate, aklaline
phosphatase, lactate dehydrogenase, transaminases, creatinine
143
phosphokinase, amylase and cholesterol
Although the selective removal and modification of blood com­
ponents offer considerable potential for the treatment of many 
disorders, there remains a major requirement for the replacement 
of products withdrawn by apheresis. The replacement fluid should 
be selected on the basis of the clinical condition of the patient 
and the rationale for the exchange. With the possible exception 
of plasma replacement in thrombotic thrombocytopenic purpura, in 
some forms of SLE, and where there is a bleeding tendency there 
are no therapeutic data on which to assess the relative merits 
of one form of replacement over another.
*
The nature and volume of fluid replaced will depend on the / 
volume of fluid removed, the physiological needs for replacement 
and the therapeutic objective. Additionally the availability, 
convenience and cost of the replacement fluid must also merit 
attention.
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2. Available Replacement Products
1. Patient's Own Plasma
The best replacement fluid would seem to be the patient's 
own plasma minus the offending component. Only in 
cryoglobulinaemia is this readily accomplished by pre­
cipitation of the abnormal protein from plasma stored 
at 4°C.
The removal of the offending component from the patient's 
own plasma, either by secondary separation, or by the 
combination of apheresis procedures with column techniques 
has already been discussed. Clearly, there are considerable 
problems to be overcome before the preferential elimination 
of identified components becomes a routine cost effective 
procedure.
2. Fresh Frozen Plasma
Acid Citrate Dextrose (ACD) or Citrate-Phosphate Dextrose 
(CPD) plasma separated from red cells within a few hours of 
donation, frozen rapidly and stored at -30°C has a coag­
ulation factor content which will remain at near normal 
levels for up to 12 months. If kept at -20°C it should 
be stored for not more than 6 months. (See Table 7).
Fresh frozen plasma requires to be thawed rapdily at 37°C 
with continuous agitation and transfused within 30 minutes 
to avoid rapid post-thaw deterioration of coagulation 
factors. The volume varies from about 200 ml from random
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Table 7
Volume:
Storage:
Administration:
Potential advantages:
1 39
PLASMA PRODUCTS
FRESH FROZEN PLASMA
200 ml - 10% - random donor 
500ml - 10% - selected donor
In frozen state at below -30°C for 1 year
Must be thawed (30 mins) and transfused as 
soon as possible (within 2 hrs)
Must be given ABO group specific (occasionally 
Rh(D) specific).
Normal levels of: coagulation factor (not cryo-
supernatant)
antithrombin III and other 
inhibitors
immunoglobulins
complement
enzymes and carrier proteins 
Iso-oncotic and isotonic
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donors to 400-600 ml for apheresis donors. About 40-50 ml 
of the original citrate anticoagulant will be present in FFP 
and if infused at rates above 50 ml/min symptoms of hypocal- 
caemia are observed.
FFP should be given to ABO compatible recipients. It should 
contain all the non-cellular coagulation factors. As such 
it can be used to replace any of them. The volume which a 
patient can receive without being overloaded is limited and 
this determines the amount by which a particular factor can 
be raised in a patient's circulation. This is particularly 
true of FVIII,which has a short in-vivo half life.
The incidence of allergic reactions is greater with plasma 
than with any other replacement fluid and is particularly 
common if used as sole replacement fluid. The majority of 
reactions are mild urticarial reactions, but occasionally 
bronchospasm, tachycardia, hypotension and anaphylasis 
occur.
FFP is not, in many cases, a practical replacement fluid to 
use in plasma exchange by virtue of its relative inaccess­
ibility, the problems of grouping and the incidence of 
allergic reaction. In conditions where a source complement 
is required it is the ideal fluid replacement.
3. Cryoprecipitate
When plasma is frozen and then thawed the small amount of 
protein precipitated is rich in Factor VIII. After decanting
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almost all the supernatant plasma, the protein can be re­
dissolved by warming to give a small volume of solution 
containing about 50% of the Factor VIII activity of the 
original unit. Cryoprecipitate can be stored at -20°C for 
at least 2 years with full preservation of Factor VIII
activity. Only a small number of donors are used and thus
156
the risk of transmission of viral hepatitis is decreased 
It contains all the plasma proteins in normal amounts, except 
for fibrinogen, Factor VIII and fibronectin.
4. Albumin Solutions
Human albumin is a highly soluble, symmetrical, slightly 
heterogeneous protein which weighs about 67,000 daltons. It 
is responsible for 80% of the colloid osmotic pressure of 
plasma.
Three manufactured albumin products are available:
1. Albumin 5%
2. Plasma Protein Fraction
3. Albumin 25%
Plasma protein fraction yields somewhat more useful protein 
per litre of starting plasma in the fractionating process.
The non albumin proteins are quickly removed from the cir-^ 
culation because of heat denaturation. Shelf-life depends 
on storage temperatures; 3 years are permitted at below 37°C 
and 5 years at 2 - 10°C. (See Table 8).
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Table 8
Volume:
Storage:
Administration:
Potential advantages:
Potential 
Disadvantages:
PLASMA PRODUCTS139 
ALBUMINOID SOLUTIONS
Variable, but 100 ml and 500 ml sizes common
In liquid state at ambient temperature (5-25°C) 
for 3-5 years (depends on manufacturer).
Ready for immediate use
No blood group restriction
+ 24-
Can be supplemented with electrolytes (K orCa ) 
if required
No hepatitis risk
No fibrinogen or complement (inflammatory media­
tors )
Minimal allergic reactions
4-5% solution is essentially isoosmotic and 
isotonic
Expensive
No coagulation factors 
No immunoglobulins
No trace plasma proteins (e.g. enzymes)
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Albumin 5%
Albumin may be produced commercially and non-commercially, 
the final product containing not less than 95% albumin. It 
is available not only in a 5% solution but also in a more 
concentrated form. The solution contains approximately 
130-160 mmol/1 of Na and not more than 1 mmol/1 of K.
The product is heated to 60° C for ten hours to inactivate 
the hepatitis B virus.
Plasma Protein Fraction (PPF)
PPF is a liquid preparation containing about 45 g of 
protein per litre. By itself this would be a hypotonic 
solution, so 130-160 mmol of sodium chloride is added per 
litre. The protein in solution is Cohn Fraction V 
precipitate and consists of 90% or more albumin with not 
more than 10% alpha and beta globulins and is stabilised 
with sodium caprylate. Albumin in this concentration can 
be heated to 60° C for ten hours without causing undue 
aggregation of the protein. This inactivates Hepatitis B 
virus and hence the final product is non-icterogenic.
This was one of the major reasons for introducing PPF 
but since then the risk of transmitting hepatitis with 
freeze dried plasma itself has been dramatically reduced 
as a result of modern methods of testing donations for 
the presence of the hepatitis B antigen.
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Albumin 20-25%
This is sometimes called salt-poor albumin. It is a 
solution in water of human albumin, containing a low 
proportion of salt. It is clear liquid prepared from 
the plasma of suitable human donors whose transaminase 
levels are constantly checked and whose donations are 
HBsAg negative.
It contains 20% of protein, of which 97% is albumin, 
the rest being thermostable alpha and beta globulins.
20% albumin is hyperoncotic and is not suitable for 
plasma exchange unless diluted to 4-5% with an electro­
lyte solution. Caution is indicated in administering 
albumin; a careful watch must be kept for the possible 
development of pulmonary oedema. If it occurs the 
infusion must be stopped immediately.
Commercial albumin solution may be a potential source 
of intravenously administered aluminium, the long term 
effects of which remain to be assessed.
Adverse Effects of Albumin
Albumin products are inherently safe. Chronic adverse 
effects are:
1. Bacterial contamination - Occurs rarely. Occasional 
febrile reactions, transient bacteraemia, shock and 
occasional sepsis have occurred.
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Pyrogenic Reactions - 75% of all reported reactions 
are characterised by chills and fever. They are 
rarely severe.
Hepatitis - When properly heated and protected from 
subsequent contamination, albumin and PPF are unable 
to transmit hepatitis. The screening for hepatitis 
B surface antigen HBsAg and elimination of plasmas 
that are positive has resulted in'a sharp decline in 
the amount of antigen detectable.
Hypotension - It has been known for some time that 
rapid administration of PPF is frequently associated 
with transient hypotension. It has also occurred 
less commonly with albumin products. This has now 
been attributed to the Kallikrein Activator. This 
activates the recipient's own kinin system to produce 
bradykinin.
Both albumin and PPF have been extensively used in 
plasma exchange, despite the fact that they contain 
no coagulation factors, immunoglobulins or plasma 
proteins.
Caution should be exercised when albumin is infused 
repeatedly,particularly in patients with renal in­
sufficiency. In such patients' plasma aluminium 
levels should be monitored regularly and any clinical
signs and symptoms compatible with aluminium toxicity
157
should be evaluated promptly •
5. Plasma Volume Expanders
Human blood and blood products are costly fluids, in mone­
tary terms and in personal inconvenience to the donor.
Thus there are a number of plasma substitutes used as plasma 
volume expanders usually in surgical and trauma patieni^^* ’^ '’ 
None has significant advantages over human albumin products.
A requirement of artificial colloid is that they may be elim- 
ianted from the body either by excretion or by metabolism.
At the same time they should remain in the circulation 
sufficiently long to maintain the plasma colloid osmotic 
pressure while regeneration of plasma protein occurs. Plasma 
expanders are therefore required to imitate the function of 
plasma proteins particularly albumin, and should ideally be 
neutral to the body, non-toxic and non-antigenic. Three 
major problems are experienced with the available colloid 
volume expanders, namely a) tissue storage and elimination 
from the body, b) allergic and anaphylactoid reactions,c) 
production of an acquired bleeding tendency. Gelatins,
dextrans and hydroxyethyl starch are all associated with
159these side effects but not to the same extent
All artificial colliods lack carrier function and remain 
in the recipient's circulation for a much shorter time than 
albumin. Dextrans and hydroxyethyl starch interfere, in 
varying degrees, with haemostasis which limits the total 
amount that can be given to 1-1.5 litres. The problem is 
more pronounced with dextrans and the bleeding defect 
induced can be corrected only by transfusion. The major 
disadvantage of hydroxyethyl starch is the possible occurr­
ence of hypersensitivity reactions.
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Gelatins
Gelatins are macromolecular substances with average 
molecular weight of 30-25,000 daltons which are slowly 
metabolised, the intra-vascular half -life being 4-6 
hours. Gelatin is an insoluble animal collagen (from 
skin, tendon or bone) which is hydrolysed and modified 
to give a stable fluid material. The three commercial 
types are:
1. Gelofusine (oxypolygelatin) - gelatin 4%, 
sodium chloride 0.9%.
2. Plasmagel - modified fluid gelatin
3. Haemaccel (urea linked gelatin) -
gelatin 35 g/1, Na 145 mmol/1, K 5.1 mmol/1,
Ca 6.26 mmol/1, Cl 145 mmol/1.
The gelatins may be used to expand and maintain blood 
volume in shock arising from conditions such as burns 
or septicaemia. Typically 1 litre of gelatin and 3 
litres of PPF may replace 4 litres of plasma without 
adverse effects on albumin levels or on blood volume. 
They are excreted rapidly in the kidneys without renal 
impairment, with only a small percentage being meta­
bolised.
There is no effect on the coagulation or fibrinolytic 
systems except by simple dilution.
Gelatin's shelf life is 8 years at room temperature and 
is unaffected by wide temperature fluctuations.
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Electrolytes
These have no carrier function but can expand the plasma 
volume if used in sufficient amounts (about 3 times 
equivalent of plasma). The duration of the effect is 
short because of the shift into the interstitial fluid 
space. They temporarily lower the plasma colloid osmotic 
pressure and should be used with caution where patients 
have pre-existing hypoproteinaemia, i.e. with albumin 
below 30 g/1 and total protein below 60 g/1.
Electrolytes alone should not be used to replace more 
than 500 ml of plasma. However much larger volumes could 
be used during the initial part of a 3-4 litre plasma 
exchange (of the order of 75% crystalloid followed by 
25% of colloid). The replacement fluid given early in 
the procedure will be partially removed by the end so 
that where a protein (e.g. albumin) has to be replaced, 
it is more logical and cost effective to give this at 
the end of the exchange. The onset of hypovolaemia may 
necessitate the earlier use of colloid. FFP should also 
be given where there is a need for protein which cannot 
be provided in any other way (e.g. serum cholinesterase) 
and generally, in exchanges of larger volumes 4-5 litres.
The relevant features of various plasma substitutes are 
compared in Table 9.
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Table 9
COMPARISON OF PLASMA SUBSTITUTES
ELECTROLYTE
SOLUTIONS
PLASMA PROTEIN 
FRACTION
HAEMACCEL
pH 5.5 - 6.5 6.7 - 7.3 
buffering 
capacity
7.2 - 7.3 
buffering 
capacity
Oncotic pressure 
compared with 
plasma Hypo-oncotic Iso-oncotic Iso-oncotic
Interference 
with subsequent 
blood-typing and 
cross matching none none none
Interference 
with coagulation 
haemostasis none dilution dilution
Renal function improved in 
shock
improved in 
shock
improved in 
shock
Intravascular 
interstitial 
fluid balance oedema rehydration rehydration
Effective T/£ short several days 4-6 hours
Cardiovascular
overload unlikely less likely than whole blood
Possible
reactions unlikely histamine
release
anaphylactic
histamine
release
Transmission 
of disease none unlikely none
Shelf life 3 years 3-5 years 8 years
Storage Room
temperature 2 - 30°C
Room
temperature
1 1H
1.5 Applications of Plasmapheresis
1.5.1 , Rationale for Treatment
Any change produced by plasmapheresis is governed by the patho­
physiology of the disease. It is reasonable to assume that in 
disease characterised by circulating toxic factors, humoral 
mediators, altered viscosity or abnormal haemostasis, the use of 
intensive plasmapheresis is logical.
The serological abnormalities may be favourably influenced by a 
change of the "milieu interior". When factors responsible for 
the clinical syndrome are unknown or the serological markers are 
poorly associated with the activity of the disease, it is diffi­
cult to justify and interpret the results of plasma exchange.
Not surprisingly the majority of diseases are associated with 
immunological and serological difficulties.
28
The possible mechanisms by which plasma exchange could be of 
benefit to patients are suggested in Table 10. The postulated 
mechanism is correct only for some of the examples listed.
1.5.2 Protocols for Treatment
Ideally, criteria should exist for the intensity, frequency and 
duration of the procedure, for the choice of replacement fluids, 
the serological parameters to be followed and the clinical 
evaluation of the effects of the procedures. Existing protocols 
for plasma exchange are empirical and largely influenced by
111
TA
BL
E 
10
Q)cr
c
(0
Xo
X
u
(0
Eto
CD 
i—i 
CL
U
•H
-P
D
CDaco
pa)
X  
h~
C
•H
C
o
•H
•P
a
«3C
c^O
(0
E(0
•H
C
CD
JZo
CD
s:
CD
i— I
X I 
•H
CD
CD
O
a
CO
p
rj
X CLa Pc ■ D
CD CLc CDcn ‘ D U
CD CD •Hp O ■ C
Q. -P CD
CO CD Q.
cc c E E □
Ul •H CD O -PQ X P X tocr C -P TJ a •H
□ o X C CD oin CO •H p X ' C X •HH •H -P Ld cn •H E PQ 2» ■ CO C O X
CD CD CD X o P X
p •H ■ D -p CD X pLD c . a •H •H 1— cc
a D CD □
CD E O CL u X•H . E O •H •HC •H O CD . E -P OCD □ •H •H O □ -P
X rH E ■=> O X COP rH CD P p E E
CO to -P CD JZ O D
CD CD CL CD P CD
X ■ x X X D X X
e: cc cn X e: H- X
PO-P
aCO
u.
COE
CDc CO
•H ■—1
2 CO CD CL
a CD -P
n X O U
l~ CD P •H
U X >N rH a. 0-
<X ' T3 T3 CL •H
O □ E ■—i Uu. XI X} O CO a)
o •H •H a c CL-P -P □ CD
e: C C ■ CD 1—1in CD CO c o ‘ c. <pO o 3 □ •H oz -P rH E c X -pCC rj rH E □ □ X uX cc CC •H e : h- c CD
u CD i*-
LU Ct- <P U- CP a_ E Ct-
. e; □ O o o □ X fi
CD
rH •H H rH rH •H O
CO CD CO CO CO C X
> > > > > CD CDo O □ o o rH O
E E E E E CL co
CD CD CD CD CD CD ■—i
CC CC CC CC CC CC (X
• • ■ • • • • •
H CM CO in VO
112
factors such as vascular access and scheduling. They will 
remain so until the metabolism and pathogenicity of the 
abnormal plasma constituents removed by the plasma exchange are 
established.
There is, however, evidence that the period in which plasma
160
exchange is initiated may be one of the most crucial decisions
Direct measurement of the effector cells would provide meaningful
information of the necessary frequency and duration of exchange
therapy. The patients' response to the therapy and to the
X60
disease process will also influence protocol design • Procedures,
in which the volume exchanged approaches the patient's plasma
volume, remove approximately 50-60% of an intravascular 
28
substance . Four or five such exchanges over a period of 
7-10 days are generally thought to be adequate for short term 
therapy. If catabolism balanced synthesis and intravascular 
shift throughout this time, the final concentration of a substance 
would be less than 10% of its initial concentration. However 
because a sustained balance is unlikely, this value is rarely 
achieved.
In disorders where plasma exchange can be considered an established
therapy, serial clinical assessment and measurement of the
pathogenic plasma factor permit the assessment of the volume
and frequency of exchanges: , even if the distribution and meta-
28bolism of the plasma factor are not completely understood
1.5.3 Evidence of Efficacy
28
The benefit of plasma exchange can be confirmed in two,ways -
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namely, (a), demonstrable removal (or replenishment) by plasma 
exchange of an abnormal plasma component (or a deficiency of a 
normal component) in the pathogenesis of the disease or one of 
its components, (b) conclusive evidence of patient benefit from 
a properly designed randomised controlled clinical trial.
Diseases which are associated with excessive or abnormal proteins, 
lipids, toxic substances, circulating immune complexes or anti­
bodies are monitored by sequential quantifications of these
substances. In such cases the clinical effect of plasmapheresis
160
may be correlated with the level of specific disease marker 
Unfortunately the levels of many plasma factors are decreased by
the exchange and a demonstration that the removal of particular
28
factor caused the disease is difficult . Moreover, even if a 
plasma factor is known to be pathogenic, its reduction by plasma 
exchange is not necessarily associated with a clinical response, 
e.g. in maternal Rh alio-immunisation, it is not yet known 
whether plasma exchange is of benefit to the foetus, despite the 
decrease in Rh antibody concentration that can be effected by 
the procedure. There is little argument that plasma exchange 
can alter the level of a pathogenic plasma factor in each of the 
disorders listed in Table 11, but it should not be considered 
established therapy in all these disorders. When there is poor 
correlation between the serological findings and the disease 
activity or when no discrete markers exist, therapeutic assess­
ment becomes a function of clinical evaluation. Even in diseases 
which unquestionably benefit from plasma exchange, the improvement 
is usually due to relief of clinical manifestations rather than
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Table 11
Disorders in which the Efficacy of Therapeutic
Plasma Exchange can be Monitored by Measurement
28of a Pathogenic Substance in Plasma
Disorders Pathogenic Substance
Hyperviscosity syndrome
*
Monoclonal immunoglobulin
Cryoglobulinaemia
Cold antibody-type autoimmune
Cryoglobulin
haemolytic anaemia 
Factor VIII deficiency
Red-cell autoantibody
unresponsive to factor VIII Antibody to factor VIII
Post-transfusion purpura Platelet antibody (Anti-P^)
Preparation for ABO-incompatible 
marrow transplantation
Maternal alloimmunization to
Antibody to a or b antigen
Rh(D) antibody Antibody to Rh(D) antigen
Familial hypercholesterolaemia Low-density lipoproteins and 
cholesterol
Poisoning Drug
Myasthenia gravis Autoantibody to acetylcholine 
receptor
Fabry's disease Ceramide trihexoside
Refsum's disease Phytanic acid
Goodpasture’s syndrome Antibody to basement membrane
Pemphigus Autoantibody to epidermal cell- 
membrane glycoproteins
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to any effect on the underlying disease itself. The short
term improvement that is characteristic of the response of many
disorders to plasma exchange, frequently limits its value to
28
therapy for acute conditions.
1.5.4 Implications for Treatment
The economic and social implications of plasma exchanging are 
far-ranging. Both cell separator and procedure are expensive. 
Equipment costs are extremely high (although this may be reduced 
by the advent of newer membrane therapy). Each procedure it­
self is expensive including staff time, replacement fluids used 
and disposable items. The cost effectiveness of plasma exchange 
has yet to be established, whilst the feasibility of large scale
application could pose problems of plasma replacement supply.
161
It has been calculated, that if plasma exchange had been
proven successful in the treatment of rheumatoid arthritis and
made available to all potential sufferers, then not only would
the health care budget have to be increased enormously, but so
also would the number of blood donations necessary to supply the
amount of albumin needed as replacement fluid. Further, if
the report, that disseminated cancer might regress with plasma
exchange was confirmed, the cost and supply problems would be
162
almost unsurmountable.
These economic and social implications provided considerable
impetus for controlled trials to establish the efficacy of the
163
treatment and to establish a stricter evaluation. The 
diagnosis of many disorders is based partially, or totally,
116
upon a set of criteria rather than specific diagnostic tests.
Thus assessment of disease activity and therapeutic responses 
rests largely on subjective evaluation of a complex number of 
parameters by patient and doctor. The situation is further 
compromised by the fact that many therapeutic modalities can be 
associated with improvement of varying consistency and duration 
indicating a strong placebo effect.
The vast majority of trials are uncontrolled and report a much 
higher response rate to the exchange procedure than had been 
observed in the few studies based on a control group (Table 12). 
Many deficiencies have been noted in reports of randomised 
controlled trials of plasma exchange, e.g. inadequate description 
of patient selection, inadequate information on patients 
rejected and withdrawn, and effectiveness of randomisation^^.
The design of a clinical trial involving plasma exchange is
controversial. Efficacy should be established by using a trial
165in which the assignment of patients to treatments is controlled
The experimental groups of patients must be representative of the
general patient population with the disease under consideration
and should be identical in every way except for the intervention
being evaluated'*'^ ’ This must include all compounding
variables (factors other than the treatment that may influence
outcome, e.g. age, sex) and all aspects of ancillary care that
167 168may affect response to treatment during the trial ’ . Thus,
to assess the effect of removing plasma or cells during plasma 
exchange on selected groups of patients, the control must 
replicate the procedure except for the irreversible extraction 
of plasma and cells.
117
CO
h h
CO
CD
P
03
.Ca
CO
E
CO
CO
f—1
a
u
•H
-P
3
03
a
CO
p
03
-C1—
c
•H
CMT— CO(—1
u CO
•Hm P
«c f-H*
T )
CD
i— 1«H
O
P
-P
C
□ocZ3
-D
C
CO
T3
CD■—I
i—1
a
p
-pc
oo
0)
O
t
h
e
r
1 in 1 1 r—i CM
6
7
I— I
CO
•H
P E
J— CO 1 1 1 H to 1 inJO CM
TJ CD
CD mm
i— 1
iH
o
P
-P
C TJ
o CD
u CO
•H
E 1 1 to 1 CM sf vo
a in
TD
c
CO
cc
-p
p
o
CD CL
rH  0)
03 cc CM r*- CD in O CM o
c r~ CN x— CD
•H  CD
in co
CO
u
CO
H
CO
•H
P +»
J— p
Q3 □
TJ r-{ CL
CD CL CD
r—1 •H  CC VO to 03 CO 03 VO T-
i—1 -P CM 03
□ H  CD
P 3  CO
-P s: co
c u
□
a
c
= j
m
>
•H
■P rH
a  co
0) *H 1 CO VO o CM O
CL P X— x— a
CO h - T~
O
P
CL
vo o
r^ -p
cn a
P XT’ CO CD
CO cr» CO
ID 0) c
>- P t o
□ VO *— CM to sr
<*- c^ - CD CO CD CD CO
m cn 03 03 03 03 0  u i
CO *- r~ V r- CC CL
118
There are several methods for selecting the control group.
Ideally control group should be randomly selected from the study 
167
population . Much has been written about the ethics and legal
implications of the randomised clinical trail^^* r^g
process of randomisation, i.e., allocating patients to treatment
1G7 170
groups by a chance procedure * , clearly strains the tradi­
tional doctor/patient relationship. The physician is unable to 
give the patient what he may feel to be the best possible care 
and both lose the freedom to chose a particular therapeutic option. 
The design and management of a randomised trial pose ethical 
questions, namely the facts that standard treatment may be with­
held from the experimental group, the possibility that the control 
patients are denied a potentially beneficial new treatment and the
concern that patients are randomly assigned to therapies with
1 fiR 1 fi 7
different risks (if these are known). ’ This conflict
between individual patient ethics and the collective ethics
of the patient population with the disease being studied must be
resolved by both referring and participating physicians if the
trial is to be successfully completed^^,^6^,^ 9. The rights of
the individual patient must to a certain extent be sacrified in a
properly controlled clinical trial and this may affect patient
referral69 . As a result the aim of the randomised clinical tfrial
169may not be achieved . If patients enrolled in the t r i a l  are for. 
ethical or other reasons, not representative of the patient 
population for whom the study treatment is being evaluated the 
significance of the study's conclusions may be questionable.
Implicit in the process of randomisation is the concept that
patient and/or physician preference for a type of therapy is being 
169
removed . Unfortunately, however patient bias may still affect
119
the interpretation of results and may contribute to the high 
response rate reported in controlled studies of plasma exchange. 
The placebo effect must be accounted for in the assessment of 
any treatment results.
This effect could be overcome by using a placebo in the control 
group^7'"^0 . If patients are unaware of their assigned treat­
ment group then patient attitudes to the trial should be the 
same in both the placebo and the experimental groups. Any 
differences in response between these groups should then be 
real. For some therapies the appropriate placebo may not be
171
available . This applies to invasive procedure, where the 
risks to the control patients may be unacceptable and even
166
greater than the potential benefit of the experimental therapy ' 
167 The ethics of intentionally deceiving patients also 
deserve careful consideration.
Double blind studies, where neither patient nor observer know
which treatment is being administered may avoid bias and ensure
166
that there is no disparty between the groups . Double blinding 
will however further complicate the design and implementation of 
a study.
For those disorders where the definition of response to plasma
exchange involves the measurement of specific end-points, e.g.
renal function in rapidly progressive glomerulonephritis;
platelet count in immune thrombocytopenia purpura or foetal
outcome in Rh alloimmunisation, the blinding of patients is 
164
not necessary . For disorders where such objective assess­
ments are more difficult, e.g. multiple sclerosis or rheumatoid
120
arthritis, it has been suggested that the patients should under-
28
go a sham plasma exchange procedure . This is identical to a
true exchange except that, without the patient's knowledge, the
separated blood components are reinfused without any plasma
replacement. This procedure is difficult to justify bearing in
172
mind the potential complications . It has also been argued,
however, that a sham procedure which entails a temporary
extraction of plasma or cells and extracorporeal manipulations
may in itself be therapeutic and capable of inducing measurable
163 173
changes in the blood * . The irreversible extraction of
plasma, or cells, has been shown to be therapeutically more
174 175
effective than the temporary removal * .
1.5.5 Typical Applications of Plasma Exchange
The technique has been applied to a wide range of diseases as in
176 160Table 13 . The earlier invesigations were exploratory
assessments of the therapeutic potential of the procedure and
that much of the controlled testing .necessary to establish the
efficacy of the technique remained to be undertaken. This
177
deficiency is still being remedied . The present review is 
restricted to those disorders under treatment at the Glasgow 
Royal Infirmary.
Hyperviscosity States,
i. Paraproteinaemias
Paraproteins are large abnormal proteins with a high intrinsic 
viscosity. They tend to precipitate on cooling and have the 
ability to interact with other proteins. These properties 
account for the symptoms they produce in malignant and non-
121
Table 13
List of Diseases.in which Plasmapheresis has been use'
Haematological:
Macroglobulinaemia
Myeloma
Immune thrombocytopenia
Haemophilia with inhibitors
Post transfusion purpura
Acquired Von Willebrand's disease
Pruritis of myeloproliferative disease
Acute leukaemia
Bone marrow transplants
Haemolytic disease of the newborn
Autiommune haemolytic anaemia
Cold haemagglutininin syndrome
Paroxysmal cold haemoglobinuria
Paroxysmal nocturanal haemoglobinuria
Sickle cell crisis
Pure red cell aplasia
Aplastic anaemia
Renal:
Goodpasture's syndrome
Crescentic glomerulonephritis
Light chain nephritiis
Haemolytic uraemic syndrome
Henoch Schonlein nephritiis
Mesangiocap i11ary glomerulonephritis
Renal transplant rejection
Neurological:
Myasthenia gravis 
Lambert Eaton Syndrome 
Amyotrophic lateral sclerosis 
Schizophrenia 
Guillain-Barre syndrome 
Multiple sclerosis 
Parkinson's disease
Endocrinological:
Thyroid storm
Exophthalmos and pretibial myxoedema 
Insulin resistant diabetes
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Table 13 (continued)
Toxins and Drugs:
Ammanita phalloides poisoning 
Phenylbutazone overdose 
Digoxin overdose 
Paraquat poisoning 
Methyl parathion poisoning 
Aluminium encephalopathy 
Sodium Chlorate poisonng
Malignant Disease:
Disseminated carcinoma 
Melanoma
Immunotherapy blocking factor
Neuroblastoma
Hyperhephroma
Sweats and pruritus of malignant disease
Respiratory Disease:
Idiopathic pulmonary haemosiderosis 
Idiopathic pulmonary fibrosis 
Asthma
Miscellaneous Disorders
Familial hyperlipidaemia
Refsum's syndrome
Fabry-'s disease
Immunodeficiency syndrome
Thrombotic thrombocytopenic purpura
Eclampsia
Uncontrolled hypertension 
Cyclical angioneurotic oedema 
Antibodies to HLA
Dermatological:
Pemphigus
Pemphigoid
Herpes gestationis
Porphyria cutanea tarda
Necrotising vasculitis
Psoriasis
Autoerythrocyte sensitisation 
Scleromyxoedema
Table 13 (continued)
Connective Tissue Disorders:
Systemic lupus erythematosus
Rheumatoid arthritiis
Dermatomyositis
Still's disease
Scleroderma
Behcet's syndrome
Rheumatic fever
Polymyositis
Polyarteritis nodosa
Wegener's granulomatosis
Raynaud1s syndrome
Cryoglobulinaemia
Mixed connective tissue disease
Sjogren's syndrome
Infections:
Subacute bacterial endocarditis 
Meningococcal septicaemia 
Staphylococcal septicaemia 
Leptospirosis 
Leprosy
Gastrointestinal:
Hepatic coma 
Pruritis of cholestasis 
Crohn's disease
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malignant conditions.
178 179 180
It has been shown ’ * that plasma exchange can be extremely
effective at removing these paraproteins, the effectivness depend­
ing on the distribution within the vascular compartments.
ii) Waldenstrom1s Macroglobulinaemia
181—183
This disorder is due to the proliferation of an IgM
producing clone. It is characterised by many unpleasant and 
occasional life-threatening complications due to hyperviscosity, 
of which blindness, deafness, coma and retinal haemorrhage are a 
few. Conventional treatment consists of chemotherapy - 
Chlorambucil being the drug of choice. It can, however, be many 
weeks before it begins to decrease the production of IgM. One 
single plasma exchange, on the other hand, can lower the serum 
IgM by 50%, because 75% of the IgM antibodies responsible for 
the condition circulate in the intravascular compartment. There 
is also an immediate improvement in the clinical condition.
Some patients can be maintained symptom-free by two to three- 
monthly plasma exchanges without chemotherapy.
iii) Multiple Myeloma
This condition may present in a variety of ways, one of which is
184
acute renal failure . Multiple pathogenic factors contribute
185
to the problem and it is associated with a poor prognosis .
One factor known to be associated is the effect of Bence-Jones 
proteins which form obstructive casts in the distal nephrons. 
Intensive plasma exchange may remove 50% of these circulating 
proteins in patients unresponsive to more conventional therapy, 
e.g. diuretics, urinary alkalinisation and chemotherapy. The
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effectiveness of plasma exchange on the long-term management and 
prognosis of these patients is presently unknown, but it may 
well be a very useful short term measure until cytotoxic therapy, 
namely, Melphalan in combination with Prednisolone takes effect.
186,187
Hyperviscosity is also associated with Multiple Myeloma 
due to increased production of IgG and IgA. These molecules 
tend to have a higher extravascular distribution than IgM, but 
this larger extravascular load is offset by a slower re­
accumulation rate of immunoglobulins. IgG and IgA have lower 
molecular weights than IgM, making hyperviscosity a less 
frequent occurrence than Waldenstrom's Macroglobulinaemia.
Often single plasma exchanges lead to considerable clinical 
improvement during the lag period before established chemo­
therapy reduces production of the offending immunoglobulin.
iv) Cryoglobulinaemia
Cryoglobulins are paraproteins which tend to precipitate on 
cooling. Their presence is associated with many disturbing
effects namely hyperviscosity, vasculitis and Kaynaud's
188,189 r, - , • iPhenomenon . Gangrene and necrotic ulcers are common
consequences.
Therapy 190,191 is aimed at the underlying disease process, 
e.g. collagen disorders, infectious mononucleosis and 
cytomegalovirus. In the acute situation plasma exchange is 
the treatment of choice. The response is often quite dramatic 
with long-term remissions being achieved.
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Immune Based Haematological Disorders 
i) Autoimmune Haemolytic Anaemia
The Haemolytic anaemias characterised as autoimmune are 
identified by the presence of autoantibodies against red cells. 
More often than not, a specific aetiological basis is not 
identified and treatment with steroids, splenectomy or immuno­
suppressive agents aims at decreasing the distruction of
192-195antibody-coated red cells and reducing antibody production 
Some patients fail to respond to such conventional therapy and 
present with severe anaemia. In such cases it is often impossible 
to obtain compatible blood and treatment is thus difficult.
It has been shown that plasma exchange has a potential role in 
the treatment of both warm and cold antibody-mediated haemolytic 
anaemia. It causes a temporary reduction in cytotoxic antibody 
levels. The fall in titre of antibodies allows prolongation of 
survival of transfused cells and immunises the destruction of 
autologous red cells. The majority of patients will not require 
such treatment. However, where conventional therapy fails, a 
trial of plasma is recommended, especially in the setting of 
fulminant haemolysis.
ii) Idiopathic Thrombocytopenic Purpura
IgG and IgM platelet antibodies are present in the majority of
patients with I.T.P. and are implicated in platelet destruction.
Conventional therapy for I.T.P. includes the use of steroids
which are thought to block the macrophages in the spleen thus
196
decreasing platelet sequestration and destruction . If 
this fails reduction of autoantibody production is attempted by
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the use of cytotoxic agents - vincristine and cyclophosphamide,
with or without splenectomy, the spleen being the major source
of antibody production. Conventional therapy fails to produce
a substantial response in 30% of patientis, with 7% having severe
197continuous bleeding problems .
192 198
Plasma exchange * can remove a predictable amount of 
circulating immunoglobulin.
It has been demonstrated that a single plasma exchange can bring 
about a 50% decline in anti-platelet activity, with an associated 
increase in platelet counts within hours of procedure, resulting 
in an immediate improvement in haemostatic function. On available 
data, therapeutic plasma exchange has a potential role in acute
I.T.P. whenever splenectomy or immunosuppressive agents are contra­
indicated. It is also useful in preparing patients for surgical 
procedure.
The possibility that plasma exchange will result in an anti­
coagulation effect with increased risk of bleeding should also 
be considered.
1
iii) Thrombotic Thrombocytopenic Purpura
The disorder, of unknown pathophysiology, is characterised by 
microangiopathic haemolytic anaemia, thrombocytopenia, central 
nervous system dysfunction and renal impairment. The clinical 
manifestations are due to the formation of platelet thrombi in 
the microcirculation.
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Many therapies ’ have been used for I.T.P. - namely trans­
fusion, corticosteroids, antiplatelet agents and splenectomy.
In spite of such treatment, mortality rates range from 72% at 3 
months to 93% at 1 year.
Plasma exchange*^ ’ is known to bring about a rapid improve­
ment, whether by removing toxic factors or by adding normal 
stimulatory substances. It may well be that it provides a missing 
plasma factor which has a stimulatory effect on vascular endoth­
elium, producing prostacycline PG12, a potent inhibitor of plate­
let aggregation. Absence of the factor leads to platelet con­
sumption, which in turn triggers the syndrome. Since plasma 
exchange has been incorporated into the therapeutic regime, 
recovery has occurred in 70% of cases.
iv) Factor VIII Inhibitors
Antibodies to FVIII, occur in a variety of haematological and
non-haematological diseases and may be present with life
203-205
threatening bleeding. Therapeutic plasma exchange is now used 
increasingly in the treatment of patients with this disorder. 
Combination therapy, namely immunosuppression (corticosteroids) 
and plasma exchange may decrease the concentration of Factor VIII 
inhibitors by 85%. It is now the first line treatment to rapidly 
remove the inhibitor, allowing standard chemotherapy to take 
effect in the ensuing three weeks.
Alloimmunisation
i) Rhesus Haemolytic Disease
There are still a considerable number of alloimmunised women of
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child-bearing age despite the advent of immune globulin. Full- 
term pregnancy for these women can still be a major problem^ ’
It has been shown^^ ’^ ^  that plasma exchange, commenced early 
in pregnancy, can achieve a more successful outcome in a signif­
icant number of cases. Plasma exchange is known to remove 
circulating proteins, e.g. antibodies. In some cases of Rhesus 
disease the antibody concentration may be lowered by 80%. 
Sufficient amounts of the offending immunoglobulin may be removed 
and accordingly lead to a dramatic decrease in foetal wastage.
Its greatest potential is achieved when haemolytic disease begins 
after the 30th week of gestation.
Antibody Mediated Non-Haematological Disorders
i) Myasthenia Gravis
The antibody to the acetylcholine receptor is basic to the patho­
genesis of myasthenia gravis. Amongst different patients the 
correlation between the level of acetylcholine receptor antibody 
and the severity of myasthenic symptoms is not strong; changes 
in antibody level in the individual patient may parallel changes 
in disease activity. Acetylcholine receptor antibody that is
transferred from mother to foetus is associated with neonatal 
209
myasthenia gravis . In this situation plasma exchange may 
ameliorate acute myasthenia weakness^^.
Plasma exchange is often used in the preparation of an individual
for thymectomy respiratory muscle weakness. In many cases, it
may be useful to relieve weakness before immuno-suppressive
210-212therapy has become effective
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ii) Goodpasture1s Syndrome
This syndrome is characterised by rapidly progressive glomerulo­
nephritis and antibody to glomerular basement membrane. Plasma 
exchange reduces the level of this antibody, whilst immuno-
pi  0^0*1 c
suppression inhibits its further synthesis ~ . I t  is not 
been established that the exchange improves patient survival, 
nor has a comparison been made of immunosuppression therapy alone 
with immunosuppression combined with plasma exchange. It is also 
possible that the duration of the disease may significantly affect 
the outcome of the treatment because of irreversible damage to 
the lungs and kidneys by high levels of antibody.
iii) Refsum’s Disease
This rare inherited disorder is characterised by chronic poly­
neuropathy, ichythosis, deafness and retinitis pigmentosa
2XGassociated with accumulation of phytanic acid in tissues 
Plasma exchange has been used successfully to complement diet 
in the restriction of phytanic acid and in an effort to reduce 
levels in blood and tissue
/
iv) Guillain Barre Syndrome
The mechanism by which plasma exchange may benefit patients with
/ 219-222
acute Guillain Barre syndrome is unclear . The rationale
is provided by the evidence that the serum of patients affected
may contain demyelinating factors, antibodies to peripheral
nerve tissue of immune complexes. The role of these factors in
causing the syndrome is unknown.
Plasma exchange is of value in the treatment of the syndrome if 
commenced early and aggressively enough, i.e. within 10 days of
131
of the onset of muscular symptoms and removing a minimum of 15 
litres of plasma.
The median time that patients are on a respirator will be decreased 
by some 10 days, and the time to make a functional recovery is 
shortened by a mean of 73 days.
v) Aplastic Anaemia
The role of immune mechanisms in bone marrow failure associated
with aplastic anaemia suggests that the application of plasma-
223 224
pheresis could be beneficial in the treatment of the disorder * ,
The mechanisms responsible for the bone marrow failure in aplastic 
anaemias have long been studied. In some patients, serum inhibi­
tory immunoglobulin has been shown to be directed against marrow 
CFU-C. Thus, in patients in whom antibodies were shown to be 
responsible for the inhibition of in-vitro CFU-C formation, plasma 
exchange could well be beneficial.
The potential side-effects of plasma exchange in this situation
must be considered. There may be a rebound humoral immune response
and plasma exchange should be followed by immunosuppressive drug 
225,226therapy . ,
It is suggested that plasma exchange is limited to selected patients 
with active life-threatening disease to provide an acute, althpugh 
temporary, therapeutic option.
vi) Neoplasia .
Studies of plasma exchange in the treatment of patients with cancer 
have been largely confined to solid tumours. The theoretical
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basis for plasma exchange as a specific treatment, rather than
as supportive care, is controversial and involves the manipulation
of the patient's immune system into a more favourable state,
perhaps by removing immune complexes that may act as 'blocking
factors'. Anti-tumour responses have been reported after plasma
exchange in a variety of patients with solid tumours, but improve-
227-230
ments have been mostly temporary .
Partial responses have been reported in patients with heavily 
treated, chemotherapy-resistant lymphoma after a series of plasma 
exchanges.
Patients with acute myeloid and lymphatic leukaemia have been
treated with plasma exchange before and during induction
therapy. Those subjected to plasma exchange and chemotherapy
exhibited more complete and partial remissions than those patients
subjected to chemotherapy alone. However, other prognostic
factors such as age, state of infection, etc., influenced the
22 229 230
more favourable results and few conclusions can be drawn - * *
Treatment by allogeneic bone marrow transplant is favoured for 
aplastic anaemia and certain forms of leukaemia^'^*^'^. Donor 
and recipient are usually matched by human leukocyte antigen 
(HLA), but in approximately 20% of cases, a major ABO incompat­
ibility exists, i.e., the marrow recipient has anti-A or anti-B 
antibody directed against donor-type red cells.
Marrow has the same red cell content as whole blood and measures 
must be taken to reduce the possibility of a haemolytic trans­
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fusion reaction at the time of the marrow infusion. Haemolysis, 
at the time of infusion, may be avoided by the removal of red 
cells from the marrow using continuous and intermittent flow 
centrifugation, hydroxyethyl starch, gravity sedimentation 
and separation on fresh gradients.
These methods eliminate the target cell because early precursor 
red cells do not express ABO blood group antigens. Whilst 
effective, these methods may deplete the marrow of haemopoietic 
stem cells. This may be critical in some transplant situations, 
such as aplastic anaemia, where the cell dose is known to be 
important for engraftment.
Large volume plasma exchange to remove the undesired haemagglut- 
inins from the marrow receipient will avoid marrow manipulation. 
Patients treated in this way for ABO incompatibility have been 
found to engraft as rapidly as patients who are ABO matched.
The incidence of graft versus host disease and rejection is 
also reduced.
Plasma Exchange in Children
Plasma exchanges have been used in paediatric nephrology and
include renal failure in association with crescentric nephritis
due to Goodpasture's Syndrome, Henoch-Schonlein Syndrome and
idiopathJ.c nephritis. Other conditions include systemic lupus
erythematosus, haemolytic uraemic syndrome and systemic
vasculitic disorders such as polyarteritis. Some of the patients
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required peritoneal dialysis at the same time as plasma exchange 
The majority of patients have been exchanged on the continuous
flow IBM 2997 cell separator; although a few of the earlier
patients were exchanged using a Haemonetics 30 with a paed­
iatric bowl. In general, the continuous cell separator has
provided greater haemodynamic stability, as well as faster
exchanges. Plasma exchange is not a substitute for dialysis 
and it is essential that all patients are stable haemodynamically, 
before exchange is commenced.
i) Preparation for Plasma Exchange
Investigations prior to plasma exchange should include full blood, 
count, coagulation screen, Hepatitis B SAg, electrolytes, total 
protein and creatinine clearance when indicated. The child's 
body weight and resting blood pressure should be recorded. All 
patients are cross-matched and whole blood is used to prime the 
cell separator for the child's first exchange and subsequent 
exchanges if the daily pre-exchange haemoglobin is below 9 g/dl. 
The machine should be primed through to the return line with 
blood or plasma in children <  30 kg weight (if under 20 kg, 
whole blood should be used). The exchange is performed using 
plasma protein fraction 80-120 ml/kg. Fresh frozen plasma is 
given at the end of the exchange from the third day to help 
replace depleted clotting factors.
Adequate venous access is vital to the success of plasma exchange 
in children and needs to be planned before exchange. In the 
majority of children plasma exchange is a short term procedure 
undertaken in the acute illness and needs to be considered 
against the complications of the more invasive forms of 
vascular access.
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ii) Management During Exchange
Patients are given intravenous hydrocortisone and anti-histamine 
immediately before exchange to reduce the risk of allergic 
reactions. Heparin is the anticoagulant bf choice at a dosage 
of 100 IU/kg to a maximum of 2,000 units as a bolus pre­
exchange with 40 IU/min as maintainance (i.e. 20,000 IU in 
500 ml of normal saline at 1 ml/min). This may be reduced under 
certain clinical conditions, e.g. post-surgery or with coagul­
ation abnormalities. At',the beginning of the exchange the child 
should be supine and providing the observations of blood pressure, 
pulse and general clinical state remain stable, the initial flow 
rate through peripheral lines is 30 ml/min. Hyper- or hypo- 
volaemia may occur. The former is particularly common in the 
patient with renal failure. Hypovolaemia may present in children 
with irritability, restlessness, yawning, drowsiness or cramps 
which later progress to abdominal pain, vomiting and collapse. 
Cessation of the exchange and correction of the hypovolaemia by 
the plasma infusion is usually adequate.
iii) Post Exchange
Once the full exchange has been completed, it may be necessary 
to wash back the remaining blood contained in the centrifuge if 
the child remains anaemic, or the circuit was not primed with 
blood. Many patients may be haemodynamically unstable post­
exchange and on return to the ward they need to be monitored 
accordingly. The haemoglobin is checked at the end of the 
exchange.
iv) Complications
There have been 3 reported cases of septicaemia, one of which
136
was fatal. This occurred in a patient with a long line in-situ.
A haemothorax and subsequent empyema occurred in relation to 
malinsertion of subclavian line. One patient with severe 
vasculitiis developed a hemiplegia 12 hours following a second 
exchange. Subsequent CAT scan showed no evidence of haemorrhage, 
but the patient deteriorated and died.
Thus, the procedure in children is not without hazard but its 
careful application will minimise the risks and may be of some 
therapeutic value in otherwise serious disease.
1.6 Side Effect of Plasmapheresis
Initially, it was generally believed that the plasma exchange
procedure was both easy and harmless. This attitude was based
on a simplistic view of the procedure, perhaps compounded by a
mistaken extrapolation to it of the experience with healthy
blood donors. In fact, whilst major complications are few and
236
far between* minor complications are surprisingly common
1.6.1 Vascular Problems
In many cases patients have already been under extensive medical
care and venous access for purposes of therapeutic exchange has
116
already been jeopardised via peripheral routes . Repeated 
trauma through multiple venepuncture can result in thrombosis 
and sclerosis.
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In such cases access is only possible by indwelling catheters 
in, e.g., subclavian, or femoral vein, or fistula. Once again 
this may result in complications. Fatal perforations,
114
thrombosis, sepsis and circulatory interference may occur
1.6.2 Procedural
1) Circulatory Effects
Even in healthy donors the procedure can cause tiredness, vague
malaise and vasovagal reactions. These effects, presumably
caused by extracoporeal circulation and shifts in body fluid
balance, are obviously more pronounced in sick patients under-
236
going plasma exchange . Vasovagal reactions may be accompanied
by pallor, sweating and occasional hyperventilation and are
relatively common, particularly in intermittent flow centri- 
237-238
fugation . They tend to be aggravated by psychological
factors and can be minimised by reducing the patient's state of 
anxiety, whilst simultaneously correcting hypovolaemia^®®. 
Hypotension may occur, although it usually does so in patients 
undergoing plasma exchange for hyperviscosity from Waldenstrom's 
disease, due to inability of the patient's blood vessels to 
compensate rapidly to changes in the intravascular plasma volume. 
Patients who suffer from hyperviscosity or cryoglobulinaemia may 
develop severe hypotensive episodes.
Fluid overload can occur in the elderly towards the end of a 
procedure when the blood outflow has been stopped and the 
return of fluid is continuing. Cardiac failure may be precip­
itated.
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2) Anticoagulant Effects
There is an occasional occurrence of cardiac arrhythmia which 
has- been responsible for some deaths and may be related in part 
to a citrate effect. It appears to occur more often when sub­
clavian lines are used, perhaps because of the delivery of 
citrated plasma to the great veins close to the heart. Brady­
cardia, atrial, nodal and ventricular ectopics, atrial 
fibrillation and supraventricular tachycardias have all- been 
reported, but only when ACD has been the anticoagulant used.
These are due to a marked decrease in the amount of ionisable 
calcium because of the chelating effect of the citrate.
Syncope during exchange is associated with severe sinus brady­
cardia and hypotension mostly due to hypocalcaemia. Other 
manifestations of hypocalcaemia, namely circumoral paraesthesia, 
increased muscle tension, nausea, vomiting and overt tetany can 
occur but may be avoided by giving prophylactic calcium during 
exchange. It would seem that if citrate is used as anticoagulant 
then calcium and potassium supplements should be given.
Failure to obtain a homogeneous concentration of anti-coagulant
has been found to result in massive extra-corporeal blood
clotting. These manifestations are thought to be a consequence
239
of a thrombotic trend during the procedure . Actual contact
activiation of the fibrinolytic system induces a thrombotic
state during plasma exchange in which anticoagulation is
achieved by ACD alone. It is also known that, following
intensive plasma exchange, significant decreases in AT III levels
occur inducing a hypercoagulable state which may persist for some 
' 124
72 hours or more .
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3) Effects of Replacement Media
There are potential disadvantages associated with each of the
,, , . .. 137,240,241available replacement media .
Plasma Products
There is usually a delay in the administration of such 
products which are in relatively infrequent supply. The 
main d i s a d v a n t a g e  however is in the transmission of disease 
- hepatitis B and A non - B Hepatitis. This occurs despite 
screening all donors for Hepatitis B.
The incidence of allergic reactions is higher and tachy­
cardia, hypotension, bronchospasm and even anaphylactic 
shock may occur.
Albumin Solutions
These contain no coagulation factors or immunoglobulins
which may be a drawback. Occasionally anaphylactoid reactions
242 243or hypotension may occur * .
Gelatins
Gelatins may be associated with very severe allergic 
reactions which may be fatal. They will also cause a reduct­
ion in albumin levels which may result in peripheral oedema.
4) Hypothermia
Many patients feel cold and shivery during plasma exchange 
because their blood is in an extra-corporeal circuit at room 
temperature. This occurs in exchanges of long duration (4-6 
hours) and is due to the cooling of blood in the centrifugal
140
, pq^
bowl at 26°C - 2°C . The chilling may also be part of the
manifestation of the citrate effect or may aggravate the latter. 
The problem can be overcome by using a thermostatically 
controlled blood warmer in the returning line which increases 
the infusion fluid temperature to 35°C - 2°C.
5) Haemolysis
236
Red cell haemolysis is possible whenever blood comes into
contact with foreign surfaces or is moved by pumps against
resistance, i.e., as a result of cessation of blood flow through
the system and the continuation of pump rotation around a
stationary column of red cells. Input and output sensors are
normally provided on equipments to detect an appropriate blood
flow and automatically stop pump rotation. If attempts are made
to process more than venous access will .permit and the pump is
stopped by the occluded vein sensor, then negative pressure may
arise on the input side. Restarting the pump rotation manually
may result in red cell haemolysis within the channel. Further,
if the centrifuge is spinning in the absence of flow, the seal
hold-down exerts pressure on the seal surface and haemolysis of
red cells may occur in the area of the seal. In intermittent
flow centrifugation procedures, the presence of a kink in the
244
tubing leading to the reinfusion bag can cause haemolysis 
This will seldom occur in continuous flow centrifugation 
systems.
The red cells may be more damaged than the degree of visible 
haemolysis would appear to indicate. Haemolysis is less likely 
to occur if priming saline is opened to alleviate negative 
pressure while attempting to reinstate blood flow. If flow is
141
stopped because of venous access and new bleeding or return 
sites are needed, the centrifuge may be safely turned off for 
procedures using the single-stage channel. For dual-stage 
procedures, reducing the centrifuge speed from 1400-1200 rpm 
usually prevents haemolysis and red cell spill over into the 
spiral channel, so that platelet collection may continue when 
flow is resumed.
6) Loss of Medication
Obviously the removal of a patient's plasma will also remove
236any medications that may at the time be carried in the plasma . 
This can be deleterious in a patient whose stable clinical 
state is dependent on a level of medication in the blood, e.g. 
anti-convulsant therapy. Supplemental medication may be needed 
during or immediately after a procedure.
1.6.3 Mortality
It is estimated that about 10,000.procedures are carried out
annually in the UK and no deaths due to the procedure have been 
236reported . In the USA 23,000 procedures are undertaken annually 
and 16 deaths have been reported over 3 years. Most of the 
respiratory and cardiac deaths were associated with the use of 
plasma, which is more commonly used outwith the UK (Table 14).
The typical cardiac death usually is preceded by an arrhythmia 
followed by cardiac arrest. It is thought to be due to a 
reduction in serum ionised calcium levels produced by infusion 
of citrated plasma. Respiratory deaths are usually preceded 
with development of signs and symptoms of acute noncardiogenic 
pulmonary oedema.
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SCOPE OF THESIS
Over the period 1981 to 1985, 2,685 plasma exchange procedures 
were carried out on 201 female and 125 male patients in the 
course of treatment for a range of clinical disorders. The 
procedures were all performed on an IBM 2997 Cell Separator 
(continuous flow). During this period of time a number of 
individual studies were undertaken. These involved an 
evaluation of
(1) the efficiency of the selected replacement fluids used 
in the treatment of 3 groups of patients
(2) the effectiveness of the procedures in the treatment 
of:
1. Cold Haemagglutinin Disease
2. Waldenstrom's Macroglobulinaemia and Hyper­
viscosity due to Multiple Myeloma
3. Immune Haemolytic Anaemia
4. Factor VIII Inhibitors
5. Polyneuropathy
6. Myasthenia Gravis and Eaton Lambert Syndrome
/
7. Guillain Barre Syndrome
8. Glomerulonephritis and Goodpasture's Disease.
9. Aplastic anaemia together with pure red cell 
aplasia.
10. Polymyositis
(3) Leukapheresis in the management of patients with acute 
and chronic myeloid and lymphatic leukaemia.
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A complete record of each patient's clinical response to treat­
ment was kept throughout the period of the individual studies.
2.1 Details of Patients and Exchange Procedure
2.1.1 Study of selected replacement fluids
One hundred and forty patients with Myasthenia Gravis, Guillain- 
Barre Syndrome, chronic relapsing polyneuropathy and polymyositis 
were studied in 3 groups as detailed in Table 15. No patient had 
an intercurrent disease likely to affect the parameters measured.
Three fluids, namely 5% albumin, plasma protein fraction and 
gelatins (Haemaccel) were used to replace plasma withdrawn during 
the exchange. The efficacy of selected types of replacement 
fluids was studied by examining the reactions to plasma exchange 
of the 3 groups of patients, as below.
Group 1:- 60 patients, who underwent 300 exchanges
each patient received as replacement fluid, 
Polygeline I,consisting of
1. 1 litre of 5% albumin
2. 1 litre of Haemaccel
3. 0.5 litres of normal physiological saline
Group 2:- 60 patient, who underwent 300 exchanges
each patient received as replacement fluid,
Plasma protein solution consisting of
1. 2 litres of 5% albumin
2. 0.5 litres of normal physiological saline
145
Cl
in
ic
al
 
Co
nd
it
io
ns
 
of
 
Pa
ti
en
ts
 
Tr
ea
te
d 
By
 
Pl
as
ma
 
E
x
c
h
a
n
g
e
 
 
Us
in
g 
Se
le
ct
ed
 
Re
pl
ac
em
en
t 
Fl
ui
ds
 
 
 
_
ga> in 
x  -p 
e G 
3 0 ft s ' 
-p
r-i 00 a. cd
■p
o  <H c  
H  O  H
oto
<H
O  IQ 
■P 
G G 
0 0 
.Q -ri
6 -P 3 0 
S ft
O
CO
N o
r-i t-i
CO
o
CO
00 O  
CM r-i
CO
t>>
X•P
cd
fto
G
3d>
0
E £o
-E)
r-i
O
ft
G
bOi>>
CO G
•ri
VI) CQ
G
51
ftcd
r-i
ft
1
d)ft
G a•r-i
cd •ri
r-i G
H oG
3 .G
CD U
O
CM
to in io in
t»
X
■P
cd
ft
0
G
3d>
d)
E £ .o r-i ;
G O
X3 ftG
bi)
CO G
•H
VD CQ
G ft'G cd
CO r-i
ft 0
1 &  iG
•ri O :
cd •ri i
r-i G |
r-i 0 !
•ri G3 5 1
CD u
. i
G0)
TO
Go
CQ
•rl
Q
•P
G0)
•H
•P
cd
ft
in
•ri
5
6 
cd
•ri
Ga)
-p
CQ
cd
>>s
X
•P
0
f tO
G
3
0
0 C
E £>O r-i
G O'O ft
G bU
CO G
•ri
V0 CQ
G ft
G 0cd r-i
ft 0
1 ft
G
•ri O
cd •ri
H G
r-i 0
•ri G
3 X
CD O
CQ
•ri
•P
•H
CQ
O
!>>E
>>r-i
O
ft
CQ•H
§
&
cd .
•ri
Ga>
X
•p
CQ
cd
£
co•H
•P
•ri
CQ
O
>>
E
>>
r-i
O
ft
CQ
•ri
id
6
•ri
Ga)
Xi
■p
CQ
cd
>>s
CQ
•ri
-P
•ri
CQ
O
J>>
G 'O a) Q>
e  wa) D
9 'O'cd -H 
r-i 3
0) [r,
ft
H
a>
G
•ri
H0)
bfl
i>»r-i
O
ft
G
•ri
0
■P
O
Gft G
O
0 •H
E •P
m 3
0 r-i
r-i O
ft CO
(X
3O
G
CD
G.
3O
G
CD
CM
ft
3o
GCD
HH
0)
G
•ri
HQ>
bO
!>>H
O
(X
CO
(X
3O
G
CD
146
Group 3:- 20 patients, who underwent 100 exchanges
each patient received as replacement fluid, 
Polygeline II, consisting of
1. 2 litres of Haemaccel
2. 0.5 litres of normal physiological saline
For the majority of patients venous access for plasma exchange 
was via an antecubital vein, but arteriovenous shunts or fistula 
were used in 49 cases.
Approximately 2.5 litres of plasma was exchanged during each 
procedure, undertaken daily for 5 consecutive days (i.e. a 
total of 12.5 litres of plasma was exchanged in each patient). 
Heparin was used as anticoagulant, each patient being given a 
loading dose of 5,000 units followed by a further 3,000 to 
5,000 units during the procedure. On 5 occasions only, 
protamine sulphate was used to reverse the effect of Heparin.
2.1.2 Study of Selected Disorders
The patients were aged between 18 and 65 years with a mean age 
of 42 years and were treated for a variety of clinical disorders 
as indicated in Table 16 and below:
1. Cold Haemagglutinin Syndrome
Eight patients received treatment, 4 were known to have a 
lymphoma, 1 to have an adenocarcinoma of the lung and 3 had 
proven viral illness. All patients were anaemic, some pro­
foundly so. All had failed to respond to conventional 
chemotherapy.
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Table 16
Age and Sex Distribution of 186 patients treated for 
Various Disorders by Plasma Exchange at the Glasgow 
Royal Infirmary over the period 1981 - 1985
Number
Sex Age Group No. of
Ex­
changesDISEASES of 20 • 30 40 50 60
Patients M F 30 40 50 60 70
Cold haemagglutinin 
Syndrome 8 6 2 0 2 3 2 1 36
Macroglobulinaemia 18 10 8 0 2 6 8 2 171
Myeloma with 
Hyperviscosity 12 7 5 0 1 2 9 0 60
Immune Haemolytic 
Anaemia 3 0 3 0 1 1 1 0 12
Factor VIII Inhibitors 8 1 7 3 3 0 2 0 40
Chronic Polyneuropathy 15 5 10 8 5 2 0 0 50
Myasthenia Gravis 18 6 12 3 6 5 4 0 80
Eaton Lambert Syndrome 5 2 3 0 0 2 3 0 20
/
Guillain Barre Syndrome 27 14 13 14 10 2 1 0 162
Glomerulonephritis/ 
Goodpasture's Syndrome 36 13 23 18 15 3 0 0 252
Pure red cell aplasia 4 3 1 0 1 2 1 0 16
Aplastic Anaemia 2 2 0 2 0 0 0 0 6
Polymyositis 10 7 3 6 4 0 0 0 35
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A total of 36 exchanges were undertaken using plasma protein 
solution as replacement fluid, 86 litres of plasma were 
exchanged in total.
2. Waldenstrom's Macroglobulinaemia
Eighteen patients with hyperviscosity syndrome each received 
treatment by means of plasma exchange. 65% of patients exhibited 
neurological symptoms, 55% suffered from general malaise, 50% 
suffered from bleeding and 15% from non-specific pain. Patients 
were aged 35 - 79 years. The mean age on the onset of symptoms 
was 55 years and on diagnosis of disorder was 60 years.
A total of 171 plasma exchange procedures were carried out over 
a 3 year period 1982 - 1985. The mean value of plasma exchanged 
during each procedure was 2.5 litres. The replacement fluid was 
generally plasma protein solution but this was, on occasions, 
partially replaced by Haemaccel (some 15 procedures).
A further seven male and five female patients with hyperviscosity 
due to multiple myeloma underwent sixty exchanges. They were 
aged between 39 and 58, with a mean age of 49 years. They were 
each receiving haemodialysis.
3. Immune Haemolytic Anaemia
Three female patients received treatment. One had Evans'
Syndrome, one was post-infectious and one had a malignant 
lymphoma. All had severe haemolysis and had failed to respond 
to steroid and immuno-suppressive therapy. One patient had had 
a splenectomy.
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A total of 12 procedures was carried out. The mean value of 
plasma exchanged during each procedure was 2.5 litres. The 
replacement fluid was primarily plasma protein solution, but 
this was, on occasions, partially replaced by Haemaccel or 
fresh frozen plasma. All patients had simultaneous immuno­
suppressive therapy. None received a blood transfusion during 
the period of exchange.
4. Factor VIII Inhibitors
Eight patients aged between 22-58 years received treatment.
Two patients suffered from systemic lupus erythematosus, two 
were post-partum, one from rheumatoid arthritis, one from 
ulcerative colitis, one from dermatitis herpetiformis and one 
had recently received penicillin (i.e. drug-induced).
Five daily plasma exchanges were carried out in which 2.5 
litres of plasma was replaced on a daily basis by 1.5 litres 
of plasma protein solution and one litre of fresh frozen 
plasma. A reduced dose of 2,500 units of heparin was used as 
anti-coagulant.
5. Chronic Polyneuropathy
Five male and ten female patients with chronic inflammatory 
polyneuropathy, aged between 25 and 45 years (mean age 35 years) 
underwent a total of 50 plasma procedures in each of which 2.5 
litres of plasma protein solution and 500 ml of physiological 
saline were exchanged. All patients received concurrent 
treatment, with immunosuppressive therapy, initially using 
prednisolone 60 mg/day, and when no response was obtained, 
azathioprine 150 mg/day, or cyclophosphamide 90 mg/day was added.
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If there was no response to corticosteroids and one cytotoxic 
agent, then the other cytotoxic agent was also added, i.e. 
triple therapy.
6. Myasthenia Gravis and Eaton Lambert Syndrome
Twelve female and six male patients with ages ranging from 22
to 58 years (mean age 40 years) underwent 80 plasma exchanges.
In the majority of cases plasma protein solution was the 
replacement fluid used with a small quantity of Haemaccel.
All patients were receiving anticholinesterase drugs'* namely, 
neostigmine or pyridostigmine and immunosuppressive therapy, 
namely, corticosteroids or azathioprine tapered according to 
the patient's clinical condition.
Five patients with Eaton Lambert Syndrome aged between 48 and 66 
years underwent 20 plasma exchanges. Of the 3 males and two 
females, 4 patients had histologically proven carcinoma of the 
bronchus, and 1 patient had histologically proven carcinoma of 
the breast.
They differed from the patients with Myasthenia Gravis in that 
they presented with marked proximal limb weakness, with less 
frequent involvement of the ocular muscles. They were receiving 
no concurrent medication.
In all exchanges plasma protein solution was the replacement 
fluid of choice.
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/7. Guillain Barre Syndrome
Fourteen male and thirteen female patients aged between 14 and 
56 years (mean age 35 years) underwent 162 plasma exchanges using 
plasma protein solution and Haemaccel as replacement fluids in 
equal quantities. The patients satisfied the following criteria:
1. the duration of symptoms was less than 30 days.
2. there was no clinical evidence of improvement in 
limb function at the time of assessment.
3. no previous treatment with prednisolone or immuno­
suppressive agents.
4. no other concurrent disease.
All patients had developed a progressive flaccid quadriparesis 
and all required ventilation. The mean duration between the onset 
of symptoms and the start of plasma exchange was 8 days.
8. Glomerulonephritis and Goodpasture's Syndrome
Thirteen male and 23 female patients aged between 24 and 45 years 
(mean age 33) were treated. Twelve patients had mesangiocapillary 
glomerulonephritis MCGN Type 1, six patients had Type II MCGN.
Four patients had membranous nephropathy and three patients had 
mesangial IgA disease. The remaining eleven patients had Goodpasture’s 
Syndrome; 10 showed evidence of nephritis and pulmonary haemorrhage 
and 1 had nephritis alone. A renal biopsy was carried out on all 
patients. Immuno-fluorescence showed linear IgG along the GBM in 
all biopsies. Circulating anti-GBM antibody was detected in all 
patients.
All patients received azathioprine and cyclophosphamide for periods of 
6 - 8  weeks. Prednisolone was commenced at a dose of 60 mg/day 
and reduced gradually. Patients underwent 252 plasma exchanges 
over periods ranging from 6 months to 7 years prior to plasma 
exchange and thus served as control patients.
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9. Aplastic Anaemia and Red Cell Aplasia
Three male and one female patient had a diagnosis of pure red 
cell aplasia. They had severe anaemia for some 8 - 3 2  months,
(mean period 20 months). Two male patients had aplastic_______
anaemia of unknown aetiology and had had severe pancytopenia for 
6 months. None of the patients had a matched bone marrow donor 
and they were all steroid and androgen therapeutic failures.
The patients underwent 22 plasma exchanges, each exchange 
removing 2.5 litres of plasma which was replaced by 5% 
albumin.
10. Polymyositis
Ten patients, seven male and three female, ages ranging from 
23-38, mean 31 years with florid polymyositis underwent 35 
plasma exchanges of 2.5 litres of plasma, replaced by 5%
Albumin (85%) and Haemaccel (15%). All were concurrently 
treated with corticosteroid and azathioprine.
2.1.3 Study of Leukapheresis
Of 58 patients aged between 22 and 71 years treated by leuk­
apheresis, 5 had acute lymphatic leukaemia, 14 acute myeloid 
leukaemia, 3 acute myelomonocytic leukaemia and 25 chronic 
myeloid leukaemia and 11 chronic lymphatic leukaemia.
In each leukapheresis procedure 3 litres of blood (mean value 
2.5 litres) was processed through the IBM.type 2997 cell 
separator in times ranging from 60 to 150 minutes. Heparin 
was used as anti-coagulant.
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Fluid replacement consisted of 5% Albumin, physiological saline, 
and very occasionally Plasma Protein Solution. Platelet con­
centrate was transfused post-pheresis in severely thrombocytopenic 
patients.
2.2 Parameters Examined
2.2.1 Study of Selected Fluids
2.2.1.1 Sampling
Haematological, biochemical and clinical response of each patient 
was continuously monitored throughout the sequence of exchange 
procedures. The haematological and biochemical base-line 
investigations were made:-
immediately pre-plasma exchange 
immediately post-plasma exchange 
12 hours post-plasma exchange 
24 hours post-plasma exchange 
3 days post-plasma exchange 
5 days postvrplasma exchange
The only pre-requisites before plasma exchange were that each 
patient was HBsAG negative and had normal base-line coagulation 
screen.
All samples were collected into the appropriate containers 
through a 16 gauge cannula without venous stasis and without 
frothing. Blood for coagulation: studies was collected in 1/100
volume of 40% sodium citrate. Plasma was separated after centri­
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1.
2 .
3.
4.
5.
6.
fugation at 1800 G at 4 °C for 15 minutes. All coagulation 
studies were performed immediately or the sample was frozen at 
-30°C and studies carried out at a later date. The prothrombin 
time (PT) the Kaolin Cephalin Clotting time (KCCT) and Thrombin 
Clotting Time (TCT) were carried out immediately at 30 minutes, 
4 hours and 24 hours post-exchange respectively. The platelet 
counts were performed on blood collected in ethylene diamine 
tetra-acetic acid.
2.2.1.2 Haematological Parameters
1. Standard full bood counts
Haemoglobin estimation,packed cell volume (haematocrit) 
and white blood cell count were determined using Coulter 
Counter Model 'S'.
2. Platelet Count
Platelet counts were determined using routine Coulter S 
analysis.
3. Coagulation Screening
a) Prothrombin time
245Prothrombin time was evaluated by a one stage method in 
which 0.1. ml of plasma was placed in the bottom of a 75 x 
10 ml tube in a water bath at 37°C and 0.1. ml of rein­
suspension added to it after 60 seconds. 0.1 ml of warmed
0.025 mmol/1 calcium chloride was added and the contents 
mixed. The time taken for the development of a fibrin 
clot marking the end point was measured. The normal range 
is 10 - 14 seconds.
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b) Kaolin Cephalin Clotting Time
246The Kaolin Cephalin Clotting Time was evaluated by 
incubating 0.1 ml of plasma with 0.2 ml of a well-shaken 
Kaolin phospholipid mixture which allows activation of 
contact factors. Platelet activity is replaced by phos­
pholipid. Ten minutes was allowed for maturation of 
incubation at 37°C at which point 0.1 ml of pre-warmed cal­
cium chloride is added. The time taken for a clot to form 
is noted. The normal range is 35 - 45 seconds.
c) Thrombin Clotting Time
Thrombin clotting time was measured by placing 0.2 ml of 
normal plasma in a standard glass tube at 37°C with 0.1 ml 
of thrombin and noting the time for a clot to form. The 
normal range is 6 - 9 seconds.
4. Quantitative Assays of Coagulation Factors
a) Fibrinogen
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This was estimated by a modified quantitative method i 
which measures fibrinogen as Thrombin clottable protein.
The fibrinogen in plasma is converted into fibrin by the 
action of thrombin and fibrin is collected on glassi beads, 
washed, boiled with sodium hydroxide and its tiozine content 
estimated. Normal values 2 - 4  g/1.
b) Prothrombin
248
This was carried out using a two-stage method with 
Taipan Snake venom which converts prothrombin directly to 
thrombin in the absence of any other non-clotting factor.
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A dilution of plasma is mixed with venom in the presence 
of phospholipid and calcium chloride. The amount of 
thrombin generated is estimated by adding Fibrinogen and 
determining the clotting time. Normal range 50-100 IU/dl.
c) Factor VIII
Estimation is based on the partial thromboplastin time 
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test performed on mixtures of Factor VIII deficient 
plasma and various dilutions of both standard and test 
plasma. A standard curve is prepared by plotting the 
clotting time of each mixture against the calculated con­
centration of Factor VIII. The relative concentration of 
Factor VIII in the patient's plasma is extrapolated from 
this graph by testing similar dilutions of unknown plasma. 
Normal range 50 - 100 IU/dl.
d) Factor IX
Assays of Factor IX activity are effectively determined
250
using the KCCT method . This is performed in exactly 
the same way and has the same limitations as that for 
Factor VIII assays, except that known congenitally Factor 
IX-deficient plasma is used in place of Factor VIII- 
deficient substrate. Normal range 50-150 IU/dl.
e) Factor X
Specific assays of Factor X are performed using substrate
plasma for a patient who is known to be congenitally devoid 
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of Factor X . Such substrate can be used in an intrinsic 
assay system using the KCCT test. Normal range 50-150 
IU/dl.
157
2.2.1.3 Biochemical Investigations
1. Urea and Electrolytes
These parameters were estimated on the Technicon Auto- 
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analyser .
Normal range : Sodium 135-145 mmol/1
Potassium 3.5 - 5.0 mmol/1 
Chloride 97-107 mmol/1 
C0J content 23-30 mmol/1 
Urea 2.5 - 8 mmol/1 
Creatinine 40-130 yumol/1
2. Liver Function Tests
Serum bilirubin, serum asparate transaminase (AsT), 
alanine transaminase (AIT) and serum alkaline phosphatase 
were estimated on the Technicon Auto-analyser. Serum bili­
rubin was estimated using the DPD method, asparate trans­
aminase, alanine transaminase and alkaline phosphatase were
253 254 255
estimated by established methods ’ ’ .
Normal range Asparate transaminase 1 2 - 2 4  units/1 
Alanine transaminase 3 - 5 5  units/1 
Alkaline phosphatase 88 -280 units/1
3. Plasma Proteins
256
The proteins were measured by the Biuret method and 
albumin concentration determined by the Brilliant Crystal 
Green technique. The globulin factor was calculated by 
subtraction of the albumin value from the total protein 
value.
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Normal range total proteins 62-82 g/1 
albumins 35-55 g/1
globulins 23-33 g/1
4. Serum Calcium and Phosphate 4
257
The parameters were measured on the Technicon Auto-analyser .
Normal range calcium 2.2 - 2.6 mmol/1
phosphate 0.7 - 1.4 mmol/1
5. Serum Iron and Total Iron Binding Capacity
Values were determined by a routine method on the Auto-
258,259 
analyser .
Normal range iron (males) 9 - 3 0  mmol/1
iron (females) 6 - 25 mmol/1
total iron binding
capacity 45 - 75 mmol/1
6. Serum Immunoglobulins
These components were measured by an immunonephelometric 
method using a Technicon Auto-analyser.
Normal range IgM 0.4 - 3.0 g/1
IgA 0.8 - 4.5 g/1
IgG 6.0 -15.0 g/1
2.2.1.4.Statistical Analysis
The numerical data was subjected to statistical analysis260*261 
as under:
1) Standard parameters, mean X, variance, standard
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deviation (S.D.) and standard error of the mean 
values were calculated by an electronic calculator.
2) Significance jTests
Student's t tests were used for comparison of the means 
of two samples. For non-paired comparisons the appropriate 
t test was used and the degrees of freedom calculated 
according to whether or not there was a significant 
difference between the variances to the two samples.
The significance of all probabilities was determined 
from statistical tables using the 'two-tailed' 
criterion.
2.2.2 Study of Selected Disorders
Tests were carried out on patients treated for the selected
disorders as under:
1. Cold Haemagglutinin Syndrome
Haemoglobin and serological parameters were measured 
pre- and post- plasma exchange. The antibody con­
centrations were determined.
2. Waldenstrom's Macroglobulinaemia and 
Hyperviscosity due to Multiple Myeloma
Serum immunoglobulins and plasma viscosity were measured 
pre-plasma exchange and post-plasma exchange. Serum immuno­
globulins were measured as before using a Technicon Auto­
analyser. Whole blood viscosity was measured at three 
shear rates using a Contraves LS 30 Viscometer, and plasma 
viscosity was measured using the Harkness Capillary Viscometer.
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3. Immune Haemolytic Anaemia
The haemoglobin and serological parameters were measured 
pre-and post- plasma exchange. Quantification of the 
antibody was graded on a scale of 1 to 5 (i.e. + low titre 
increasing to +++++ high titre).
4. Factor VIII Inhibitors
The antibodies were detected by incubating test plasma at 
37°C with a source of Factor VIII C and then performing 
serial coagulation tests. The results were expressed 
in Bethesda Units. Coagulation screens including one-stage 
prothrombin time, Kaolin Cephalin Clotting time and Thrombin 
time were estimated pre- and post-exchange.
5. Chronic Polyneuropathy
Full neurological examinations were carried out on each 
patient and the response to treatment was measured pre- and
post-plasma exchange by the noted improvement in the level
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of function, which is graded 1 - 6  as under:
0 = Healthy
1 =• Minor symptoms or signs
2 =• Able to walk 5 meters without assistance
3 = Able to walk 5 meters with assistance
4 = Chair bound
5 = Requiring assisted ventilation for at least
part of the day or night
6 = Dead
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The neurological examination included records of muscular 
strengths for 8 movements in each arm and 6 in each leg in 
accordance with the scale indicated below:
F - normal
E =• movement against gravity and resistance
D = complete movement against gravity
C = complete movement in the absence of gravity
B - flicker
A = no movement
The following variables were assessed:
1 Time to onset of improvement in muscles spasm.
2 Time to onset of change in functional grade
3 Change in functional grade after 2 weeks,4 weeks,
3 months, 6 months and one year
Myasthenia Gravis and Eaton Lambert Syndrome
i) The response to treatment was also assessed by an 
improvement in the level of function, graded 1 - 6  
as previously defined.
ii) The levels of acetylcholinesterase antibody activity 
were determined pre- and post- exchange.
iii) Vital capacity pre-*and post- exchange, was measured by 
analysis of a single forced expiration and used as a 
means of monitoring respiratory function.
Guillain-Barre Syndrome
The clinical status and amelioration of symptoms of each 
patient was measured pre- and post- exchange, and graded on 
a scale of 1 - 5, as previously defined for chronic poly­
neuropathies.
Glomerulonephritis and Goodpasture's Syndrome 
Urea and electrolytes, routine biochemical parameters, were 
measured pre- and post- plasma exchange, and the progression 
of renal failure assessed. The anti-GBM antibody titre was 
also measured pre- and post- plasma exchange in those 
patients with Goodpasture's syndrome.
Aplastic Anaemia
Haemoglobin, and serological parameters were measured pre- 
and post- plasma exchange. A white cell precursors CFU-C 
assay (colony forming unit in culture) was undertaken to 
evaluate serum inhibitory factors. The effects of incubating 
bone marrow at 37°C for 60 minutes with a small quantity 
of each patient's, or control, serum was determined in the 
presence and absence of fresh guinea pig serum. If the 
serum was found to inhibit CFU-C this sufficed to prove that 
the inhibitory factor was immunoglobulin. The immunoglobulin 
class responsible for the suppression was characterised using 
a Technicon Auto-Analyser.
Polymyositis
Biochemical parameters were measured pre- and post- plasma 
exchange. An improvement in clinical status was also 
estimated on a scale of 1 - 6.
Study of Leukapheresis
Haematological changes were measured pre- and post- leukapheresis
in all patients. The patient was continuously monitored for
changes in white blood count (WBC), platelets and haematocrit
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using routine Coulter S analysis. The efficiency of leukapheresis 
in harvesting white blood cells was assessed as under:
Efficiency % - WBC's Yield
WBC's entering centrifuge
x 100
The number of white cells entering the centrifuge was estimated 
from the volume processed (flow rate x time) and the average WBC 
The average WBC is defined by:
WBC1s entering = Pre + mid + post WBC x volume processed
3
=• mean WBC's/mm3 x flow rate x run time.
A close watch was maintained over the pabient at each exchange 
procedure and any adverse reactions were noted. The condition 
of the patient was carefully monitored over the course of each 
study.
The response of all patients to initial and subsequent leuk­
apheresis procedures was studied in the short-term and in the 
long-term. Each patient was clinically assessed with particular 
reference to the size of lymphadenopathy and hepatosplenomegaly 
and regular haematological monitoring was carried out weekly after 
the last leukapheresis. As all patients received chemotherapy at 
the time of, or after, leukapheresis no comparison between leuk­
apheresis and chemotherapy was possible.
164
3. RESULTS
3.1 STUDY OF SELECTED REPLACEMENT FLUIDS
Details of the statistical comparisons of the haematological 
and biochemical data obtained during tests on the three 
groups of patients are given in Appendix A.
3.1.1 HAEMATOLOGICAL PARAMETERS RESPONSE TO PLASMA EXCHANGE 
STANDARD FULL BLOOD COUNTS
Values of Haemoglobin estimation (Hb), white blood cell 
count (WBC) and haematocrit (HCT) for patients in Groups 
1, 2,3 prior to plasma exchange in day 1 and post-exchange 
in day 5 are given in Table 17. The values on the 5th day 
are marginally lower than the pre-exchange values on the 
first day of all 3 groups of patients.
The values of haemoglobin and white blood cell count in 
Group 1 patients, pre- and post- plasma exchange were not 
significantly different (p >  0.05) from those of patients 
in Group 2 and Group 3. The values of haematocrit in Group 
1 patients, pre- and post- plasma exchange were not 
significantly different (p> 0.05) from those in Group 2 
and Group 3 patients, but the values of haematocrit in 
Group 2 patients differed from those in Group 3 patients 
pre-plasma exchange (0.05 >  p >  0.02) and post-plasma 
exchange (0.02> p >  0.01).
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PLATELET COUNT
Values of the platelet counts prior to plasma exchange and 
at selected intervals post-plasma exchange are given in 
Table 18 and 19 respectively and in Figure 10.
Platelet counts for the 3 groups of patients fell precipit­
ously after the first exchange procedure to almost half the 
pre-plasma exchange level in the first 12 hour period of 
post-exchange. Thereafter the values decreased marginally with 
each succeeding procedure to a quarter of the pre-plasma 
exchange level after the fifth procedure. This downward 
trend in the platelet counts of Group 1 patients differed 
significantly (p <■ 0.001, 0.05 >  pj> 0.02, 0.01> p >  0.002) 
from those of Groups 2 and Group 3 patients over the first 
three days, but this difference was not significant (p“>  0.05) 
on the fifth day. The downward trend in the platelet counts 
of Group 2 patients was not significantly different ( p >  0.05) 
from that of Group 3 patients over the 12 hour period but 
thereafter the difference became significant ( p <  0.001,
0.05 >  p >  0.02).
COAGULATION SCREENING
Values of prothrombin time (PT), Kaolin Cephalin Clotting 
Time (KCCT) and thrombin clotting time (TT) prior to plasma 
exchange and at selected intervals post-plasma exchange ; 
are given in Table 20 and in Figure 11.
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TABLE 18
Values of Platelet Counts Pre-Plasma Exchange
Normal Range
Platelets 150-400 x 109/1
TABLE 19
Values of Platelet Counts Post-Plasma Exchange 
(Results expressed as percentage of initial count)
Percentage Value
GROUP 1 GROUP 2 GROUP 3
Polygeline I
Plasma Protein 
Solution Polygeline II
Pre-Exchange Normal Normal Normal
30 min Post-Exchange 
12 hours "
24 hours " n 
3 days 11 u 
5 days 11 "
60 - 2.5 
57 t 2.5 
45 - 2.8 
33 - 2.7 
25 i 2.4
57 ± 4.6 
51 ± 3.8 
44 i 2.5 
36 i 2.1 
28 i 2.05
58 i 2.5 
52 i 2.6 
48 i 2.7 
39 i 2.6 
27 i 2.5
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TABLE 20
Values of Coagulation Screening Pre- and Postr-Plasma Exchange
Time of 
Test
MEAN VALUES (seconds)
GROUP 1 
PATIENTS
GROUP 2 
PATIENTS
GROUP 3 
PATIENTS
Pre-Exchange 1 4 - 2 1 3 - 1 14 i 1
Post-Exchange 
30 minutes
19 i 1 18 i 2 20 i 2
Prothrombin
Time
Post-Exchange 
6 hours 16± 2 16 - 1 16 ± 1
Post-Exchange 
24 hours 13 i 2 13 - 1 1 3 - 1
Pre-Exchange 38 ± 3 40 ± 4 40 t 4
Kaolin 
Cephalin 
Clotting Time
Post-Exchange 
30 minutes 66i 4 68. - 5 6 3 - 5
Post-Exchange 
6 hours
+ 
100 43 i 3 4 2 - 3
Post-Exchange 
24 hours 39 - 3 39 - 2 39 i 3
Pre-Exchange 7 - 1 7 - 1 7 - 1
Thrombin
Post-Exchange 
30 minutes 1 6 - 1 14 - 1 15 i 1
Clotting Time
Post-Exchange 
6 hours 9 i i 10 i 1 10 - 1
Post-Exchange 
24 hours 7 i i 7 - 1 7 - 1
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Figure 11. Effect of Replacement Fluid on Values of Coagulation 
Screening Post-Plasma Exchange
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The mean values of PT, KCCT and TT at 30 minute post-first 
plasma exchange are 40%, 70% and 100% respectively, higher 
than the pre-plasma exchange values for all 3 groups of 
patients. These values had returned to almost pre-plasma 
exchange levels within a period of 24 hours post-exchange.
With succeeding daily exchanges the values remained high 
for the second and third day but thereafter fell on the fourth 
and fifth day to values which were marginally higher than the 
initial pre-exchange.
The values of PT for Group 2 patients differed significantly 
(p<r 0.001) from those for patients in Groups 1 and 3 
over the initial 30 minute period after plasma exchange.
Over the remaining 24 hour period the values were not 
significantly different (p^> 0.05). Only at 30 minutes post- 
plasma exchange did the PT values for Group 1 patients differ 
significantly (pcO.OOl) from those of Group 3 patients.
The values of KCCT of Group 1 patients differed from those of 
Group 2 patients^0.01 >■ p :> 0.002, 0.02 >• p >  0.01) and of 
Group 3 patients (0.05 >  p >  0.02, 0.01 >  p>- 0.002) over the 
initial 30 minute period after plasma exchange, thereafter 
the difference was not significant (p>0.05). The values of 
KCCT of Group 2 patients differed significantly (p <0.001) at 
30 minutes post-plasma exchange.
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The difference in values of TT for- all three Groups of 
patients was not significant (p"> 0.05) pre-plasma exchange 
and 24 hours post-plasma exchange. After 30 minutes and 6 
hours post-plasma exchange the values for each Group were 
significantly different ( p c  0.001).
QUANTATATIVE ASSAYS OF COAGULATION FACTORS
Values of Factor 1 (fibrinogen), Factor II (prothrombin),
Factor VIII, Factor IX and Factor X pre-plasma exchange and at 
selected intervals post-plasma exchange are given in Table 21, 
Table 22 and Figure 12, Table 23 and Figure 13, Table 24 
and Figure 14, Table 25 and Figure 15 and Table 26 and 
Figure 16 respectively.
All values fell relatively sharply in the 12 hour period 
immediately following the first plasma exchange procedure to 
approximately 30%, 35%, 40%, 30%, and 30% of the initial 
pre-plasma exchange value. Thereafter values continued to 
decrease but to a much lesser extent in succeeding daily 
procedures. After the fifth procedure, values had been 
reduced to 15%, 25%, 20%, 25% and 25% respectively of the 
initial pre-exchange levels.
Over the five day period the values of the percentage reduction 
in Factor I and Factor II levels in Group 1 patients were 
significantly different ( p c  0.001, 0.01 >  p >  0.002) from
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those in patients of Groups 2 and 3. The values of the 
percentage reduction in Factor 1 levels in Group 2 patients 
were significantly different (p <. O.OOl) from those of Group 
3.only at 24 hours post-exchange (0.05 ;> p J> 0.02) and at 
3 days post-exchange, whilst the values of the percentage 
reduction in Factor II levels in Group 2 patients differed 
significantly from those in Group 3 patients only at 30 
minutes (p <0.001) and at 3 days (0.02> p >  0.01) post- 
plasma exchange. The values of the percentage reduction 
in Factor VIII levels in Group 1 patients were significantly 
different (p<c 0.001) from those in Group 2 patients over 
the five day period. The values of the percentage reduction 
in levels in Group 3 patients differed significantly 
( p <  0.001) from those in Group 1 and Group 2 patients at 30 
minutes and 3 days post-plasma exchange.
Over the five day period the percentage reductions in the 
levels of Factor IX in Group 2 patients were significantly 
different (p <  0.001) from those in Group I and Group 3 
patients. The values of the percentage reduction in levels_of 
Factor IX in Group I patients differed significantly from 
those in Group 3 patients at 30 minutes, 3 days (p <  0.001) 
and 5 days (0.01> p >• 0.002). The percentage reduction in 
levels of Factor X in Group I patients differed significantly 
(p.< 0.001) from those in Group 2 and Group 3 patients 
except at 12 hours post-plasma exchange. The percentage 
reduction in Factor X levels in Group 2 patients differed 
significantly (p <  0.001) from those in Group 3 patients except 
at 30 minutes and 5 days post-plasma exchange.
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TABLE 21
Quantitative Assays 'of Coagulation 
Factors Pre-Plasma Exchange
FACTOR NORMAL RANGE
Fibrinogen g/1 2.0 - 4.0
Prothrombin u/1 50 - 150
Factor VIII u/1 50 - 150
Factor IX u/1 5 0 - 1 5 0 I
Factor X u/1 50 upwards
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TABLE 22
Quantitative Assays of Coagulation Factors Post-Plasma Exchange
Factor I Fibrinogen 
(Results expressed as a percentage of Initial. Value.)
Time
of
Assay
PERCENTAGE VALUE
GROUP 1 
Patients
GROUP 2 
Patients
GROUP 3 
Patients
Polygeline I
Plasma Protein 
Solution Polygeline II
Pre-Exchange Normal Normal Normal
Post-Exchange 
30 minutes 3 4 - 1 . 8 30 i 1.7 30 - 1.2
Post-Exchange 
12 hours 27 ± 1.6 28 — 1.5 28 t 2.1
Post-Exchange 
24 hours 27 - 1.3 25 - 1.6 26 i 1.1
Post-Exchange 
3 days 24 - 1.5 23 - 1.4 25 - 2.0
Post-Exchange 
5 days 18 i 1.2 15 i 1.5 ' 16 - 1.1
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Figure 12. Effect of Replacement Fluid on Coagulation 
Factor 1 Post-Plasma Exchange
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TABLE 23
Quantitative Assays of Coagulation Factors Post-Pl'asma Exchange
Factor II
(Results expressed as a percentage of initial value)
Time
of
Assay
PERCENTAGE VALUE
GROUP 1 
Patients
GROUP 2 
Patients
GROUP 3 
Patients
Polygeline I
Plasma Protein 
Solution Polygeline II
Pre-Exchange Normal Normal Normal
Post-Exchange 
30 minutes 40 - 2.5 39 i 1.9 43 i 2.2
Post-Exchange 
12 hours 33 ± 2.4 36 - 2.3 36 i 3.0
Post-Exchange 
24 hours 28 - 1.7 30 ± 2.3 3 0 - 2 . 0
Post-Exchange 
3 days 2 6 - 1 . 8 28 i 1.9 27 - 2.4
Post-Exchange 
5 days 25 - 2.1 2 6 - 2 . 0 27 i 2.6
178
PE
RC
EN
TA
G
E 
OF
 
IN
IT
IA
L 
VA
LU
E
50
O--------O POLYGELINE 1
O-------------O PLASMA protein SOLUTION
O Q POLYGELINE 1140
30
O — -o
-  -  o
20
DAY 5DAY 3 DAY 4DAY 2DAY 1
POST - PLASMA EXCHANGE
Figure 13 Effect of Replacement Fluid on Coagulation 
Factor II Post-Plasma Exchange
179
TABLE 24
Quantitative Assays of Coagulation Factors Post-Plasma Exchange
Factor VIII C 
(Results Expressed as a Percentage of Initial Value)
PERCENTAGE VALUE
Time
of
Assay
GROUP 1 
Patients
GROUP 2 
Patients
GROUP 3 
Patients
Polygeline I
Plasma Protein 
Solution Polygeline II
Pre-Exchange Normal Normal Normal
Post-Exchange 
30 minutes 47 i 2.9 51 ± 1.5 45 i 2.5
Post-Exchange 
12 hours 38 i 2.0 39 i 1.7 38 i 1.4
Post-Exchange 
24 hours 36 - 1.7 37 i 2.2 36 i 0.9
Post-Exchange 
3 days 33 i 2.5 34 - 1.4 31 ± 1.5
Post-Exchange 
5 days 19 i 2.4 20 i 2.1 18 i 2.5
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Figure 14. Effect of Replacement Fluid on Coagulation 
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TABLE 25
Quantitative Assays of Coagulation Factors Post-Plasma Exchange
FACTOR IX
(Results Expressed as a Percentage of Initial1 Value)
PERCENTAGE VALUE
Time
of
Assay
GROUP 1 
Patients
GROUP 2 
Patients
GROUP 3 
Patients
Polygeline I
Plasma Protein 
Solution Polygeline II
Pre-Exchange Normal Normal Normal
Post-Exchange 
30 minutes 40 ± 2.1 35 i 2.3 34 ± 1.2
Post-Exchange 
12 hours 30 - 2.3 33 ~ 1.9 30 ± 1.2
Post-Exchange 
24 hours 28 - 1.8 31 i 1.6 28 - 2.2
Post-Exchange 
3 days 25 ± 2.2 30 i 1.7 27 i 1.3
Post-Exchange 
5 days 25 i 2.4 28 i 1.3 26 i 1.0
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TABLE 26
Quantitative Assays of Coagulation Factors Post-Plasma Exchange
FACTOR X -
(Results expressed as percentage of initial value)
Time
of
Assay
PERCENTAGE VALUE
GROUP 1 
Patients
GROUP 2 
Patients
GROUP 3 
Patients
Polygeline I
Plasma Protein 
Solution Polygeline II
Pre-Exchange Normal Normal Normal
Post-Exchange 
30 minutes 35 i 1.5 33 i 1.6 32 i 1.5
Post-Exchange 
12 hours 31 i 1.4 30 i 1.5 29 i 1.8
Post-Exchange 
24 hours 29 - 1.6 28 - 1.4 27 i 1.6
Post-exchange 
3 days 26 i 1.6 27 i 1.8 25 i 1.8
Post-Exchange 
5 days 22 i 1.3 24 - 1.2 23 i 1.4
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Factor X Post-Plasma Exchange
3.1.2 BIOCHEMICAL PARAMETERS
Urea and Electrolyte Evaluation
Values of urea and electrolytes pre-plasma exchange on
day 1 and post-plasma exchange on day 5 are given in Table 27.
The values of sodium in Group 1 patients were not significantly 
different from those in Group 2 and Group 3 patients pre- and 
post- plasma exchange (p > 0.05). The sodium levels in Group 2 
patients differed significantly from those in Group 3 
patients at pre-plasma exchange only (p*=r: 0.001). The values 
of potassium in Group 2 patients differed from those in Group 
1 and Group 3 patients at pre-plasma exchange (0.01 >  p >  0.002), 
but were not significantly different at 5 days post-plasma 
exchange ( p >  0.05). The values of potassium in Group 1 
patients were not significantly different frbm those in 
Group 3 patients pre-plasma exchange ( p >  0.05) but became 
different at 5 days post-plasma exchange (0.05 >  p >  0.02).
The values of calcium in Group 1 patients were not significantly 
different from those in patients of Groups 2 and 3 pre-plasma 
exchange (p>0.05), but became increasingly different at 5 days 
post-plasma exchange in the case of Group 1 and Group 2 
patients (p <  0.001). The values of calcium in Group 2 
patients differed from those in Group 3 patients pre-plasma 
exchange (0.05 >  p >0.02), but the difference was not signif­
icant at 5 days post-plasma exchange (p*> 0.05).
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The values of magnesium in Group I patients were not 
significantly different from those in patients of Groups 2 
and 3 pre- and 5 days post-plasma exchange (p •> 0.05).
The chloride levels in Group 2 patients differed from those in 
Group 1 patients (0.01:> p >  0.002) and Group 3 patients *
(0.05 >  p >0.02) pre-plasma exchange only, otherwise the 
values were not significantly different ( p >  0.05).
The values of phosphate in Group 1 patients differed signific­
antly from those in Group 2 and Group 3 patients pre- and 5 
days post-plasma exchange (p c  0.001).
The values of urea in Group 3 patients were not significantly 
different from those in Group 1 patients pre-plasma exchange 
and in Group 2 patients 5 days post-plasma exchange (p •> 0.05). 
The differences between all other values were significant
(0.01 >  p >  0.002, p C  0.001).
The values of creatinine in Group 1 patients were not 
significantly different from those in patients of Groups 2 
and 3 pre-plasma exchange (p>0.05). The values of creatinine 
in Group 2 patients differed from those in Group 3 patients 
pre-plasma exchange (0.01> p >  0.002).
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2 Liver Function Tests
Values of serum bilirubin, asparate transaminase, (AsT) alanine 
transaminase (ALT), and alkaline phosphatase pre-plasma on day 
one and post-plasma exchange on day 5 are given in Table 28.
The bilirubin concentrations in Group 1 patients were not signif­
icantly different from those in patients of Groups 2 and 3 a,t pre­
plasma exchange (p >  0.05), but were significantly different at 
5 days post-plasma exchange (0.002 > p >  0.001, 0.05> p >0.02).
The bilirubin concentrations in Group 2 patients were not signif­
icantly different from those of Group 3 patients at pre- and 5 days
post-plasma exchange.
The asparate concentrations in Group 1 patients differed from those
t
in Group 2 patients at pre-plasma exchange (0.022*p >0.01) and - 
became significantly different at 5 days post-plasma exchange
(p <  0.001).
The asparate values in Group 3 patients were not significantly 
different from those in patients of Groups 1 and 2 at pre-plasma 
exchange, but became significantly different from those of Group 
1 patients at 5 days post-plasma exchange (0.01 :> p >0.002).
There were no significant differences in the alanine transaminase 
concentrations of all three groups of patients at pre- and 5 days 
post-plasma exchange (p >  0.05).
The concentrations of alkaline phosphatase in patients of all 
three groups were significantly different at pre-plasma 
exchange (p <  0.001). At 5 days post-plasma exchange the
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concentrations of alkaline phosphatase in Group 2 patients 
only were not significantly different from those in Group 
3 patients.
3 Plasma Proteins
Values of total protein, albumin and globulin pre-plasma 
exchange and at selected intervals post-plasma exchange are 
given in Table 29 and Figure 17.
Values of total protein and albumin concentration exhibited 
a sharp fall in the first 30 minute period post-plasma 
exchange. The reduction in values in patients of Groups 
1 and 2 was much less than that in patients of Group 3.
The calculated globulin concentrations in patients of Groups 
1 and 2 showed less variation than those in Group 3 patients. 
In the case of Group 1 and Group 2 patients values of 
concentrations showed partial recovery to the initial pre­
plasma exchange levels after a period of 12 hours. In the 
case of Group 3 patients the values of total protein and 
albumin concentrations continued to fall. All concentrations 
had returned to their initial pre-plasma exchange levels 
immediately after plasma exchange on the fifth day.
At pre-plasma exchange, values of the total protein concen­
tration in Group 2 patients were not significantly different 
from those in patients of Groups 1 and 3 (p >  0.05). At 30
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minutes post-plasma exchange the values of total protein 
concentration in Group 1 patients were not significantly 
different from those in Group 3 patients. All other values 
of total protein concentration in the patients of Groups 
1, 2 and 3 were significantly different (p 0.001) during 
the period up to 5 days post-plasma exchange.
At pre-plasma exchange, the values of albumin concentration 
in Group 1 patients were similar to those in Group 3 patients 
(p > 0.05). All other values of the albumin concentration 
in the three groups of patients were significantly different 
(p <  0.001) during the five day period post-plasma exchange.
The values of the globulin concentration in patients of 
Group 1 differed significantly from those in patients of 
Groups 2 and 3 at pre-plasma exchange and throughout the 
five day period post-plasma exchange (p c  0.001), except in 
the case of patients in Groups 1 and 3 where the concentrations 
were similar (p >- 0.05) at 5 days post-plasma exchange.
The values of the globulin concentrations in Group 2 patients, 
were not significantly different (p"> 0.05) from those in 
Group 3 patients at pre- and 3 days post-plasma exchange. 
Thereafter the difference between concentrations was . 
significant (p <  0.001).
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Serum Iron and Total Iron Binding Capacity
Values of serum iron and total iron binding capacity pre­
plasma exchange on day 1 and post-plasma exchange on day 5 
are given in Table 30.
The concentrations of serum iron in the patients of all three 
groups were not significantly different at pre-plasma 
exchange, (p >  0.05). At 5 days post-plasma exchange 
the difference in values between patients of Group 1 and 
Group 2 and between patients of Group 2 and Group 3 became 
significant (p <0.001, and 0.01>- p > 0.002 respectively).
The total iron binding capacities of Group 3 patients were 
not significantly different from those of Group 1 and Group 2 
patients at pre- and 5 days post-plasma exchange. The 
capacities of Group 1 patients differed from those of patients 
in Group 2 at pre- and post-plasma exchange (0.01 >  p .> 
0 .002),
4 Serum Immunoglobulins
Mean values of serum immunoglobul'ins IgG, IgA and IgM pre­
plasma exchange and at selected intervals post-plasma 
exchange are given in Table 31 and Figure 18. Immediately 
after the first plasma exchange procedure the levels'of all 
three immunoglobulins fell to around 30% of their pre-plasma 
exchange level and continued to decrease with each succeeding
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procedure to around 10 or 15% of their initial value after 
the fifth exchange.
Over the first 24 hour period post-plasma exchange the 
values of the percentage reduction of serum immunoglobulin 
IgG levels in Group 1 patients were not significantly 
different (p"> 0.05) from those in Group 2 patients but 
thereafter the difference in values became significant 
(p <  0.001). The values of the percentage reduction of 
IgG levels in Group 1 patients became increasingly different 
from those in Group 3 patients (0.02 >  p >*0.01, p<0.001), 
except at 24 hours post-plasma exchange when there was no 
difference (p >  0.05). The values of the percentage 
reduction of IgG levels in Group 2 patients differed from 
those in Group 3 patients at 12 hours (0.01 > p >0.002) 
and at 3 days ( p <  0.001) post-plasma exchange.
Over the first 12 hours period post-plasma exchange the 
values of the percentage reduction of serum immunoglobulin 
IgA levels in Group 1 patients did not differ (p >  0.05) 
from those in Group 2 patients, but thereafter the 
difference became significant. The values of the percentage 
reduction of IgA levels in Group 1 patients were different 
from those in Group 3 patients (0.02 >  p >0.01, p <0.001) 
except at 24 hours and at 5 days post-plasma exchange when 
there was no difference (p >  0.05). The values of the 
percentage reduction of IgA levels in Group 2 patients
200
were similar to those in Group 3 patients only at 30 
minutes post-plasma exchange (p>0.05). Thereafter the 
difference was significant (0.002 > p >  0.001, p -c 0.001).
The values of the percentage reduction of serum immuno­
globulin IgM levels in Group 1 patients were significantly 
different from those in Group 2 patients (0.01 >  p >  0.002, 
p <  0.001) pre- and up to 3 days post-plasma exchange.
The difference in values was not significant at 5 days 
post-plasma exchange. After the initial 12 hour post­
plasma exchange the values of the percentage reduction in 
IgM levels in Group 1 patients differed significantly from 
those in Group 3 patients (p< 0.001). The values of the 
percentage reduction of IgM levels in Group 2 patients 
were different from those in Group 3 patients (0.02 > p >
0.01, 0.01 >  p >  0.002, p <  0.001), except at 3 days post- 
plasma exchange.
3.1.3 CLINICAL RESPONSE
The short-term side effects experienced by some of the 3 
groups of patients during treatment by plasma exchange are 
summarised in Table 32. In the 700 procedures undertaken 
on 140 patients there were 84 instances of identifiable 
side effects. More than one side effect was observed in
201
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some patients. The incidence of side effects was greatest 
in Group 3 patients and least in Group 1 patients.
Urticaria, rigors and shivering, itch and hypertension 
were particularly prevalent in Group 3 patients and occurred 
in around 25% of the procedures.
No side effect was severe and certainly not life threatening. 
No procedure had to be terminated because of side effects 
but 8 exchanges were stopped because of other difficulties. 
One patient exchanged with plasma protein solution and one 
patient exchanged with polygeline exhibited bronchospasm. 
Neither patient had a past history of asthma and in neither 
case was it severe or distressful.
Only one episode of bleeding was encountered.
The response to treatment by plasma exchange of all three 
groups of patients with myasthenia gravis, Guillain Barr/ 
Syndrome, chronic relapsing polyneuropathy and polymyositis 
is summarised in the consolidated Table 33. This response 
was not significantly affected by the choice of the 3 
replacement fluids investigated, nor was one replacement 
fluid more effective than another in the treatment of any 
of the 4 disorders studied.
204
CO
fe <c
O  Oh
H CO
H
r-f
3.2 STUDY OF SELECTED DISORDERS
1. Cold Haemagglutinin Disease
Values of Hb and antibody titres (anti-l) prior to plasma 
exchange and post-plasma exchange are given in Table 3*4.
In all patients there was a significant increase in the 
Hb and decrease in the cold antibody titre.
Four patients required to be transfused during the period of 
exchange, but only required 2 units of packed cells. One 
patient relapsed 4 days after the fourth exchange with a ,
i
subsequent high titre cold antibody and unfortunately 
died from a myocardial infarction-.
2. Waldenstrom's Macroglobulinaemia
Values of full blood viscosity at 3 shear rates and of 
plasma viscosity pre-plasma exchange and post-plasma exchange 
are given in Figures 19 and 20 respectively. The change 
in serum immunoglobulin IgM during the course of 3 plasma 
exchanges is shown in Figure 21.
There is significant reduction in the whole blood viscosity 
at all 3 shear rates and in plasma viscosity immediately 
after plasma exchange. The value of serum immunoglobulin 
IgM decreased with each plasma exchange procedure and had 
fallen to about half of its pre-exchange value after the 
third procedure.
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TABLE 34
Cold Haemagglutinin Disease
Measurements of Haematological and Serological Parameters 
Pre- and Post-Plasma Exchange
PRE-THERAPY POST-THERAPY
Hb
g/dl
Ab
Titre
a + -• 1 4  ° C  Anti 1
Hb
g/dl
Ab
Titre
a  i 4  °C Anti 1
1 Lymphoma 9.5 1/128 12.8 1/64
2 Lymphoma 9.5 1/256 13.0 1/64
3 Carcinoma of Lung 7.8 1/64 10.1 1/16
4 Plasma cell 
leukaemia 8.6 1/512 10.8 1/128
5 Post-infection 6.4 1/64 8.9 1/16
6 Post-infection 5.5 1/64 8.9 1/16
7 Lymphoma 5.0 1/1204 7.8 1/512
8 Post infection 4.8 1/128 8.6 1/64
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All but one patient noticed a marked improvement in 
clinical status. 2 patients at pre-coma state were dramatically 
improved, whilst in one patient both vision and deafness 
improved dramatically.
Hyperviscosity due to IgA and IgG Myeloma
Values of full blood viscosity at 3 shear rates and of 
plasma viscosity pre-plasma exchange and post-plasma 
exchange are given in Figures 22 and 23 respectively.
There is a significant reduction in the whole blood 
viscosity at three shear rates and in plasma viscosity 
immediately after plasma exchange. All but two patients 
noticed a marked improvement in the clinical status and in 
one patient there was a dramatic improvement in clinical and 
renal status.
Immune Haemolytic Anaemia
Values of Hb and antibody titre pre-plasma exchange and post­
plasma exchange are given in Table 35. In all patients 
there was a significant rise in Hb with an associated 
decrease in warm antibody titre. In the three cases studied, 
plasma exchange resulted in, at least, temporary control of 
haemolysis and patients achieved a measure of stability to 
allow other modalities time to act.
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Myeloma.
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TABLE 35
Immune Haemolytic Anaemia
CLINICAL FEATURES PRE-EXCHANGE POST-EXCHANGE
Hb
g/dl Ab titre
Hb
g/dl Ab titre
1 Evans’ Syndrome 6 + + + 9.5 +
2 Post infectious 8 + + . + + 9.8 + +
3 Malignant Lyniphoma 5 + + + + 9.2 + +
i
Ab titre graded from . + (low titre) to + + ■ + + + '  (high titre)
214
4 Factor VIII inhibitors
Values of Prothrombin time, Kaolin Cephalin Clotting Time, 
Thrombin Clotting Time, Factor VIIICjFactor VIII Rag and 
an inhibitor quantification pre-plasma exchange and post­
plasma exchange after the fifth procedure are given in 
Table 36.
Values of PTT, TT and Factor VIII Rag are not significantly 
altered by plasma exchange. The values of KCCT and 
the Inhibitor Sctreen were significantly reduced and the 
Factor VIII C concentration was markedly increased.
5 Chronic Inflammatory Polyneuropathy
The change in clinical status of the ten patients after 
plasma exchange may be seen from Table 37.
It will be noted that with the exception of one female and 
three male patients in whom there was no discernable change, 
the clinical status of all other patients improved after 
treatment. One patient unfortunately died.
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TABLE 37
Effect of Plasma Exchange on Clinical Status of
Patients with Chronic Inflammatory Polyneuropathy
PATIENT DETAILS DURATION 
' OF SYMPTOMS 
MONTHS
CLINICAL STATUS
No Age . 
Years
Sex Pre-Plasma
Exchange
Post-Plasma
Exchange
1 28 F 6 5 4
2 31 M 9 5 5
3 26 M 12 4 4
A 34 M 8 3 4
5 35 F 18 4 4
6 31 M 12 5 6
7 29 F 6 5 3
8 26 M 8 5 3
9 30 M 6 4 3
10 25 M 5 5 4
Performance Grading
0 - Healthy
1 - Minor Symptoms
2 - Walking without assistance
3 - Walking with assistance
4 - Bed bound
5 - Requiring ventilation
6 - Dead
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6 Myasthenia Gravis and Eaton Lambert Syndrome
Measurements of patient Anti-AchR and patient vital 
capacity, pre- and post-plasma exchange are coupled with 
the corresponding change in patient status in Table 38.
It will be noted that in all patients there was a significant 
reduction in the value of patient Anti-AchR and a correspond­
ing increase in the patient vital capacity as a result of 
plasma exchanges. The clinical status was unchanged 
three patients. A marked improvement.(Grade 4 to Grade 1) 
was seen in three patients with high initial values of 
Anti-AchR (86, 68, 75 and 86) respectively.
Eaton Lambert Syndrome
Measurements of clinical status and vital capacity were 
measured pre- and post exchange as seen in Table 39.
It will be noted that three patients achieved a significant 
improvement in clinical status and vital capacity and two 
deteriorated significantly.
/
7. Guillain Barre Syndrome
The change in clinical status of the 27 patients on the 14th 
day after plasma exchange is summarised in Table 40.
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TABLE 39
Effect of Plasma Exchange on Clinical Status
of Patients with Eaton Lambert Syndrome
PATIENT DETAILS PATIENT STATUS
PATIENT VITAL 
CAPACITY (Litres)
No Age Sex
Pre-Pl!asma
Exchange
Post-Plasma
Exchange
Pre-Plasma
Exchange
Post-Plasma
Exchange
1 48 F 3 1 2.05 - 0.15 2.65 i 0.12
2 56 M 3 4 1.95 - 0.25 1.45 ± 0.25
3 61 M 3 1 2.35 - 0.35 2.85 ± 0.25
4 66 F 4 1 2.68 i 0.45 2.35 i 0.35
5 64 F 3 5 1.85 - 0.35 1.45 - 0.25
GRADING
1 Minimal' disability
2 Moderate disability, but able to walk
3 Walking without assistance
4 Walking only with assistance
5 Bed bound
6 Totally incapacitated
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TABLE 40
Effect of Plasma Exchange on Clinical Status of
Patients with Guillain Barre' Syndrome
PATIENT
DETAILS Duration of 
Symptoms until 
Diagnosis. Days
Duration from 
Diagnosis until 
Plasma Exchange* 
Days
CLINICAL STATUS 
OF PATIENT
No
Age
Years Sex
Pre-Plasma
Exchange
Post-Plasma 
Exchange 
14th day
1 32 M 8 2 5 4
2 22 F 6 1 5 3
3 41 F 7 1 5 3
4 21 M 12 1 5 4
5 36 F 8 1 5 4
6 26 F 10 2 5 4
7 33 M 10 2 5 3
8 28 M 9 1 5 2
9 42 F 7 1 5 3
10 27 M 6 3 5 3
11 25 F 14 2 4 3
12 56 M 12 1 4 3
13 24 F 11 1 5 2
14 35 M 10 1 5 3
15 23 F 12 1 5 3
16 38 M 13 2 5 3
17 26 F 9 1 4 2
18 35 M 6 2 4 2
19 21 M 5 1 5 3
20 31 F 5 1 4 3
21 32 M 7 1 5 3
22 31 M 8 2 5 3
23 26 F 8 1 5 3
24 21 F 10 2 5 3
25 23 F 12 1 5 2
26 22 M 11 2 5 3
27 33 M 10 1 5 3
A total of 162 Plasma Exchanges were carried out (each of 2.5 litres)
STATUS GRADING
0 - No disability
1 - Minimal disability
2 - Moderate disability
3 - Walking without assistance
4 - Walking with assistance
5 - Bed bound
222
The greatest change was observed in patients 8, 13 and 25 
(from Grade 5 to Grade 2) in whom the duration of symptoms 
ranged from 9 to 12 days and for whom plasma exchange was 
carried out in one day after diagnosis of disease.
8 Glomerulonephritis and Goodpasture's Syndrome
The change in values of serum creatinine pre- and post- 
plasma exchange is given in Table 41 for 23 G N patients.
The serum creatinine was significantly lowered by plasma exchange.
Regular plasma exchange appeared to prevent progression to 
renal failure in 9 out of 12 patients with Mesangio- .
capillary Type 1 GN (MCGN) for a mean duration of 18 months.
In one patient plasma exchange was stopped following a rise 
in serum creatinine.
In MCGN Type 11 two patients did not progress to renal failure. 
Despite an initial reduction in serum creatinine, four patients 
progressed to renal failure although the plasma exchange 
procedures were continued. Three patients with mesangial 
I.gA disease had virtually stable serum creatinine during 9 
months of plasma exchange.
In idiopathic membranous nephropathy two patients progressed 
to end stage renal failure despite plasma exchange.
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Pulmonary haemorrhage occurred in 10 patients , and was 
rapidly controlled in 4.
Long-term follow up revealed that 8 patients are stilT alive, 
five with functioning allografts and 3 maintained on dialysis.
The changes in values of serum creatinine and anti - IgM Ab 
(% binding) produced by plasma exchange in the 10 patients 
with Goodpasture's syndrome are given in Table 42. Both serum 
creatinine and anti-IgM Ab were significantly lowered by 
plasma exchange. Improvement in clinical status was noted in 
6 patients, 4 patients proceeded to dialysis and 2 ultimately 
died. In both sets of patients the recovery of renal function 
was clearly related to the severity of glomerular damage. The 
prognosis for patients presenting with creatinine of 550 
jx mol/1 or less was significantly better than for those with 
creatinine of 600 mol/1 or greater.
9 Aplastic Anaemia with Pure Red Cell Aplasia
The benefit conferred by plasma exchange on four patients 
with red cell aplasia and on two patients with aplastic 
anaemia is seen from Table 43. The increase in the numbers 
of CFU-C units post-plasma pheresis is significant in all 
patients.
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TABLE 43
Effect of Plasma Exchange on Pure Red CelT 
Aplasia and Aplastic Anaemia
Patients Age/Sex Nos of CFU-C in Presence of Control
Pre-pl'asma
pheresis
plasma
Post-plasma
pheresis
plasma
1 58 M 1 ± 1 15 i 5 12 - 3
2 46 F 2 - 1 16 - 3 12 i 2
PURE RED
CELL 3 41 M i i i 14 i 3 9 - 2
APLASIA
4 34 M 3 - 1 12 - 2 1 0 - 2
*5 24 M 2 i 1 8 - 1 6 i 1
APLASTIC
ANAEMIA *6 21 M 1 ±  1 6 -  1 4 - 1
* SLE
* IgM Cryoglobulinaemia
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Polymyositis
Values of biochemical parameters Creatinine Kinase, Asparate 
Transaminase, Alanine Transaminase, and Lactate Dehydro­
genase pre- and post-plasma exchange in all 10 patients, 
together with the changes in clinical status, are shown in 
Table 44. The values of CK, very markedly, AsT, AIT,and LDH 
were reduced post-plasma exchange. The clinical status of 3 
patients improved by 1 grade and 7 patients by 2 grades.
Clinical Status of Patients in Study of Selected Disorders •
Short term side effects observed in patients during their 
treatment for the selected disorders are summarised in Table 
45 and considered in detail under two groupings, namely, 
those effects attributable to replacement fluids and those 
attributable to the exchange procedures.
Side effects attributed to the replacement fluid are :
1. Plasma protein solution (albumin). Undesirable side 
effects were relatively few, feverish reactions 
constituting the majority and there were 30 incidents of 
rigors (3% of all procedures), 16 occurrences of 
vasovagal attacks (1.6% of all procedures) and 21 cases 
of minor skin reactions, namely urticaria pruritis and 
burning sensations. These cases tended to be short lived and 
usually occurred in patients with well known sensitization
Table 44
Effects of Plasma Exchange on Biochemical 
Parameters and Clinical Status in Patients with Polymyositis
PATIENT
DETAILS
CLINICAL
STATUS
BIOCHEMICAL PARA­
METERS PRE-PLASMA
BIOCHEMICAL PARA­
METERS POST-PLASMA
Pre- Post- EXCHANGE EXCHANGE
No Age Sex Plasma
Exchange
Plasma
Exchange
CK
1
AsT AIT LDH CK AsT AIT LDH
1 23 M 5 4 580
(u/
34
'D
50 520 150
iH\ 
CO 
3 
C\1
)
42 400
2 32 F 5 3 1200 63 58 816 380 50 42 520
3 34 F 6 4 960 72 39 750 250 42 30 602
4 35 M 5 3 480 86 46 650 100 56 36 600
5 38 M 4 3 2000 70 69 500 100 52 48 357
6 36 M 5 3 1500 65 69 '475 480 62 40 529
7 29 F 4 3 1100 58 70 675 250 38 60 479
8 21 M 5 3 750 52 65 820 100 48 48 500
9 22 M 4 2 688 66 75 960 100 52 54 475
10 28 M 4 2 1275 75 89 450 475 50 75 300
GRADING
1 Minimal disability
2 Moderate disability but able to walk
3 Walking without assistance
4 Walking only with assistance
5 Bed bound
6 Totally incapacitated
BIOCHEMICAL PARAMETERS
CK - Creatinine Kinase 
AsT - Asparate Transaminase 
AIT - Alanine Transaminase 
LDH - Lactate Dehydrogenase
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to blood or its derivatives.
2. Haemaccel (Polygeline). The most frequently observed 
side effects are minor skin reactions, 29 cases of 
urticaria were noted (2.9% of all the procedures) 
followed by 12 instances of vasovagal attacks (1.2% of 
all procedures) and 6 occurrences of rigors (0.6% of 
all procedures).
Taking into account that the number of procedures in which 
Haemaccel was used was considerably fewer than that which 
plasma protein solution was used, the incidence of side 
effects with Haemaccel was greater than that with PPS.
3. Fresh Frozen Plasma. Very little fresh frozen plasma
(2 litres only) was used in the study and no side effects 
were noted.
Side effects attributed to the exchange procedure include :
1. Hypotension. Hypotension was the commonest side effect 
encountered. It tended not to produce symptoms and was 
noted only because all patients were constantly monitored 
throughout the procedure. The lowest blood pressure 
recorded was 80/60 and responded to simple non-invasive 
measures.
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2. Bleeding. Only one episode of bleeding was encountered 
in the total number of procedures undertaken. Its 
aetiology was uncertain. Only small doses of Heparin, 
namely 7,500 IU were used as anticoagulant making it 
an unlikely contributory aetiological factor.
3. Removal of Medication. Many of the patients treated for 
myasthenia gravis were given a supplement of medication 
during and occasionally after plasma exchange to ensure the 
regular level of medication in the blood necessary to 
maintain a stable clinical state.
Long-term effects observed in patients during and, in some 
cases, after their treatment for selected disorders were 
identified as under :
1. Hypercoagulable state
The studies have confirmed that intensive plasma exchange 
profoundly influences coagulation parameters and results in 
a thrombocytopenia, elevation in prothrombin time, kaolin 
Cephalin clotting time and reptilase time and a reduction in 
factor level.
In addition reductions in antithrombin III and plasminogen 
levels with an associated rise in Factor VIII pro-coagulant 
levels have been observed. This results in a hypercoagulable
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state and in fact spontaneous thrombotic episodes. There is 
also some evidence to suggest that activation during the 
mechanical stimulus of plasma exchange may also contribute 
to the hypercoagulable state. In the present study, 2 cases 
of thrombotic episodes were observed, deep venous thrombosis 
occurred in one female patient and iliofemoral thrombosis 
in one male patient. Four patients had proven thrombosis
1.expositive venograms approximately 72 hours after their 
5th plasma exchange. Treatment consisted of intravenous 
heparin followed by oral warfarin therapy for some 3 months. 
There were no apparent residual side effects and no known 
pre-disposing features.
2. Bacterial infection
Intrinsic plasma exchange has been shown to reduce a marked 
depletion of immunoglobulins. This can result in the 
possibility of complicating infections in patients also 
receiving immunosuppressive therapy, however it is known that 
many variables are involved. In the present studies 3 cases 
of proven bacterial infection were recorded. Esherichia 
coli was observed in one female patient and staphyloccocus 
aureus in one female and one male patient. All 3 patients 
developed septicaemia with positive blood cultures. All 
were receiving immunosuppressive therapy throughout the 
period of plasma exchange and were being ventilated in the 
intensive care unit. The time lag post final exchange to the
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development of symptoms was 72 hour^. After receiving 
the appropriate antibiotics all patients recovered without 
residual problems. No other patients in the unit at that tinie 
had any septicaemic episodes.
3. Viral Infection \
Information regarding the incidence of viral infection post- 
plasma exchange was incomplete. Cases of hepatitis A, 
hepatitis B and non-A non-B hepatitis have been reported.
In the present study 2 cases of hepatitis A and 13 cases of non 
-A non-B hepatitis were recorded, involving 8 female and 7 
male patients. The 13 cases of non-A non-B hepatitis were 
discovered in follow-up biochemical analysis of patients.
All patients were transiently jaundiced, but they were not 
systemically unwell. The mean period of time from diagnosis 
to the end of the last plasma exchange was 3.5 months. Long­
term follow-up of these patients is continuing, but no patient 
has more than a modest elevation of transaminases on routine 
biochemical estimation.
It is difficult to avoid the complication of hepatitis if
plasma is used as replacement fluid. The use of fresh
frozen plasma as a replacement fluid has resulted in an even
higher incidence of hepatitis. The long term follow-up of
patients who presented from outlying areas proved very difficult
and this aspect of the study is incomplete. As far as is known
at present no patient developed side effects which have had
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deleterious consequences on his/her health.
Long term effects associated with plasma exchange have been 
reported, but it is not clear whether these are directly 
attributable to the procedure. Specifically, no patient has 
contracted the Human Immuno-Deficiency Virus (HIV) as a 
result of blood products given during plasma exchange over 
the period of this study.
The change in clinical status of all patients studied above 
is summarised in Table 46.
STUDY OF LEUKAPHEHESIS
The results of the study of leukapheresis are shown in Table 
47. The volume of buffy coat cells removed during leukapheresis 
ranged from 300 ml to 1300 ml with a mean of 750 ml. This 
volume contained a mean yield of 4.50 x l(f^  white cells. The 
calculated efficiency of the procedure was 52%.
The main complication encountered during leukapheresis was 
maintenance of venous access. Many patients had poor veins 
and thus obtaining a satisfactory flow rate was a frequent 
problem. The procedure was safe, efficient and rapid.
In patients with acute leukaemia there was no evidence that 
leukapheresis provided clinical benefit. There is some evidence 
to suggest that early death is lower in patients who have
TABLE 46
Clinical' Status of Patients with
Selected Disorders after Treatment with Plasma Exchange
DISORDER
Number of 
Patients 
with 
Disorder
PATIENT STATUS AFTER 
TREATMENT
Condition
Improved
No Change 
in
Condition
Condition
Deteriorated
Waldenstrom's
Macroglobulinaemia 18 16 2 0
Multiple Myeloma 
with Hyperviscosity 12 10 2 0
Cold Haemaggiutinin 
Disease 8 7 1 0
Autoimmune 
Haemolytic Anaemia 3 1 1 1
Factor VIII 
Inhibitors 8 8 o 0
Myasthenia Gravis 18 15 3 0
Eaton-Lambert
Syndrome 5 3 0 2
/
Guillain-Barre
Syndrome 27 27 0 0
Polyneuropathy 15 10 2 3
Glomerulonephritis 26 19 0 7
Goodpasture's Syndrome 10 6 0 4
Pure Red Cell Aplasia 4 2 0 2
Aplastic Anaemia 2 2 0 0
Polymyositis 10 10 0 0
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undergone leukapheresis, but is statistically significant 
only in patients with acute lymphatic leukaemia.
In those patients with chronic myeloid leukaemia it did not 
appear to delay blast transformation but it did provide clinical 
benefit to the patient. The procedure reduced the WBC by at 
least 40% within 3-5 days of the procedure. It may be 
continued for some days thereafter. Improvement clinically 
was noted in 40% of patients, primarily those with 
neurological dysfunction e.g. blurred vision, confusion and 
in one case pre-coma. No distinct measurable improvement 
was noted in other parameters e.g. hepatomegaly, splenomegaly, 
lymphadenopathy or fever.
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DISCUSSION OF RESULTS
Rarely have investigations of plasma exchange been conducted 
under conditions which permit a direct comparison of the 
results of the many different studies. However, from a 
number of such studies, characteristic patterns of behaviour, 
or significant trends in results have emerged despite great 
differences in procedural and pathological contents.
Attention is drawn to correspondence or lack of correspondence 
between the results of the present studies and established 
findings of these other studies, where appropriate.
Study of replacement fluids
The observed values of the haematological and biochemical 
parameters pre- and post-plasma exchange, and the trends in 
the change of values where these occur, are in broad agree­
ment with those reported in the literature.
The observed stability of the haemoglobin concentration,
white blood cell count and haematocrit value has been report-
1 59 98
ed in other studies.’ * The sharp decrease in platelet
2 142count has also been recorded by others,' although in other 
1 59 98
studies ’ * no significant change in platelet count was
found.
The investigation has shown that platelet concentration fell
only if exchanges were conducted on a daily basis and that
the time needed for the recovery of platelets to normal haemo-
9
static levels (100 x 10 /l) was dependent mainly on the
intensity of the preceding exchange. Regardless of the actual 
level, it required only an average of two days (maximum of 
three days) for platelets to return to normal.
The reduction in platelet count must be interpreted in re­
lation to the initial value. Whilst a small number of plate­
lets are lost in the limited clotting which occurs in the 
centrifuge bowl, the observed decrease in platelets must be 
attributed to the removal during plasma exchange. The re­
covery of platelet counts will depend primarily on the state 
of the bone marrow and particularly on the effects of steroids 
and cytotoxic drugs. Protamine sulphate can decrease platelet 
counts but the effect is transient.
Thus, the lowest platelet counts and the greatest risk of 
bleeding occur during periods of daily plasma exchange when 
the initial counts are low.
The marked increases observed in prothrombin time, kaolin
cephalin clotting time and thrombin clotting time immediately
post-exchange are in accord with those reported in other 
2 142 143 263
studies,* ’ * although no such changes were recorded in
59another study.
However, whilst the trends in behaviour are similar, differ­
ences exist in the extent of the changes noted. Increases of 
60% and 200% in prothrombin time and thrombin clotting time 
immediately after the eleventh exchange procedure have been 
recorded in one study where the exchanged plasma was replaced 
by an equal volume of albumin 5% or plasma protein fraction
240
5%. The thrombin time and prothrombin time returned to the 
initial pre-exchange value in 4 hours and 24 hours respect­
ively, post-exchange. Even greater increases were noted in 
2
another study in which plasma protein fraction, plasma 
protein fraction and Haemaccel (4:1 ratio) and fresh frozen 
plasma were used as replacement fluids. Mean post-exchange 
values of patient-control differences in TT and PTTK were 
found to be 200% and 1000% greater than the mean pre-exchange 
values immediately after the first exchange, or after a 
succeeding exchange with an interval between exchanges of 
more than 5 days. These increases in clotting times became 
even greater as the interval between exchanges was reduced. 
Immediately after successive daily exchanges, mean patient- 
control differences in TT and PTTK of 700% and 3000% of mean 
pre-exchange values were recorded.
The effect of plasma exchange on coagulation factors has been
2 142 143extensively studied by others * * and the reported be­
havioural trends in post-exchange values are essentially 
similar to those noted in the present investigation. In 
general, the percentage reduction in the post-plasma exchange 
relative to the initial pre-exchange value of each coagulation 
factor was not significantly influenced by the patient's dis­
order or by the length of interval between successive 
exchanges (one day, two day, or more than 2 day periods). The 
extent to which coagulation factors were removed by plasma 
exchange did not appear to be influenced by their initial pre- 
exchange values. A single exchange procedure reduced the post- 
exchange values of Factor I, II, VIII, IX and X to approx­
241
imately 30%, 35%, 45%, 60% and 40% respectively of the pre-
2,142,143,150,264
exchange values.
It was noted that the extent to which Factor VIII was removed 
by plasma exchange, as estimated by biological assay differed 
significantly from that estimated by immunological assay.
In plasma exchanges undertaken on a daily or two-day basis the 
observed cumulative reduction of Factors I, II, and X was 
greater than that of Factor IX and this was in accord with 
results reported in the literature. Under these conditions 
there was considerable variation in the extent of reduction 
for different patients, but the overall reduction patterns 
were similar. Factors I, II, and X exhibited slower rates of 
recovery than Factors VIII and IX, but they usually returned 
to normal values within the 24 hours period after exchange. 
Recovery was usually rapid during the early stages post-plasma 
exchange but therefter recovery was more gradual over the 
period 4 hours to 24 hours post-exchange.
The discrepancy reported by others as existing between bio­
logical and immunological levels of Factor VIII in most 
patients may be due to true preferential removal of one com­
ponent because Factor VIII coagulant activity and Factor VIII 
related antigen may reside on separate molecules. Alter­
natively the excess coagulant activity may arise as a result 
of protease activation.
Detailed information on electrolyte change during plasma
242
exchange is sparse and no comparison of the current findings
with other data has been possible. With the exception of
potassium and calcium the pre- and post-plasma exchange values
of the electrolytes are eventually stable. In two studies,
where the electrolyte values have been determined, but no data
presented, it must be presumed that values remain stable
1 97
during plasma exchange. ' Where data are presented, one
report quotes values of Sodium and Potassium unchanged by
plasma exchange and another shows reductions in the values of
potassium and calcium after plasma exchange. Renal function
between plasma exchanges as measured by serum urea and
59 149creatinine concentration did not deteriorate. *
No published data have been found for changes in liver 
function parameters, bilirubin, asparate and alanine trans­
aminase. The decrease in the post-plasma exchange values of 
alkaline phosphatase relative to the pre-exchange values 
observed in the present investigation is comparable to that 
quoted in one study.146
The changes in the values of total protein and albumin ob­
served in the present investigation, coupled with the 
stability of the calculated values of globulin following 
plasma exchange using polygeline as replacement fluid have 
been noted in two other studies in which plasma was replaced 
by polygeline (Haemaccel).1,264 The pattern of changes 
observed after plasma exchange in which plasma protein 
solution was used as the replacement fluid, namely the de­
crease in total protein and calculated globulin coupled with
243
stable albumin values are similar to those established else-
1,59,264
where.
This difference in behaviour, as a consequence of the replace­
ment fluid used, has little clinical significance because 
total protein and albumin return to near pre-exchange values 
in 24 hours.
The observed values of serum iron and total iron binding 
capacity indicate that iron deficiency is unlikely to arise 
because of the replacement fluid selected. No other data on 
iron deficiency have been found in the literature and a com­
parison of findings is not possible.
The variation in immunoglobulin IgA, IgG, and IgM concen­
trations noted during the present series of plasma exchanges
accords with the reported data from an extensive number of
. 3,97,98,141,143,264 _ . ,
studies. One study reports reductions m
IgG, IgA and IgM concentrations to less than 45% of their
initial pre-exchange values after the first exchanges, to
less than 30% after the fifth consecutive daily exchange and
. t
to less than 10% after the tenth consecutive daily exchange. 
This behaviour was not affected by the plasma volume exchanged 
nor by the partial replacement of plasma by Haemaccel in the 
case of two patients only. The patterns of recovery 
established for serum IgG, IgA and IgM concentrations were 
similar. Concentrations continued to decrease in plasma 
exchanges conducted on a daily or two-day basis but increased 
if the interval between exchanges exceeded two days. The
244
results from the other studies confirmed these trends.
The mean percentage reductions in these proteins probably 
reflect differences in their compartmental distribution ratios. 
The largely intra-vascular IgM is more effectively removed 
than the more equally distributed IgA.
The effect of immunosuppressive therapy on IgG concentrations 
has been extensively studied. Both decreased synthesis and 
increased fractional catabolic rate have been noted in 
patients receiving steroids and/or cyclophosphamide and 
azathioprine. The absence of a significant effect of immuno­
suppression during daily exchanges, confirmed by the present 
study, may be explained by the relatively large contribution 
in the period immediately after plasma exchange of extra- 
vascular to intra-vascular re-distribution of IgG and IgA.
This mechanism which will effectively increase the serum IgG 
and IgA concentrations is unlikely to be affected by immuno­
suppression.
The response of patients to plasma exchange, as assessed by 
changes in their haematological and biochemical parameters 
measured before and after the exchange procedures, differed in 
its detail within the three groups of patients examined. In 
the comparisons of behaviour of patients from each of the 
three groups, no significant differences were observed in the 
values of many of the parameters measured, whilst significant 
differences were detected between the values of others. No 
obvious pattern of dissimilar behaviour was apparent in any
245
series of measurements or in any specific group of patients*
In general, there were fewer differences between parameter 
values which were significant than were not significant. It 
was concluded that, despite the many random differences 
between the measured haematological and biochemical parameters 
before and during the period after plasma exchange, the over­
all response of patients in the three groups was basically 
similar and thus was not influenced by the choice of the re­
placement fluid used in the study. Clinical examination con­
firmed that the response of patients from all three groups to 
plasma exchange under these conditions was essentially 
similar. No differences were observed in the incidence of 
side effects as a consequence of the plasma exchange pro­
cedures and which could be attributed to the use of Poly— 
geline I, plasma protein solution, or Polygeline II.
The findings of the present more comprehensive study involving
much greater numbers of patients, are in general accord with
the results of more limited studies on relatively few patients
and in which polygeline (Haemaccel) and plasma protein
1 2  3 264
fraction were used as replacement fluids. * * *. .
4.2 Study of selected disorders.
4.2.1 Cold haemagglutinin syndrome.
265*—268Cold haemagglutinin syndrome ~ accounts for 18% of 
all cases of autoimmune haemolytic anaemia. It is 
classified as
1. Idiopathic - which occurs in the elderly and is
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characterised by a gradual onset with a peak incidence 
in persons over 60 years. The antibody is due to a 
proliferation of a clone of IgM cells. It is usually a 
chronic problem and not severe.
2. Secondary - which commonly occurs in
(a) certain infections, such as mycoplasma pneumonia, 
infectious mononucleosis and viral infections, 
particularly cytomegalovirus infection. Only 
rarely will the titre of cold agglutinins rise to a 
particularly high level and bring about haemolysis 
in-vivo. The problem is rarely severe and the 
titres return to normal in 3-4 months.
(b) Lymphoreticular disease - certain patients with 
lymphoreticular disorders develop cold agglutinin 
disease. It appears to be the result of a malignant 
proliferation of a clone of B cells, the lesions 
being classed as histiocytic lymphoma. There is 
also an association with adenocarcinomas occasionally 
with squamous cell carcinomas.
Clinical features are characterised by acrocyanosis with 
purplish discolouration of the skin on exposed parts of the 
body of many patients. When patients are severely affected, 
they may be unable to endure contact with any cold materials 
including cold food, such as ice cream: this will cause both 
pain in the fauces and oesophagus. The agglutination may 
occasionally be seen in conjunctival vessels or in the nail bed 
on microscopic examination. The spleen is frequently enlarged, 
but rarely massively so.
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All patients exhibit the characteristics summarised in 
Table 48 below.
TABLE 48
Serological Characteristics of Patients
DAGT ELUATE
IMMUNOGLOBULIN
TYPE
SPECIFICITY
POSITIVE NO ACTIVITY IgM ANTI-I
Plasma exchange is known to bring about a decrease in the 
cold antibody titre with a variable increase in haemoglobin 
level. In general only transient responses to plasma exchange 
have been obtained, the antibody titres returning to their pre­
exchange levels in only seven days. The results of the present 
limited study confirm this view.
It should be noted that technical issues can arise with the re­
moval of plasma because ofthe expectant agglutination of blood
•4. u . 265 ■ 266as it approaches room temperature. In one case,
presumed to be post-infectious, the cold agglutinin titre
actually rose during a period of intensive plasma exchange
undergone in conjunction with steroids and cyclophosphamide.
It was suggested, that this conformed with the observation that,
during a presumed primary response, plasma exchange resulted
in the loss of feed back control of B cell function with
subsequent amplification of antibody production. This suggests
caution in the use of plasma exchange in cases of low titre
polyclonal IgM cold agglutinins that occur in an acute
presumably post-infectious condition.
248
A study of the effect of cytotoxic treatment on auto-anti­
body rebound that follows auto-antibody withdrawal showed that 
after each of two control plasma exchanges by the filtration 
method the titre in cold agglutinins declined markedly. There­
after the gamma globulin endowed with auto-antibody activity 
increased steeply in parallel with the agglutinin titre to 
values exceeding the pre-treatment levels. There was only a 
slow rise of polyclonal IgM to pretreatment levels. Two 
further plasma exchanges were administered 15 days later, this 
time in combination with ARA-C and cyclophosphamide. No re­
bound occurred and the serum agglutinin titre remained stable 
at about the same level for the ensuing three months. The 
polyclonal IgM level was not greatly affected by the treatment.
The results of my own limited study confirm that plasma ex­
change is most successful at temporarily reducing the cytotoxic
antibody levels and in allowing a prolongation of survival of
268
the transfused cells. It would be an appropriate treatment 
in acute haemolysis resistant to chemotherapy.
4.2.2 Waldenstrom's Macroglobulinaemia
181—183 269
Waldenstrom's Macroglobulinaemia ” ' is a relatively
uncommon, slowly progressive B-lymphoproliferative disorder in 
which the cells are intermediate in immunological maturation 
between those of the small cell lymphomas and the plasma cell 
dyscrasias. The disorder is rarely found in patients below 
the age of 40 years but occurs more frequently in patients of 
advancing age.
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Small lymphocytes, plasmacytoid lymphocytes and plasma cells 
accumulate in the bone marrow, in lymph nodes and in the 
spleen. Many cells synthesise a monoclonal immunoglobulin, 
cytoplasmic or on the surface membrane and the same immuno­
globulin is transferred in the serum. If the concentration 
of immunoglobulin becomes sufficiently high then Waldenstrom's 
macroglobulinaemia will result.
The clinical manifestations of Waldenstrom's Macroglobulinaemia 
are dominated by the large amounts of IgM secreted by tumour 
of small bulk which may not be detectable clinically. High 
serum concentrations may occur in the absence of physical 
signs and little or no bone marrow infiltration. Even when 
numerous lymph nodes are enlarged and the bone marrow is 
heavily infiltrated, bone marrow function may be well preserved 
and the lymphomatous element of the condition may remain static 
for several years.
IgM paraprotein, of molecular weight, IM Daltons, increases 
the viscosity of the blood at lower concentrations than IgG or 
IgA proteins. The value of viscosity increases very rapidly 
with increasing concentration in serum, so that above a con­
centration of about 30g/l small increases lead to large 
increases in v i s c o s i t y . C o n v e r s e l y  a reduction in con­
centration over the same range rapidly lowers the viscosity. 
Thus the removal of the macroglobulin contained in 1 litre of 
blood usually lowers the viscosity sufficiently to bring about 
a rapid and dramatic relief of symptoms.
Because of its high molecular weight most of the macroglobulin
produced is intravascular, so that any lowering of the
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concentration achieved by its removal, is not rapidly re­
versed by the entry into circulation of macroglobulin from 
the extravascular compartment. Unfortunately the rate of pro­
duction of macroglobulin is often so high that the serum
concentration rises to its former level in a few weeks. The
271 272
symptoms of hyperviscosity include muscular weakness,
lethargy, mental confusion proceeding to coma, purpura, 
haemorrhages from the gums, nose,gastrointestinal and genito­
urinary tracts, neuropathies, visual disturbances (e.g. 
bilateral retinal exudates, papilloedema) and deafness. Other 
neurological complications include ataxia, diplopia and 
dysarthria.
Symptomless patients with static Waldenstrom's disease are 
kept under observation without treatment and they may remain 
well for a decade or more. Symptoms arising from hyper­
viscosity are rapidly relieved by plasma exchange and may be
272
managed for several years by periodic procedures. Patients . 
with progressive lymphomatous disease and declining bone 
marrow function require chemotheraphy to reduce the total mass 
of lymphocytes, e.g. chlorambucil, cyclophosphamide or. 
melphalan are used alone or in combination with prednisolone. 
This reduces the bone marrow infiltration leading to an im­
provement in bone marrow function and it reduces the serum 
concentration of paraprotein. The hyperviscosity syndrome in 
patients who are refractory to chemotherapy may be controllable 
by plasmapheresis but rarely for more than a year. Similar 
characteristic responses to plasma exchange were observed in 
the present study of 18 patients all of whom exhibited hyper­
viscosity in association with Waldenstrom's Macroglobulinaemia.
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Hyperviscosity due to IgA and IgG myeloma.
Hyperviscosity due to IgA and IgG M components are the second
and third most common causes of hyperviscosity syndrome after
IgM-M c o m p o n e n t s . 186* IgA-M components tend to
aggregate forming true polymers linked by disulphide bonds
and containing J chains. With IgG-M components there is
usually a very high concentration of the components present,
or the presence of molecules with asymmetric configurations,
or the presence of circulating aggregates of IgG-M components.
Although hyperviscosity has been reported in association with
the other IgG subclasses, most cases are due to IgG-3 myeloma
proteins. The clinical manifestations are similar to those in
Waldenstrom's Macroglobulinaemia, and the treatment is
similar. Generally at least two to four litres of plasma
273 274have to be exchanged, every week or two. ' Following 
plasmapheresis appropriate chemotherapy namely Melphalan and 
Prednisolone is instigated.
Similar characteristic responses to plasma exchange were noted 
in the present study of 12 patients all of whom exhibited 
hyperviscosity in association with multiple myeloma.
The observed response of patients to plasma exchange in the 
present study is similar to that reported by others. On one
p*7C
investigation 9 patients with myeloma of the IgA type and 2 
patients with myeloma of the IgG type, complicated by the 
laboratory and clinical features of hyperviscosity, were 
treated by plasma exchange. In those patients with the IgA
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myeloma the hyper viscosity syndrome was related to the 
presence of high molecular weight complexes in the serum. 
Clinical improvements after plasma exchange coincided with a 
reduction of whole blood viscosity and in those patients with 
IgA myeloma, with a parallel reduction of the high molecular 
weight complexes. IgA and IgG are evenly distributed between 
the intravascular and extravascular spaces and following plasma 
exchange re-equilibrium would result in a secondary rise in 
plasma immunoglobulin concentration and in whole blood 
viscosity. The more delayed phase of the secondary rise of 
whole blood viscosity did occur but in the majority of patients 
this was of no clinical significance and only one patient 
required a second plasma exchange.
276As a part of a more extensive study, 14 patients with mono­
clonal and polyclonal gammopathies were treated by partial 
plasma exchange. The patients with varying clinical conditions 
(2 with light-chain disease, 6 with multiple myeloma and 4 with 
Waldenstrom’s macroglobulinaemia),were subjected to repeated 
manual plasma exchange procedure (0.3 to 0.61 plasma/session). 
The removed plasma was replaced by 5% albumin solution or FFP 
according to the clinical condition of the patients. The two 
patients with light chain disease were treated in 3 sessions 
and plasmapheresis was effective. The remaining 10 patients 
were subjected to a total of 22 sessions of partial plasma 
exchange. In all but 5 sessions where the amount of plasma 
exchanged was inadequate, blood viscosity decreased and the 
clinical signs of hyperviscosity improved in these patients.
In monoclonal gammopathies the improvement could not be
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attributed to partial plasma exchange alone, because the 
patients were concurrently treated by cytotoxics. In poly­
clonal gammopathies the partial plasma exchange without any 
other specific treatment was sufficient to stop severe 
clinical symptoms.
4.2.3 Warm Immune Haemolytic Anaemia
It is not known why a person should suddenly produce anti­
bodies apparently directed against his own inherited antigens. 
The incidence of the disease is difficult to assess, but it 
appears to be relatively high, perhaps, in the order of 1 in 
80,000 population.
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Warm autoimmune haemolytic anaemia occurs in both sexes,
but the incidence is higher in females than males. It can 
occur at any age but is more frequent in females over 40 years 
and males over 50 years of age. The mode of presentation is 
extremely variable. In some cases the haemolysis can be present 
insidiously and it may be months before the doctor is made 
aware of the patient's symptoms. In other cases there may be 
very rapid development of anaemia with extreme prostration and 
jaundice occurring over the period of a few days.
Autoimmune haemolytic anaemia may occur in association with 
various well defined disorders, in which case there will also 
be the signs and symptoms of the other condition. Fifty-six 
percent of cases are thought to be due to the idiopathic form 
of the disease where the autoimmune haemolytic anaemia with, 
or without, thrombocytopenia was unaccompanied by definite 
signs of another disease. Some 15% of cases were associated
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with lymphoma and certain other malignant diseases, for 
example, carcinoma of the breast, carcinoid tumour of the 
small intestine and also teratoma of the ovary. The 
association of auto-immune haemolytic anaemia with SLE and 
other autoimmune disorders, namely thyrotoxicosis, Hashimoto's 
thyroiditis, myasthenia gavis, autoimmune hepatitis, ulcerative 
colitis, rheumatoid arthritis and pernicious anaemia is well 
known.
The commonest form of autoimmune haemolytic anaemia is defined 
as "Coomb's positive", i.e., positive direct antiglobulin test. 
All patients exhibit the characteristics summarised in the 
Table 49 below.
TABLE 49
Serological Characteristics of A I H A Patients
DAGT COATING ANTIBODIES IMMUNOGLOBULINS
Positive Non-complement Rh antigens 
anti-LW
1 IgG IgG 1
2 IgA IgG 3
3 IgM rarely
The premature destruction of red cells is triggered by an 
immunoglobulin IgG or by complement components which are 
attached to antigens on the surface of the cell. Since the 
production of immunoglobulins in all immune anaemias is not 
dependent on a specific antigen, the presence of tumour- 
associated antigens and/or antigens of infectious organisms 
may play a role in the development of this immune disorder. 
The antibodies produced will have cross-reactivity with the
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red cells and therefore initiate the haemolysis. The re­
petitiveness of destruction is closely related to the amount 
of antibodies or components of the complement system and the 
avidity of antibody binding to the red cells. In the human 
body there are not only single immune products but also immune 
complexes and the application of plasma exchange would be 
justified, although the removal of endogenous antigens such as 
those associated with the onset of autoimmune haemolytic 
anaemia would be very difficult. The removal of the rest of 
the humoral components, responsible for the severity of the 
haemolytic process, may be helpful in controlling rapidly 
progressing cases.
The standard treatment of acute haemolysis is usually corti­
costeroid therapy, splenectomy, and immunosuppressive therapy. 
These aim to decrease the destruction of antibody-coated red 
cells, thus producing antibody protection. Generally, how­
ever, these modalities take some time to act. Similarly, 
plasmapheresis offers scope for the removal of antibody, for 
the removal of antigen, for the removal of antigen and anti­
body complexes and for the removal of a combination of the 
first three. The response to plasmapheresis is much faster 
than that to the standard modalities and in the case of 
fulminant haemolysis plasma exchange could be beneficial in 
the interim period.
The reported evidence on the efficiacy of plasma exchange in 
the management of haemolytic anaemia is conflicting and the 
present study is too limited to offer clarification. The 
trends in the three cases are however similar to those noted
in other studies.
, , a. j '265,277,278 . . .. ,There are isolated case reports suggesting that
plasma exchange was effective in the treatment of Evans’
syndrome in the rapid stabilization of an acute, possibly
195 265
post-infectious haemolytic process * and in the treatment
265 .
of non-Hodgkin’s lymphoma.
It should be noted that plasma exchange can be dangerous in 
patients with haemoglobin concentrations of less than 3g/dl 
who cannot tolerate shifts in their plasma volume. However, 
plasma exchanges of even as little as 2 1. of plasma can often 
result in a dramatic decrease in the intensity of the direct 
anti-globulin test, thus allowing a patient's blood to be 
matched, permitting blood transfusion and ameliorating 
symptoms. Where other forms of treatment have failed plasma 
exchange offers alternative therapy.194,279,280
4.2.4 Factor VIII Inhibitors
Acquired pathological inhibitors of coagulation are directed 
against a specific coagulation factor. Factor VIII inhibitors 
are the most frequent and occur as a complication of treatment 
in patients with classical haemophilia A. They can also occur 
in patients regarded previously as haemostatically normal.
The reported incidence in patients with haemophilia of 
inhibitors of Factor VIII varies between 5-20%, and presents 
some of the most serious and challenging problems that can be 
associated with the treatment of haemorrhagic disorders. 
Acquired inhibitors are associated with a variety of chronic
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disorders of auto-allergic type. The latter include rheumatoid 
arthritis, rheumatic heart disease, systemic lupus 
erythematosus,pemphigus, dermatitis, herpetiformis, penicillin 
hypersensitivity, Crohn's Disease, and ulcerative colitis. They 
also occur in women after childbirth and spontaneously in 
apparently healthy people.
The clinical course of inhibitors is unpredictable, but they 
usually disappear within months or years provided that the 
patient does not succumb to haemorrhage in the acute stages of 
the disease. There is not much evidence that treatment with 
steroids or immunosuppressive therapy alters the natural 
course of the disease.
The majority of the antibodies to Factor VIIIC are of the IgG 
class although IgA and IgM inhibitors have been described.
They show remarkable homogeneity with only a single light 
chain type present, usually kappa and they have been found to 
be of IgG subtype. The antibodies can be detected by incubating 
test plasma at 37°C with a source of Factor VIIIC and perform­
ing serial coagulation tests. In our laboratory the limits of 
inhibitor activity are measured in Bethesda units.
The antibodies are known to be present in plasma and serum and 
are stable at 56°C for 30 minutes. They slowly inhibit FVIII 
during incubation at 37°C.
The treatment of bleeding in haemophiliacs with antibiotics 
is difficult since the inhibitor titre rises after replacement
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therapy. Where the bleeding is moderate, FVIIIC replacement
should be avoided if possible. However if life threatening
haemorrhage occurs, large amounts of FVIII are required to
neutralise the antibody and increase the level of FVIII
coagulant activity. In some cases porcine or bovine FVIII
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have been infused. Activated FIX preparation, and daily 
infusions of activated concentrates (FEIBA) have also been used 
successfully. Immunosuppressive therapy has also been used.
The clinical course in non-haemophiliac patients with in­
hibitors is much more variable than in haemophiliac patients.
Bleeding episodes can be exceedingly difficult to treat and
204 282there is significant mortality. ’ Following FVIII in­
fusions an anamestic response is not invariable but may still 
be quite marked.
Plasma exchange has long been recognised as an option in the 
management of Factor VIII inhibitors and the results of the 
present limited study of patients with a variety of conditions 
confirms this view. The observed trends in the values of 
coagulation screening Factor VIIIC, Factor VIII Rag and 
inhibitor screen are similar to those reported in other studies.
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In one such study 2 plasma exchanges were performed in a 
three week period in the surgical management of a subdural 
haematoma. An elderly patient with a sub-lingual haematoma 
was given 6 exchanges of between 1.5 to 6.0 1 each over a 
period of 13 days whilst a patient being prepared for elective 
surgery was exchanged 8 times over a 6 week period.
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282Further, a patient who had developed a very large abdominal 
wall haematoma after appendicectomy was given 14 plasma ex­
changes each of 4 1 over 15 days. Bleeding stopped after the 
second exchange with factor concentrate and complete healing 
followed without other treatment. Haemostasis was also 
achieved in a patient with benign prostatic hypertrophy after 
a 4 1 plasma exchange followed by Factor VIII prior to trans­
urethral section. The patient made a complete recovery and 
his plasma showed only minimal residual inhibitory activity.
284A further study reported the successful use of plasma ex­
change in the treatment of a patient with a massive anterior 
abdominal wall haematoma following an uneventful caesarian 
section for foetal distress, a patient with large ileopsoas 
haematoma and femoral nerve palsy and a patient with prolonged 
post-dialysis bleeding from fistula arterial and venous 
puncture sites.
To be effective large volumes of plasma (3-51)have to be ex­
changed and the flow of antibody from the extra vascular space 
requires the procedure to be repeated on several occasions, 
although immediately following each exchange full Factor VIII 
coagulant activity may be achieved with Factor VIII infusions.
Plasma exchange is much less expensive than the use of highly 
purified porcine Factor VIII, superdose Factor VIII and 
activated prothrombin complex concentrates.
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4.2.5 Relapsing Inflammatory Polyneuropathy and Chronic 
Inflammatory Polyneuropathy
The natural history of acute inflammatory, polyneuro-
.. 175,285-287 . . . . . ...pathy is progressive over one to two weeks with a
subsequent delay of one to two weeks prior to an improvement 
which is then followed by further improvement which may bte 
rapid or gradual. Less than 10% of patients experience re­
lapse. Thus chronic inflammatory polyneuropathy occurs in 
people who have had a previous episode of acute polyneuro­
pathy with a recurrence in rapid or slow fashion. The re­
lapsing form may show excellent recovery if the episodes are 
acute at onset, but with repeated episodes accumulating dis­
ability may occur. Chronic inflammatory polyneuropathy occurs 
when there is progression in a monophasic or stepwise manner
over more than 30 days, usually over more than three
,, 285months.
In most instances the aetiology is uncertain and the following
associated diseases are known to be connected with disorders
in the immune system: monoclonal gammopathy, paraproteinaemia,
multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma,
systemic lupus erythematosus, macroglobulinaemia, cryoglobulin-
aemia, amyloidosis and polyclonalgammopathy. This association
285is probably not by chance.
Conventional treatment has been based on corticosteroids and 
immunosuppressive drugs, but their efficiacy is often in­
complete and in some cases patients do not respond.
261
Plasmapheresis was first used in 1978 for the treatment of
acute polyneuropathy. Subsequent reports285’286 have suggested
improvement in some or all of the patients treated. The
limited response to treatment by plasma exchange by patients
in the present study is similar to that found in other in-
288
vestigations. Whilst there have been many reports of
successful use of plasma exchange in the treatment of chronic
inflammatory polyneuropathy even in cases where Prednisolone
and Azathioprine had failed,286 289 there are also reports
where treatment has been unsuccessful288’289 and it does not
seem possible to predict which forms will respond to plasma
289
exchange therapy. In one study, patients who did not
respond had electrophysiological signs, suggesting severe
axonal lesions. The beneficial effect was also observed in
patients whose liver biopsy showed segmental demyelination
290
with little axonal destruction. Since patients with
prominent axonal degeneration failed to respond to plasma
exchange, the magnitude of the axonal lesions could thus be
290
important in determining the efficacy of plasma exchange.
175In a controlled double blind trial 29 patients with a dis­
ability score of greater than 50 points were randomly assigned 
into twice-weekly whole plasma volume exchanges or sham plasma 
exchanges for a period of 3 weeks. All patients in the sham 
procedures were subsequently treated by plasma exchange. The 
neurological deficit was monitored periodically; nerve con­
duction, computer assisted sensory examination and various 
quantitative measurements of muscle strength were noted. At 
entry the groups were comparable. Five of 15 patients treated
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by plasma exchange showed a greater improvement in the dis­
ability score than was observed in the control group. Of the 
14 patients receiving plasma exchange after the sham pro­
cedure, 4 showed a greater improvement than had been found 
after the sham treatment only.
If plasma exchange is beneficial its mechanism is yet to be
clarified. The clinical improvement is much too rapid to be
explained by a remyelinating process. It has been suggested
improvement may stem from the clearance of a substance re-
290
sponsible for a reversal of conduction block. Several 
findings are consistent with the role of a humoral factor in 
the pathophysiology of the disease. Many reports have shown 
evidence of IgG and IgM deposits at the surface of nerves as 
well as the existence of antimyelin antibodies. In one re­
sponding patient antibodies of the IgG class have been found 
directly against the human sciatic nerve. A conduction block 
has been observed after injection of the serum in one patient. 
The block although markedly present before plasma exchange 
persisted but decreased as the patient's condition improved.
No conduction block could be induced with the serum of another 
patient. No evidence of myelination was found after injection 
of serum of patients who were successfully treated with plasma
exchange. The existence of a circulating factor responsible
290for a conduction block has yet to be confirmed. At the 
present time it is not possible to determine whether plasma 
exchange should be used in:
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1. Chronic inflammatory demyelinating polyneuropathy 
resistant to steroids and or. cytotoxic drugs.
2. Severe forms with respiratory impairment for which 
prompt amelioration is desirable.
3. Any case of chronic inflammatory demyelinating poly­
neuropathy in the hope that should the patient improve 
it will be possible to reduce the dosage of steroids 
and cytotoxic drugs required.
4.2.6 Myasthenia Gravis
209—212 291—293
Myasthenia gravis * is a disorder of the neuro­
muscular junction characterised by weakness and easy fatigue 
which have a marked diurnal variation with noticable deterior­
ation as the day progresses. Symptoms are generally improved 
by rest. The symptoms occur in women, generally, between the 
ages of 20 and 30 years and in men between the ages of 50 and 
70 years. In the younger age group the onset is gradual with 
spontaneous improvement over the first one to two years. In
the older age group the disease usually shows consistent pro- 
291gression.
The disorder is characterised by asymetrical ptosis, diplopia,
nystagmus of the extra ocular muscles, difficulty with chewing
and swallowing and proximal weakness predominantly in the
291
deltoid and iliopsoas muscles. Myasthenia gravis is an
auto-immune disorder in which the pathogenic role of the
specific auto-antibodies for the neuromuscular symptoms is
well documented. These antibodies are directed against the
acetylcholine receptor in the post-synaptic end-plate of the
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skeletal muscle. The receptor antibodies disturb the neuro­
muscular function by blockade of transmitter binding, by 
increased rate of internalisation of receptors and by 
complement-mediated destruction of the post-synaptic end-plate.
All these mechanisms lead to a relative defect in functioning 
294
receptors.
There is now evidence for a spontaneous occurrence of anti­
bodies complimentary to the receptor antibodies. These anti­
bodies bind idiotypic determinants on the receptor antibody 
and should be defined as auto-anti-idiotypic antibodies.
Auto-anti-idiotypic antibodies have also been reported to occur 
in other auto-immune disorders. Auto-anti-idiotypic anti­
bodies are, under certain conditions, able to drive the
differentiation of B cell pre-cursors to the state of anti- 
294
body production.
The prevalence in concentration of acetylcholine receptor 
auto-anti-idiotypic antibodies is especially high during the 
early stages of myasthenia. Receptor antibody of the IgM type, 
although on very low concentrations, is also found more often 
in early and in late disease. Both receptor antibodies of IgM 
class and acetylcholine receptor auto-anti-idiotypic anti­
bodies are decreased in concentration as the IgG receptor anti­
bodies rise. The disease may be treated by administering
1. Anticholinesterase drugs to enhance remaining functions.
2. Immunosuppressive drugs for auto-antibody production.
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•Acetylcholine esterase antibody synthesis can be
reduced by steroid, anti-metaboliser alkalating agents,
but they are not rapidly effective in controlling
symptoms. (At least 3-12 months are required to
295
achieve maximum benefit).
Thus the combination of plasma exchange (which rapidly pro­
duced onset of benefits) with steroids and antimetabolites 
(which give long term control) should offer scope in the treat­
ment of this disorder.
In the present study plasma exchange failed to secure improve­
ment in only three patients whilst in 15 patients there was an 
improvement usually of 2 or 3 grades. This trend is similar 
to that observed in other studies.
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A reported protocol for the treatment of myasthenic patients, 
consisting of 3 exchanges each of 2 plasma volumes or 4 ex­
changes of 1.5 plasma volumes over a 7 day period sufficed to 
clear 65% of IgG and 84% of anticholinesterase antibodies. In 
the present study, the protocol used removed from 60 to 88% of 
Anti-Ach R.
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In one study 27 patients were submitted to immune-modulatory 
protocol treatment because their condition was deteriorating 
rapidly and was not responsive to immunosuppression alone or 
they exhibited chronic disabling symptoms incompletely 
responsive to immunosuppression alone or were steroid dependent. 
Twenty-two percent of patients achieved complete remission at
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the end of the plasma exchange cycle,. 56% showed marked im­
provement, 15% mild improvement and 7% were unchanged. After 
12 months only 22% of the patients worsened and received a new 
cycle of plasma exchange therapy. Patients with short duration 
disease (less than 6 years) responded promptly to treatment 
while patients with long duration disease were low responders 
suggesting a very low number of reworkable acetyl-eholinesterase 
receptor. No correlation could be found in the non-responder 
group. Side effects included 12 cases of citrate toxicity, 6 
allergic reactions to plasma components, one case of mild 
myasthenic crisis in a non-responder patient and 5 cases of 
non-A and non-B hepatitis.
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In another study 60 patients were treated with plasma ex­
change and varying immunosuppressive therapy, namely cortico­
steroids, and azathioprine, azathioprine alone and cyclo­
phosphamide alone. Thirty nine patients had prior thymectomy,
42 had prior corticosteroid therapy. In patients with a mean 
illness of about 3 years duration the disease disappeared. In 
patients with a mean illness of greater than 10 years duration 
the response to treatment was less marked. The incidence of 
thymcma was much higher in the best responding patients and 
non-thymoma patients appear to be less amenable to plasma 
exchange although this could be related to the duration of the 
illness.
The anti-acetylcholinesterase receptor titre did not predict 
the response to plasma exchange but the percentage reduction 
of autoantibody titre correlated with the clinical response 
to the exchange.
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Some patients required to be exchanged every 2, 3 or 4 weeks. 
All were chronically severe, the majority were respirator 
dependent, all had thymectomy, none had had thymoma and all 
had received maximum treatment with Prednisolone and 
Azathioprine and a large number of exchanges (40-100) over a 
long period of time. Patients were switched from Azathioprine 
to Cyclophosphamide during treatment and all attained stable 
remission without further exchanges.
Thus plasmapheresis has an accepted role in the treatment of 
patients with disabling or life-threatening symptoms, to hasten 
the onset of control or to maintain control of symptoms during 
the latent period of immunosuppressive agents.
Lambert Eaton Myasthenic Syndrome.
This is a rare disorder, sometimes associated with carcinoma
(usually of the oat-cell type) or with other auto-immune 
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diseases. It produces proximal weakness, loss of tendon
reflexes and autonomic effects (dry mouth, constipation,
impotence). It is a pre-synaptic disorder in which the number
of packages of acetylcholine released by each nerve impulse is 
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greatly reduced. Recent evidence indicates that this defect
is due to an IgG auto_antibody binding to nerve terminal de- 
299
terminants. Freeze fracture studies of Lambert Eaton cases 
show abnormalities of the active zone particles at the nerve 
terminal which may be the target for the auto-antibody.
Part of the evidence for the auto immune nature of this dis-
299 300order is the response to plasma exchange. * The latency
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of the clinical response is about 10-20 days (and not all 
patients respond). This latency is much greater than that 
observed in myasthenia gravis and presumably reflects the 
slower turn over rate of the structures to which the antibody 
binds. For this reason ten or more exchanges in a single 
course may be required to observe a clear response. Patients 
with the non-carcinomatous form of the disease respond 
favourably to immuno suppressive drug treatment (prednisolone 
and or azathioprine) but as in myasthenia gravis there is no 
evidence that plasma exchange enhances the efficacy of such 
treatment.
The results of the present limited study support this view in 
that the condition of three patients improved whilst that of 
two patients deteriorated.
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In one study the syndrome associated with carcinoma of 
the bronchus in one patient and with immunological disorders 
in two patients improved after plasma exchange. Prednisolone 
and azathioprine treatment led to almost complete remission in 
one and improvement in the other of the non-neoplastic cases. 
It also indicated that an IgG auto antibody binding to nerve 
terminal determinants may be responsible for the disorder of 
the neuromuscular transmission.
The passive improvement that PE produces, particularly in the 
less severely affected patients makes the procedure a useful 
additional treatment for the disease.
269
4.2.7 Guillain-Barre Syndrome (Acute Inflammatory Polyneuropathy)
219-222 301-303 
Acute inflammatory polyneuropathy * is a seg­
mental demyelinating polyneuropathy with paralysis sensory 
impairment and autonomic dysfunction. The disease may follow 
many different types of infection, surgical procedures, or 
vaccinations and has also been known to be associated with 
pregnancy.
Ventilatory failure and its associated complications or auto­
nomic dysfunction induced by paralysis are major causes of 
morbidity and a mortality rate of 10%. 10-20% of all patients
require assisted ventilation and a number will require a 
tracheostomy. Full recovery occurs in 60% of surviving 
patients within one year and many patients still have a 
residual neurological deficit after 2 years. The interval
between peak weakness and the onset of recovery is of prog-
.. , 220 nostic value.
Acute inflammatory polyneuropathy results from a cell-mediated 
immunological disturbance with a selective attack against 
myelin. Circulating lymphocytes are sensitised to peripheral 
nerve antigens and lymphocytes from acute inflammatory poly­
neuropathy patients will produce demyelihation in tissue 
culture. Humoral factors are also implicated. Complement 
fixing antibodies against the neural tissue have been found 
in 50% of AIP cases. Demyelination has been produced in 
tissue culture by cell-free serum. Both IgG and IgM have 
been identified on sections of nerves in AIP patients and IgG
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directed against peripheral nerve appears to be specific. 
These antibodies are best demonstrated during early and pro­
gressive disease and are reduced during recovery. Immune 
complexes have been demonstrated in the circulation or de­
posited in the kidney. Current methods appear to lack dis­
crimination necessary to identify the precise immunological
.. . 220 disorder.
Corticosteroid therapy has not been shown to be effective 
during the acute stages of the disease and may predispose to 
relapse. Other forms of treatment namely Cyclophosphamide, • 
Methylprednisolone and 6-Mercaptopurine have been moderately 
successful. The mechanism by which plasma exchange may bene­
fit patients with AIP is unclear but there is definite 
evidence to suggest some patients can respond rapidly and 
beneficially to the treatment.
In the present study all patients showed some improvement in 
clinical status after plasma exchange, 10%, 65% and 25% of 
patients exhibited improvements of 3, 2 and 1 grades re­
spectively. The greatest response was seen in those patients 
whose disorder was most quickly diagnosed and subsequently 
treated.
301—303
A review of the literature suggests that the response
to treatment by plasma exchange has been achieved in 70% of 
cases and a negative response in 14% of cases.
Improvement was seen during the first exchange procedure,
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the progression of the disease being halted after the first
session and in most cases motor deficit which appeared latest
began to improve. With subsequent sessions benefit appeared
to maximise and following this, improvement was slower and
further deterioration was prevented. This decreased the
necessity for assisted ventilation. Sensory deficit seemed
to respond more slowly and the likelihood of response was
increased the younger the patient. If the disease had not
yet progressed to plateau level and muscle wasting had not
commenced before plasma exchange had started the probability
of rapid improvement was increased. If there was evidence of
denervation, the prognosis for improvement was poor. Once
demyelination had occurred it was unlikely that treatment
would be effective because nerve function could only be re-
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stored with remyelination which takes place very slowly.
Data has been released in a number of controlled trials of
plasma exchange in the treatment of Guillain-Barr/ Syndrome. 
221 301—303
* In one American study of 224 patients 2 groups
were compared in terms of
1. Clinical outcome at 4 weeks.
2. The time taken to improve one clinical grade.
3. The time on a ventilator.
4. The time to improve to walking capability.
By all these criteria, plasma exchange had beneficial effects 
on the outcome of patients. The early initiation of exchange 
was associated with a better outcome than when plasma exchange
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was not started until later in the disease.
In one French study over a 3 year period, 183 patients were 
randomised within 18 days of the onset of muscular symptoms. 
Preliminary results on 63 patients treated by plasma exchange 
and 70 patients without plasma exchange showed that distinct 
benefits were conferred by plasma exchange. The frequency of 
septicaemia, pulmonary, respiratory or cardiac complications 
was the same in both groups. Intercurrent complications or 
adverse effects led to the termination of plasma exchange in 
11 patients, 6 of the patients not treated by plasma exchange 
died.
In patients with severe disease when plasma exchange has been 
started early in the course of the illness, plasma exchange may 
shorten duration of motor weakness sufficiently to reduce 
hospital stay. For patients able to breathe without 
ventilatory support at the time of the first plasma exchange, 
the procedure can also reduce the time spent on a respirator, 
if ventilatory assistance is subsequently needed. Plasma 
exchange is recommended only for GBS patients with, at a 
minimum, severe weakness at the time of the first plasma ex­
change (i.e. patients able to walk only with support). It is 
not clear whether patients able to walk without support will 
benefit from plasma exchange.
4.2.8 Glomerulonephritis and Goodpastures Disease
. . . 110,304-307 ... , ^
There is evidence that most, if not all, types of
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glomerulopathies are caused by deposition of circulating 
proteins or protein aggregates in the glomerulus. Glomerulone­
phritis due to auto-antibodies to the glomerular basement 
membrane (GBM), or associated with the deposition of immune 
complexes carries a poor prognosis, with a rapid deterioration 
in renal function leading to renal failure within a year. The 
role of anti-GBM antibodies is well defined, their patho­
genicity having been demonstrated by transfer of the disease 
to primates, and by the observation that the disease recurs 
rapidly in renal allografts if circulating antibody is present 
at the time of operation. However, the role of immune com­
plex deposition in the kidney remains controversial.
The types of glomerulonephritis were classified as:
Non Antibody Mediated GN
1. Mesangiocapillary GN Type 1 - in which there is a layer 
of tissue beneath the GBM giving it a double contour. 
This is a sub-endothelial extension of mesangial 
matrix and cells containing immune deposits and C3.
2. Mesangiocapillary GN Type 2 - in which C3 associated 
electron dense material is incorporated into the GBM.
3. Mesangial IgA Disease - perhaps the most common 
glomerular pathology worldwide, characterised by diffuse 
mesangial proliferation and associated with recurrent 
macroscopic haematuria.
Antibody Mediated GN
In Anti-GMB Antibody Nephropathy there is a neutrophilic cell
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infiltrate, heavy fibrin deposition and extensive epithelial 
erescent formation, Anti-GM antibodies have been seen to be 
responsible for the immunologically mediated renal damage in 
this condition, and it has been demonstrated that there is a 
positive correlation between antibody levels and plasma 
creatinine on presentation. Although the production of anti- 
GBM antibodies is self-linking this may take years in un­
treated cases, by which time renal failure is usual.
In view of the grave prognosis in both types of disease, 
treatment with steroids and cytotoxic drugs was introduced in 
an attempt to control the underlying immune response and limit 
the effects of inflammation. The response of the kidney is 
dependent upon the severity of glomerular damage at the on­
set of treatment, it is apparent that the earlier treatment 
is instigated, the higher the chance of recovery.
Plasma exchange can be combined with drug therapy in order to 
rapidly reduce antibodies (to undetectable levels within 6-8 
weeks) pending the effects of cytotoxic agents.
From our small series it can be readily seen that those 
patients presenting with a creatinine of 550 jumol/1 have an 
encouraging response to aggressive plasma exchange. Where 
extensive damage has already occurred dialysis is the end 
result.
In one studyf04 44 patients with anti GBM disease, ages 
ranging from 4-72 years were treated to daily 4 1 plasma
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exchanges using PPF and an immunosuppressive regimen of 
prednisolone (60mg reducing to 20mg/day in 4 weeks), cyclo­
phosphamide (3mg/kg daily) and azathioprine (lmg/kg daily). 
Within 8 weeks, antibody was not detectable in 21 of 34 
patients. Of 22 oliguric patients, none recovered renal 
function, 16 remained dialysis dependent and 6 died. Of 5 
patients presenting with creatinine>600 jmol/1 (6.8mg/dl), 
one improved and 4 proceeded to dialysis. Of 17 patients 
with creatinine levels< 6 0 0 jumol/1, 15 recovered renal 
function, one became dialysis dependent and one died. Only 2 
of the patients subsequently deteriorated.
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In another study, 4 patients with diffuse proliferative GN 
and 2 patients with focal proliferating GN (one of which had>  
50% crescents) were treated with either corticosteroids or 
corticosteroids and immunosuppressive drugs. This failed to 
improve kidney function proteinuria and/or the amount of 
circulating immune complexes. 9.8 - 3 1 plasma exchanges were 
performed on each patient using 5% Human albumin and the 
immunosuppressive treatment was maintained.
In 5 of the 6 patients serum creatinine, creatinine clearance, 
proteinaemia and/or the amount of circulating immune complexes 
declined. Kidney biopsies from 4 patients who-were re-biopsied 
showed a change towards sclerosing GN in all cases and in 
the patient with focal proliferating GN, a decrease of the 
number of crescents to-<'50%.
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A study has been made of 22 patients with rapidly pro-
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gressive glomerulonephritis and severe renal impairment (12 
cases were idiopathic, 7 had a positive immunofluorescence,5 
had a negative immunofluorescence, and in 8 cases a vasculitis 
could be demonstrated). All patients received prednisolone 
(lmg/kg) and cyclophosphamide (2mg/kg). An intensive plasma 
exchange regime was applied in 11 cases, 2 positive IF-RPGN3 
4 negative IF-RPGN and 5 cases of vasculitis.
Improvement was seen in 5 over 6 plasma exchange treated 
idiopathic RPGN cases, 4 of them showing negative IF pattern, 
in 3 a sustained improvement was obtained and 2 went into ESRF 
after 17 and 33 months. In the group of 6 idiopathic RPGN 
cases on which plasma exchange was not carried out 3 patients 
died and 3 did not show any improvement.
Renal function improved in 2 patients with vasculitis- 
associated RPGN treated by plasma exchange. In one case 
improvement remained 34 months after treatment but in the 
other case a progressive loss of renal function was observed, 
starting haemodialysis five months after. In three other 
cases,no changes were seen in one and two patients died.
Some beneficial effect of plasma exchange treatment in idio­
pathic RPGN mainly in its negative IF form seems possible. The 
effectiveness of plasma exchange in the treatment of RPGN 
vasculitis-associated was not established.
Goodpasture1s Syndrome.
~ , . , „ . 118,213,214,215,308,309 . ■Goodpasture's Syndrome ’ * * is characterized
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by pulmonary haemorrhage and glomerula nephritis. The syndrome 
is most commonly initiated by anti-basement membrane antibodies 
which can be identified as linear immunoglobulin G (IgG) de­
posits along the glomerular basement membranes (GBM) and the 
alveolar basement membranes. Circulating anti-GBM antibody 
can also be shown by indirect immunofluorescence and more 
recently by radio-immunoassay. The specificity of the linear 
deposits detected by immunofluorescence can be confirmed by . 
elution studies.
Steroid therapy is now considered useful in the management 
of pulmonary haemorrhage but there is less evidence that 
either steroids and/or immunosuppressive agents are beneficial 
in the management of the renal manifestations of the syndrome. 
Nephrectomy has also been considered to be of benefit in some 
patients with life-threatening pulmonary haemorrhage but the 
results have not been consistent and fatal pulmonary 
haemorrhage has occurred in nephrectomized patients.
Intensive plasma exchange permits the immediate removal of 
antibody and, with the appropriate replacement fluid, can 
deplete inflammatory mediators such as complement and 
fibrinogen, whilst the immunosuppressive drugs provide the 
longer term control of anti GBM.
In the present study plasma exchange was only partially 
successful in securing improvement in the clinical status of 
patients treated and this appeared to be dependent on the 
creatinine concentration on presentation rather than on the 
depletion of circulating immune complexes. Other studies
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have also reported conflicting responses of patients to plasma 
exchange.
In one study^^ an improvement has been reported in 7 cases 
of Goodpasture's syndrome treated by combined immuno­
suppression and plasmapheresis. The contribution of plasma­
pheresis to the survival of 6 of this group is difficult to 
assess because of the large doses of immunosuppressive drugs 
employed at the same time. There is often a striking fall in 
the level of antibody at the initiation of therapy. Some of 
the effects of plasma exchange may be due to the removal of 
inflammatory mediators such as complement C-reactive protein 
and fibrinogen.
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In another study a case was reported of antiglomerular 
basement membrane antibody induced Goodpasture's syndrome in 
which the patient required haemodialysis and was treated with 
immunosuppressive agents and plasmapheresis. A severe (80%) 
crescentic lesion was reversed and crescentic lesion was 
stablized at 2.5mg/dl at one year follow-up. Fifteen other 
reported cases of Goodpasture's syndrome in which the patients 
were treated with plasmapheresis were reviewed. Short term 
follow-up showed that nine of these patients were alive 
without need of dialysis, five were receiving dialysis and 2 
had died.
There have been instances of the recurrence of circulating 
anti-glomerular basement membrane antibody at different times 
after immunosuppressive treatment and plasma exchange. In one
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patient, antibodies reappeared after an absence of 3 years 
and linear IgG staining of the glomeruli was shown by immuno- 
fluorescent studies. Renal function did not change and there 
was no evidence of pulmonary haemorrhage. Antibody levels 
then fell spontaneously over the succeeding 18 months. Two 
cases have been reported in which Goodpasture's syndrome re­
curred 13.5 and 38 months after kidney transplantation. In 
one patient there were additional recurrences at 18.5 and 30 
months associated with kidney graft dysfunction and proteinuria. 
Dramatic improvement of graft function occurred after each 
series of plasma exchange and has persisted for 41 months 
after the last plasma exchange. The second patient returned 
to haemodialysis one month after plasma exchange when graft 
biopsy showed vascular lesions of chronic rejection. Anti 
GBM antibodies initially detected in both patients disappeared 
after the first plasma exchange.
4.2.9 Aplastic Anaemia and Red Cell Aplasia.
When there is a deficiency or defective utilization of an 
essential factor, erythropoiesis may fail and haemopoietic tissue 
may disappear. Haemopoietic hypoplasia may result from 
damage to the haemopoietic stem cells by means of a toxin 
acting against later erythroid cells or from damage to marrow 
stroma. These result in pancytopenia, i.e., anaemia, leuko­
penia with neutropenia, and thrombocytopenia and are referred 
to as aplastic anaemia. When the white cells and platelets 
are not affected, pure red cell aplasia is the result.
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Aplastic Anaemia.
^ ^ , . 223,224,225,310 .
A number of different mechanisms lead to marrow
aplasia. In about a third of all patients, this appears to be 
due to a drug, e.g., Chloramphenicol. The maintenance of an 
adequate vascular microcirculation is necessary to support 
growth of haemopoietic tissue. Destruction of the sinusoidal 
structure of a marrow may result in aplastic anaemia from 
atrophy of haemopoietic tissue and recovery requires re­
storation of medullary vascularity. Stem cell defects may be 
primarily responsible in this case. An autoimmune mechanism. 
may operate in some cases, e.g., selective aplasia of the 
erythroid cells, where there is frequently an association 
with other aberrations in the immune system such as thymoma 
and IgG antibodies to erythroblasts. There is some evidence 
of lymphocyte-mediated stem cell inhibition in cases of 
aplastic anaemia.
Haematopoietic stem cells and their progenitors differentiate 
to mature blood cells under the influence of bone marrow micro­
environment and haemopoietins. Stem cells have surface anti­
gens that are different from those of mature cells and anti­
bodies specific for precursor cells do not bind to mature 
cells. The exact nature of the elements of bone marrow en­
vironment responsible for haematopoietic differentiation are 
unknown. In-vitro granulopoiesis is dependent on colony 
stimulating factors secreted by the monocyte macrophages and 
probably regulated by prostaglandins, serum factors and 
cellular interactions. The role of immune mechanisms in bone
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marrow failure associated with aplastic anaemia provides the 
rationale for treatment in plasma exchange.
The present very small study shows some evidence that plasma­
pheresis could be beneficial in very few patients in whom 
antibodies are responsible for the inhibition. In the 
patients described in this study, the serum factor was IgG- 
anti DNA antibody in the patient with SLE; IgM in the patient 
with cryoglobulinaemia and also in the remaining patients.
Similar beneficial results of plasma exchange have been re-
224ported in other investigations. One study of in-vitro 
granulopoises in 21 patients with aplastic anaemia showed that 
12 patients had no in-vitro abnormality which accounted for 
the failure of the marrow to form colonies. It was thus 
assumed that the pancytopenia was secondary to a still un­
known stem cell or micro-environmental abnormality. The three 
abnormalities identified were (1) bone marrow hyperactive 
suppressor T cells directed against the precursor cells in 
three patients (2) circulating immunoglobulins directed 
against marrow colony forming units in culture (CFU-C) in 
three patients, and (3) abnormalities in the function of 
colony-stimulating factor in three patients. Plasmapheresis 
combined with cytotoxic therapy proved to be effective in 
removing the serum antibody and in the recovery of bone marrow 
in the three patients in whom serum factors, that were in­
hibitory to the bone marrow precursor cells, were depleted.
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Plasma exchange has been used in the treatment of a patient,
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with aplastic anaemia and serological evidence of systemic 
lupus erythematosus, whose serum contained complement- 
dependent immunoglobulin IgG antibody that inhibited both 
granulocyte and erythroid colony formation by normal human 
bone marrow in-vitro. Incubation of normal human bone marrow 
cells with the patient’s serum and a source of complement 
caused a 95% reduction in myeloid colony formation. The 
addition of the patient’s serum plus complement, to normal 
marrow cultured in methylcellulose, also produced a 98% re­
duction in erythroid colony numbers. Assay of serum immuno­
globulin fraction showed that inhibitory activity was con­
tained in the IgG function. After a series of procedures in 
which 5 to 6 litres of plasma were exchanged isovolumetrically 
with type AB fresh frozen plasma at monthly intervals, the 
titre of the inhibitor fell, the marrow cellularity and 
peripheral counts returned to normal. Incubation of the 
patients recovery marrow with stored pre-plasma pheresis 
serum and complement did not produce reduction in myeloid 
colony formation.
Red Cell Aplasia.
c i .. . 225,226,311-313 , - .Some types of aplastic anaemia have their
counterparts in cases where only the erythroid cells are
affected. They are characterised by the main absence of
erythroblasts in an otherwise normal marrow. In some cases
tryptophane metabolism may be involved in the genesis of
erythroblastic hyperplasia, i.e., it may be associated with
riboflavin deficiency. Other acquired cases appear to be due
to antibody-directed specificity against erythroblasts and/or
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erythropoietic factors. This is often associated with a 
thymoma, occasionally with myasthenia gravis and in a pro­
portion of cases it may be possible to demonstrate the serum 
anti-nuclear factor, LE cells, and a positive direct anti­
globulin test. IgG serum inhibitor erythropoiesis has been 
demonstrated by both in-vitro and in-vivo assays.
The effects of autoantibodies include interference with haem 
synthesis, as demonstrated in suspension cultures of normal 
bone marrow, complement-dependent lysiscf erythroblasts and 
complement-independent inhibition of erythroid progenitors. 
Occasionally antibodies are directed against erythropoietin.
The treatment of red cell aplasia of the antibody type is 
based on thymectomy for thymoma and immunosuppression, e.g. 
cyclophosphamide or antilymphocyte globulin. Plasma exchange 
offers potential for the treatment of patients who may not 
respond to immunosuppressive therapy.
The present study, involving only two patients, was too 
limited to properly reflect the efficacy of plasma exchange
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in the treatment of aplastic anaemia. In one reported study, 
plasma exchange was applied to a patient with pure red cell 
aplasia who did not respond to immunosuppressive therapy.
The patient’s plasma contained antibodies that inhibited 
erythroid formation of autologous and normal bone marrow cells. 
Extensive plasma pheresis removed the auto antibody and re­
sulted in complete normalisation of erythropoiesis that had 
persisted for more than 2 years.
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In a further study, a patient with fulminant lupus 
pneumonitis, renal failure and red cell aplasia not re­
sponsive to massive corticosteroid therapy showed sustained 
improvement after plasma pheresis and haemodialysis. The 
patient's respiratory and renal function improved and 
gradually returned to normal.
For selected patients with life threatening disease unre­
sponsive to conventional therapy plasmapheresis provides an 
albeit temporary experimental therapeutic option. Additional 
experience may show whether patients with less severe disease 
activity may be responsive to such therapy.
4.2.10 Polymyositis
Polymyositis identifies a group of diseases in which muscular 
weakness and wasting may be associated with muscle pain and 
tenderness or with evidence of some form of connective tissue 
disease or collagen disorder. The term is used to include 
cases with florid skin change, i.e., dermatomyositis, usually 
taken to indicate the so-called idiopathic syndrome and ex­
cludes disorders such as polymyalgia rheumatica and acute
myositis resulting from infections with micro-organisms and 
314-318
viruses.
The aetiology suggests an organ-specific autoimmune disease, 
while in cases showing involvement of skin or joints, it can 
be accepted as being the muscular manifestation of non-organ 
specific-auto immune disease.
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The commonly demonstrated relationship between polymyositis 
and dermatomyositis on the one hand and malignant disease on 
the other suggests that the condition may also on occasion be 
the result of conditioned auto-immune response in patients 
suffering from cancer. It is a condition occurring in many 
races world-wide and in both sexes.
Apart from occasional acute cases in which widespread muscle 
pain, fever, constitutional upset and rapidly progressive 
paralysis occurs, the condition usually runs a sub-acute or 
chronic course. Muscle pain and tenderness occur in 50% of 
cases, as does dysphagia. Cutaneous manifestations are seen 
in 66% of all patients. Helioptrope erythema and periorbital 
oedema are particularly characteristic and so is congestion 
of the nail beds. In 25% of cases, joint pain and stiffness 
occur at some stage. Proximal limb muscles are invariably 
involved and the neck muscles are affected in about 60% of 
all cases. Involvement of distal limb muscles is less common, 
but weakness may be generalised in about 33% of all cases. 
Because of the progressive nature of the disease, it has been 
suspected that a pathogenic autoantibody might be involved. 
Although it has not yet been demonstrated, there is some 
evidence from muscle biopsies carried out, that an autoanti­
body with specificity for muscle tissue may be present. 
Diagnosis is usually by demonstrating a markedly elevated 
serum creatinine phospho kinase, a myopathic pattern of 
volitional activity electromyographically and by means of a 
muscle biopsy. The latter demonstrates wide-spread necrosis, 
and phagocytosis of muscle fibres and interstitial and peri-
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vascular infiltrates of inflammatory cells.
The mainstay of treatment is cortisteroid therapy in moderate 
to high dose in the first instance. In those patients re­
fractory to this therapy, immunosuppressive and cytotoxic 
therapy is instituted.
If cellular and humoral immune mechanisms contribute to the 
muscle and skin injury then plasma exchange should provide 
some relief. In the present study 7 patients exhibited an 
improvement in clinical status of 2 grades and 3 patients of 
one grade after plasma exchange following significant re­
ductions in the values of creatinine kinase, asparate trans­
aminase, alanine transminase and lactate dehydrogenase.
Similar behaviour has been reported by other workers.
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In one study, 27 patients with polymyositis were treated 
with a weekly series of large volume plasmapheresis (5-6% 
body weight) until an end point was reached where the CK had 
normalised or reached a plateau and there was no additional 
benefit. All patients had been treated previously with 
moderate to high dose corticosteroids but had either respond­
ed inadequately or could not tolerate a dosage adequate to 
suppress disease activity because of side effects. Cyclo- 
phoasphamide was added daily at the time of the first ex­
change. Patients who developed side effects were switched to 
chlorambucil. All but 2 patients showed at least 1 grade of 
improvement on a 7-step scale of muscle testing. The best 
responses were seen in patients whose disease was quite
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active as determined by the rate of clinical progression and 
the height of the CK activity. CK was found to be a muscle 
enzyme which seemed to correlate better with disease activity 
than other commonly measured enzymes such as SGOT adolase or 
LDH.
Patients with slowly progressive disease had the least and no 
response to plasma exchange. Serum CK activity decreased in 
all patients in whom it was initially elevated and normalized 
at some point in two-thirds of the patients. It took up to 30 
treatments over prolonged period of time to completely 
normalize CK in some patients.
Post-exchange biopsies from patients with highly active 
disease showed no evidence of fibre necrosis, phagocytosis 
and interstitial and vascular inflammation. Two patients 
had mild perifascicular atrophy.
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In another study, electro-myography and muscle biopsy were 
abnormal in each patient. An IgG kappa monoclonal para­
protein was found in the serum of all three patients. Muscle 
biopsy specimens showed linear deposits of IgG kappa along 
the sarcolemmic basement membrane of the individual fibres. 
Stains for lambda light chains, other immunoglobulins and 
complement components were negative. The patients failed to 
respond to prednisolone for periods longer than 3 months.
The addition of plasma exchange performed 3 times a week for 
3 weeks produced a fast clinical improvement in all 3 patients. 
Muscle biopsies after plasma exchange showed no immune de-
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posits. Monoclonal immunoglobulin is demonstrated in the 
serum and along the sarcolemmic basement membrane in three 
patients.
Two of the four patients with polymyositis clinically im-
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proved after an intensive course of plasma exchange. One 
patient showed marked, and the other moderate clinical re­
sponse. No relation was found between the degree of clinical 
improvement and the duration of illness before plasma exchange. 
No statistically significant biochemical response could be 
demonstrated.
4.2.11 Clinical Status of Patients.
The side effects observed in the study are in accord with 
those recorded in an extensive literature.^6-244.
The most frequently reported side effects of Haemaccel are 
minor skin reactions, urticaria and burning sensations. An 
occasional case of facial oedema, a rise in body temperature, 
hypotension and respiratory difficulties have been observed. 
Cases of bronchospasm and circulatory collapse have occurred 
very infrequently. Haemaccel is generally considered to be 
non-immunogenic, i.e., it does not trigger production of 
antibodies on repeated challenge.
Whilst not encountered in the present study, it is known that 
the rapid infusion of plasma substitute can cause the release 
of detectable small amounts of histamine. The exact mechanism 
is unclear but it may be due to direct chemical action on
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mast cells. It has also been suggested that histamine 
liberation may be related to individual sensitivity and to 
the rate of infusion of solution.
Feverish reactions constitute the majority of side effects 
experienced with plasma protein solution. These tend to be 
short lived and usually occur in cases of known sensitisation 
to blood and its derivatives. Other side effects which have 
arisen were usually due to the procedure. In France there 
are many reports of fever and shivering associated with the 
use of 4% albumin as replacement fluid. This was attributed 
to the purity and variability of the preparation. Albumin 
of placental origin purified by chromatographies sub­
stantially reduced the frequency of the febrile reactions. 
Where volumes of fresh frozen plasma larger than those 
employed in the present study have been used significant 
side effects have been encountered.
4.3 Leukapheresis
18-22
Acute leukaemia results from the uncontrolled proliferation
of poorly differentiated immature cells (blasts) in the blood and 
bone marrow and their invasion into the rest of the body organs 
is chiefly responsible for the devastating effects of the disease. 
The clinical manifestations and the response to therapy may vary 
with the type of blast cell involved in the leukaemia process.
Acute lymphatic leukaemia accounts for over 80% of the cases in 
children, whilst acute myeloid leukaemia constitutes at least 85% 
of adult patients.
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There are two fundamentally different forms of chronic leukaemia, 
namely chronic granulocytic and chronic lymphocytic leukaemia.
The latter is a disease of the elderly, the former occurs at all 
ages and is especially associated with middle age.
Cell morphology provides the basis of diagnosis and classification 
and immunological techniques are used to detect antigens and other 
molecules on the cell surface. Standardised treatment strategies 
have now been devised based largely on intensive drug regimes.
However leukapheresis, by continuous flow centrifugation, has 
been employed in the management of both acute and chronic 
leukaemia . It is a method by which a large and relatively pure 
population of white blood cells can be harvested in a short period 
of time. This controlled depletion of peripheral white cells 
occurs without a significant loss of red cells or platelets. It 
has been employed for:-
1. The therapeutic cell depletion for the reduction of the 
tumour burden in chronic leukaemia and the prevention of 
leukastasis in acute leukaemia.
2. The collection of peripheral stem cells from patients 
with chronic myeloid leukaemia.
3. The collection of allogenic leukaemic blasts for immuno­
therapy as an adjunct to chemotherapy in prolonging 
remission in acute myeloid leukaemia.
It is known that leukostasis, i.e., the occurrence of intra- 
vascular leukocyte aggregates and thrombi, is most frequently
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associated with acute non-lymphatic leukaemia with peripheral 
leukocyte counts in excess of 100 x 10 /l. Any increment added 
to the total cytocrit by transfusion may aggravate morbidity and 
mortality, as may the institution of conventional chemotherapy. 
Clinically the morbidity and mortality is predominantly of pul­
monary and central nervous system origin and onset symptoms may 
occur in the last few hours of life. Despite few histological 
confirmations of leukostasis in patients subjected to leuka- 
pheresis, dramatic improvement in the clinical status of patients 
has been noted.
12The urgent removal of 0.5 to 2.4 x 10 /I cells can rapidly re-
9
duce the WBC to less than 50,000 x 10 /l.
Leukapheresis, as sole therapy for chronic myeloid leukaemia, 
requires repetitive procedures at high cost relative to medical 
therapy and does not achieve marrow remission. The transient 
lowering of leukocyte counts to relieve symptoms attributed to 
extreme leukocytosis, while cytotoxic therapy is being intiated, 
would seem justified.
The occasional leukapheresis procedure can be useful in selected
patients with chronic lymphatic leukaemia in whom the WBC is 
9
100,000 x 10/1. In some patients there is a reduction in 
magnitude of the hepatomegaly and/or splenomegaly over the 
duration of the procedure. Leukapheresis should never be employed 
as sole therapy in cases of chronic lymphatic leukaemia as it is 
unsuccessful in alievating anaemia or thrombocytopenia.
Occasional patients (less than 10$ with stage IV disease) appear
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to respond to leukapheresis at one to four week intervals with 
increases in haematocrit and/or platelet count.
The present study has confirmed that leukapheresis provides a 
relatively rapid means of safely reducing the circulating white 
cell count. It will certainly bring clinical improvement, by re­
ducing the circulating WBC by 40% within three hours of the first 
procedure. Leukapheresis relieved respiratory symptoms in 2 out 
of 10 patients, and neurological symptoms in 3 out of 10 patients. 
The optimal treatment would therefore appear to be leukapheresis 
followed by chemotherapy because the response to chemotherapy is 
improved if the white cell count has been reduced by serial 
leukapheresis.
In the treatment of chronic myeloid leukaemia leukapheresis has 
not proved to be a superior form of treatment and does not appear 
to delay blastic transformation. In the treatment of chronic 
lymphatic leukaemia leukapheresis will result in reductions in 
lymphocyte count, spleen size, lymphnode size, bone marrow in­
filtration and liver size, but it should be used for those 
patients failing other forms of treatment.
319-324
There is considerable literature on the application of
leukapheresis in the treatment of leukaemias. In one study
leukaemia patients with extremely high peripheral white blood
counts and who had experienced a cellular hyperviscosity syndrome
were leukapheresed to reverse the associated neurological dys- 
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functions. Leukapheresis had effectively been used to rapidly 
reduce high blast counts in acute leukaemia for the management of
leukostasis. Temporary control of leukocytosis has also been
321 322
managed by cytopheresis techniques. .* Regression of the
disease has been reported with intensive leukapheresis in chronic
lymphocytic leukaemia. Leukapheresis has been safely used as an
alternative to chemotherapy in the treatment of leukaemia during 
323
pregnancy.
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A single urgentleukapheresis has been recommended prior to con­
ventional chemotherapy to reduce the leukocyte count to the 50 x 
10/1  range. Considerable variation was found in the separation 
conditions for leukaemia cells but there were immediate clinical 
benefits, namely improved cerebral function, reduction in spleen 
size and decreased dyspnoea. There was considerable CNS and pul­
monary morbidity and late mortality in the treated group. A serum
3
LDH rising to greater than 4 x 10 units was associated with a 
poor prognosis.
Nineteen patients with acute leukaemia (6 lymphoblastic, 8
myeloblastic and 5 myelomoncytic) and 13 patients with chronic
leukaemia (9 myelocytic, 3 lymphocytic and 1 hairy cell) have been
21subjected to leukapheresis procedures. The patients, 16 male 
and 16 female, ranged from 5 to 80 years, and were subjected to 
17 and 38 procedures respectively. The lymphoblastic patients, 
myeloblastic patients, myelomoncytic patients, myelocytic 
patients, lymphocytic patients and hairy cell leukaemia patient 
were subjected to 6, 8,5, 9, 6, and 21 procedures respectively.
In most of the acute cases the leukapheresis was performed as an 
emergency procedure and was lifesaving in some instances. The
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chronic patients were leukapheresed either because of blastic 
transformation (CML) or because they were refractory to con­
ventional therapy. In some cases there were minor improvements 
in respiratory function, WBC, neurological dysfunction and 
anaemia sifter leukapheresis, but no improvement was noted in 
splenomagaly, hepatomegaly, nodular involvement and fever. Only 
44% of the acute leukaemia patients survived 21 days past the 
first leukapheresis. Those not surviving died shortly after the 
procedure because of leukostasis or haemorrhage. All of the 
chronic leukaemia patients survived beyond 21 days.
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In one study, 20 leukapheresed patients were compared with 78 
non-leukapheresed patients (control group), 12 male and 8 female 
(aged 11-59 years), 9 newly diagnosed patients with acute lympho­
blastic leukaemia and 11 with acute non-lymphoid leukaemia. All 
patients were given 1, 2 or 3 leukapheresis (42 in all) followed 
by induction chemotherapy. A 30-35% decrease in initial WBC was 
obtained after each leukapheresis.
In ALL , 7 of the 9 leukapheresed patients achieved complete
remission without early death. In ANLL, 5 of the 11 leuka­
pheresed patients achieved complete remission, while 6 died.
It was concluded that early death rate was lower in the leuka­
pheresed patients, but statistically significant only in ALL 
patients ( p < 0.01) and the complete remission rate was higher in 
the leukapheresed patients than in the control group.
The leukaemic mass removed after second leukapheresis procedure did 
not increase any more.
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FUTURE DEVELOPMENTS
5.1 Technical
If, in the course of time, therapeutic apheresis is assessed 
to be no more than adjunctive or palliative and not curative 
and of short-term rather than long term benefit, the 
application of blood cell separators and apheresis techniques 
will be justified by their contribution to the improvement 
of the clinical management of several disorders by cellular 
or plasma depletion or by rapid erythrocyte or plasma re­
placement. Randomized clinical trials being undertaken at 
present or in the future will undoubtedly increase the scope 
of potential applications of the procedures and, hopefully 
will add to the understanding of the separation character­
istics of different cells and the kinetics of cell population 
and lead to an improvement in the rationale of treatments 
based on apheresis procedures.
The separation of blood components by centrifugation methods 
is relatively crude and some measure of inter-constituent 
contamination is inevitable. Further, because of the 
diminishing incremental effect of the removal or addition of 
a substance in a patient by plasma exchange, the complete 
removal of a harmful substance will be difficult and the 
removal of even the bulk of a substance will require a 
number of large volume exchanges with appropriate intervals 
to allow the diffusion of extra vascular antibody into the 
intravascular space for subsequent removal. This method of 
removal of a substance is inefficient and wasteful in that
the number of desirable components are also ^discriminating­
ly removed and then require to be replaced by appropriate 
fluids which in themselves can introduce further com­
plications. Clearly there is a need for procedure that will 
permit the expeditious return of the patient's own plasma 
from which the offending component or components have been 
selectively removed in the course of the exchange. Apheresis 
by filtration rather than by centrifugation offers advantages. 
The resulting plasma should be completely free of particulate 
matter above 0.6 pm in size which should render it more re- • 
sistant to blockage in long procedures or in small bead 
packed columns. The continuing development of less costly, 
more efficient, faster operating membranes for the specific 
removal of plasma constituents may be expected.
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It has been generally predicted that the likely overall 
demands for the future will require an input from every 
million of the population of between 10,000 and 12,000 litres 
of plasma annually, the bulk of which will have to be fresh. 
There is general agreement that the efficient and economical 
use of blood implies that patients be transfused only with 
the specific component of blood required. The cellular com­
ponents of blood can be separated into packed red cells, 
platelets and white cells. Plasma is a source of albumin or 
labile clotting factors. The most economical source of 
plasma is from whole blood drawn for red cell transfusion. 
There is clearly scope for equipment and procedure develop­
ment that will maximize the yield of components, minimize 
the inter-component contamination and component cost.
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Improvements can also be expected aimed at reducing the 
variability of components particularly in cellular quantity 
and character.
It is likely that by combining apheresis procedures with 
existing and future column techniques greater progress will 
be made in achieving the above objectives. The bio­
compatibility of column packing can be markedly improved by 
passing only plasma through the column and returning the by­
passed cellular elements directly to the patient.
There are already indications that progress is being made in
7the selective isolation and collection of plasma constituents. 
There is increasing application of protein A which not only 
can remove IgG sub-classes 1, 2 and 4 but can apparently re­
activate a suppressed immune system either by removing 
blocking antibodies or stimulating the cellular system.
Cells bearing IgG on their surface may also be adsorbed out 
provided the size of bead in the column is increased to 300 
jm to allow free passage of cells through the interstices.
A and B blood group antibodies have been removed by totally 
synthetic antigens rendered bio-compatible by cellulose 
nitrate/albumin coating cholesteral and/or low-density lipo­
proteins have been removed by Heparin-agrose. Inhibitors to 
Factor VIII and Factor IX have been adsorbed by protein A — 
sepharose. Further studies along these lines may be expected 
to continue.
Questions remain regarding composition of column or filter
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effluents and the modified plasma. The mechanics of specific 
and non-specific removal of factors such as coagulation, 
anti coagulation, complement and other plasma constituents 
requires further clarification. Further evaluation is re­
quired of the reactions encountered in the course of plasma- 
perfusion to determine whether they can be prevented. The 
premise that a specific sorbent should exist for each of the 
many plasma constituents likely to require removal provides 
the impetus for further developments.
The perfusion of leukocytes will become feasible if the 
problems of cell blockage can be overcome. The use of large 
microbeads (300 jm diameter) has been advocated but these 
have very low capacity and a tendency to high non-specific 
binding. The newer microspheres (0.1-0.2 jm diameter) may 
offer greater scope, particularly when coated with appropriate 
antibodies and labelled with fluorescein or magnetic colloids. 
They can bind to the target cell surface at multiple sites 
and be removed in a second stage filter column of immobilised 
anti-fluorescein or magnetic filters. Such a procedure 
would be useful in the treatment of diseases where changes
in the T cell suppressor/helper subsets is known to be bene-
73ficial, e.g., multiple sclerosis.
Advantages have been conferred by combining membrane and 
column techniques in a single integrated film absorber in 
which carbon is embedded in cellulose nitrate film. This 
improves the internal diffusion limits set by larger beads 
and can be expected to form the basis for further development.
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5.2 Therapeutic.
Lymphopheresis is not yet of practical use in haematologic - 
oncologic disorders. It would be applicable if the lympho­
cytes producing the harmful substances could be identified.
The ability to remove only specific lymphocytes would be of 
value in diseases mediated by lymphocyte immune activity but 
this awaits the development of labelling techniques. Lympho­
pheresis is currently used in graft versus host disease follow­
ing bone marrow transplantation.
The contributions of transfusions of donor granulocytes are 
now reasonably well defined. It is unlikely that further 
studies in the forseeable future will significantly alter the 
indications of their use. If haemopoietic stem cells are 
present in the human circulation in appreciable numbers, 
their use in preference to stem cells harvested from bone 
marrow could have various specific advantages.
5.3 Replacement Fluids.
By the end of March 1986, 340 cases of Acquired Immune 
Deficiency Syndrome had been recorded in the United Kingdom.
Of these 5.5% were the recipients of blood products. Most 
at risk were haemophiliacs because some 20,000 donors could 
have contributed to each vial of American Factor VIII con­
centrate. Since the introduction of heat-treated Factor 
VIII, the risk of infection has been reduced.
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Patients who had had transfusions of blood and blood pro­
ducts, namely, platelet concentrate and fresh frozen plasma, 
are also at risk, although the risk is much lower. British 
blood donors, who are voluntary, have always had a lower 
incidence of hepatitis than those in the U.S.A., who are 
paid; the same is true of HIV. The screening of blood 
donors is now routine in the U.K., the U.S.A. and an in­
creasing number of other countries. The potential donor is 
warned that this is happening and is asked not to donate if 
he considers himself at risk of infection. Despite this, 
and because of the increased incidence of Acquired Immune 
Deficiency Syndrome and the possibility of transmitting 
the HIV through plasma exchange, great concern has been 
raised about the use of fresh frozen plasma as a replacement 
fluid.
Since March 1986, no fresh frozen plasma has been used as 
replacement fluid at the Royal Infirmary. Since November 
1985, the Canadian Apheresis Group decided to dispense with 
fresh frozen plasma because it considered that the product 
posed a serious threat to continued patient enrolment.
Thus, in the future only Albumin and Gelatins will be used as 
replacement fluids and this should decrease concern over the 
possibility of infectious complications.
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CONCLUSIONS.
The fluids normally used to replace large volume plasma removed
during plasma exchange procedures were plasma protein fraction,
albumin 5% and very occasionally fresh frozen plasma. It was
found that the consumption of albumin 5% could be substantially
reduced by substituting wholly or partly with polygeline. The
response of patients treated for myasthenia gravis, Guillain- 
/
Barre syndrome, polyneuropathy and polymyositis by plasma exchange 
was essentially similar when plasma protein solution, plasma 
protein with Haemaccel or Haemaccel were used as replacement 
fluids.
Therapeutic plasma exchange has not proved to be the panacea for 
all disorders. It is, however, finding its level of application; 
specific for some treatments, useful for others and to be used in 
certain cases when all conventional therapy has failed.
Although crude in its selectivity, plasma exchange is capable of 
removing any toxin located mainly within the blood stream. The 
problem is more complicated when the toxin is distributed both 
within and outside the vasculature, with the two compartments in 
dynamic equilibrum. If the source of supply of fresh toxin can 
be interrupted (and provided that no irreversible harm has been 
done to the target organ) then again the removal of the toxin from 
the plasma in sufficient quantities will benefit the patient. The 
toxins in Goodpasture's syndrome and myasthenia gravis are re­
spectively antibodies against the glomerular basement membrane and 
acetylcholine receptors and their production may be diminished .by
immunosuppressive drugs. Survival and recovery of renal function 
in Goodpasture's syndrome is improved by plasma exchange, whilst 
its use to circumvent the known delay in the action of immuno­
suppressive drugs is clearly indicated in severe and life- 
threatening myasthenia gravis.
The success of plasma exchange in specific antibody mediated 
diseases does not justify its use in others. In most cases treat­
ment by immunosuppressive drugs will prove effective. If immuno­
suppressive drugs cannot be used then the antibody will rebound 
to the initial or even higher concentrations. In diseases 
mediated by immune complexes, plasma exchange can lift the 
blockade imposed by circulating complexes on their clearance by 
the reticuloendothelial system. It is also possible that plasma 
exchange may modulate the immune response by influencing the com­
position of the complexes and their distribution between body 
components. However, the effectiveness of plasma exchange in the 
treatment of immune complex disease has yet to be established.
There is a need for more satisfactory controlled studies which 
are not easy to organise because the diseases are rare, action 
is often urgent and protocols may often prove inappropriate. 
Further, without sufficient knowledge of the underlying pathogenic 
mechanisms interpretation of the results must be difficult.
3. Leukapheresis may be used for acute myeloid leukaemia patients 
with high white cell counts and associated symptoms; it is not 
recommended as routine therapy or as a form of tumour debulking.
It can be useful in the treatment of some patients to whom chemo-
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therapeutic drugs cannot be administered immediately or in whom 
initial chemotherapy has not produced the required rapid fall in 
white cell count.
Intensive repeated leukapheresis for chronic myeloid leukaemia 
patients produces falls in peripheral leukocyte count, improve­
ment in systemic symptoms and reduction in hepatosplenomegaly, 
but only rarely are these sustained. The overall course of the 
disease appears to be unchanged. In the treatment of patients 
with advanced chronic lymphocytic leukaemia intensive leuka­
pheresis may offer some benefit from falls in circulating lympho­
cyte counts, variable regression in the degree of bone marrow 
infiltration, adenopathy and splenomegaly. However, it is un­
likely that the proliferation of leukaemia cells could be in­
fluenced by bulk removal of cells, so as to increase sensitivity 
to specific chemotherapy.
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